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Abstract 
The hypotheses under test were as follows. Firstly that sequential immunisation 
of humans with two candidate vaccines recombinant for the same malarial DNA 
sequence would be safe, would produce higher frequencies of antigen-specific T 
cells in peripheral blood and greater efficacy than repeated immunisation with 
one vaccine. Secondly that recombinant viral malaria immunization would be 
more immunogenic in malaria-exposed than malaria-naive individuals. The third 
hypothesis was contingent on the conduct of a field efficacy trial; liver-stage 
specific T cells induced by the regimen with greatest immunogenicity would 
provide protection against natural infection. Three delivery systems were 
evaluated -a circular plasmid DNA molecule (DNA), modified vaccinia virus 
Ankara (MVA) and fowlpox strain 9 (FP9); each recombinant for the multiple 
epitope - thrombospondin related anonymous (or adhesion) protein (ME-TRAP) 
P. falciparum DNA sequence. DNA ME-TRAP and MVA ME-TRAP were safe but 
poorly immunogenic when given alone in both UK and Gambian adults. Two 
doses of 1 mg DNA ME-TRAP administered intramuscularly followed by one dose 
of 3x 107 plaque forming units (pfu) MVA ME-TRAP administered intradermally 
induced higher effector T cell frequencies as measured by ex vivo y-interferon 
ELISPOT (enzyme-linked immunospot) assay than three doses of either alone. A 
second MVA ME-TRAP immunisation did not increase immunogenicity above 
that after a single immunisation. At these doses the DNA/MVA regimen was more 
immunogenic in malaria-experienced Gambian adults than in malaria-naive 
British adults. Increasing the dose of DNA to 2mg and MVA to 1.5 x 108 pfu 
increased immunogenicity further. Two doses of FP9 ME-TRAP showed a trend 
towards to being less immunogenic than two doses of DNA ME-TRAP prior to a 
single MVA immunisation. The heterologous DNA/MVA regimen afforded 
protection manifested by delay in time to parasitaemia in a clinical challenge 
model in the UK. Therefore a randomised double-blind controlled trial was 
conducted in men aged 15-45 in The Gambia. This trial confirmed safety and 
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high immunogenicity but there was 10.3% (95%Cl -22% to +34%) efficacy for 
the time to infection primary endpoint. Potential reasons for failure of the 
intervention include an unfavourable CD4+/CD8+ T cell ratio, inadequate TRAP 
expression in infected hepatocytes, inadequate cross-reactivity and the duration 
or magnitude of the peak T cell immunogenicity. (363 words) 
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Chapter 1 
Preface 
1.1 Background to the thesis 
In 1996 workers in Professor Hill's Molecular Immunology group at the John 
Radcliffe Hospital, Oxford had discovered that DNA immunisation followed by 
MVA immunisation with vaccines encoding either P. berghei circumsporozoite 
protein (CSP) or TRAP greatly increased T cell immunogenicity and efficacy in a 
mouse model of malaria. 
In August 1999 I started working as a clinical research fellow for Professor Adrian 
Hill. My task was to design and conduct a series of phase I trials of DNA and 
recombinant viral vaccines against liver-stage P. falciparum malaria to evaluate 
the hypothesis that the animal model finding would transfer to enhanced 
immunogenicity and protection against P. falciparum in humans. 
In early 2000 1 wrote the application for and was awarded a Wellcome Trust 
Training Fellowship in Clinical Tropical Medicine for the Gambian studies in this 
thesis. 
Through the year 2000 I conducted several small phase I studies with DNA ME- 
TRAP and MVA ME-TRAP in Oxford. In addition I conducted the first malaria 
vaccine study with experimental challenge to occur in the UK in collaboration with 
Imperial College, London. 
By September 2000 we had found that three immunisations with 1 mg i. m. DNA 
ME-TRAP or MVA ME-TRAP 3x 107 W. were safe but poorly immunogenic. We 
were then faced with the difficult question of how to discover the most 
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protectively immunogenic regimen with three available routes of administration, 
an unknown optimum immunisation interval and dose-escalation necessary. 
Professor Hill and I designed studies comparing i. m. DNA and DNA administered 
by needleless delivery device as priming immunisations for subsequent i. d. MVA 
ME-TRAP boosting with varying numbers of priming and boosting immunisations 
and increasing dose. 
From September 2000 onwards I spent some of my time at the MRC 
Laboratories, The Gambia. Once it became clear that we were unable to disprove 
the heterologous prime-boost hypothesis in terms of immunogenicity my aim was 
to optimise immunogenicity of a regimen with some evidence of protection in the 
Ila model. Between September 2000 and April 2002 I fulfilled this aim with data 
gathered in two phase I trials in adults and one phase I trial in children aged 1-5. 
The first Gambian adult phase I trial generated data consistent with the finding 
that immunogenicity of DNA ME-TRAP followed by MVA ME-TRAP or MVA ME- 
TRAP alone was higher in Gambian than British volunteers. Between June 2001 
and January 2002 we designed and conducted a study to explore 
immunogenicity of MVA ME-TRAP alone in children. If such increased 
immunogenicity was seen in children then it may have been appropriate to 
proceed to an efficacy trial in children. Data from this phase I trial however 
indicated that immunogenicity in Gambian children was similar to that in British 
adults. 
During 2001 data from phase I trials in Oxford indicated that FP9 ME-TRAP could 
replace DNA ME-TRAP for priming prior to MVA ME-TRAP boosting with at least 
equivalent Ila efficacy and that increasing the dose of DNA and MVA greatly 
increased immunogenicity. The UK FP9 ME-TRAP data are not part of this 
thesis. 
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Between November 2001 and June 2002 we designed and conducted a phase I 
trial in Gambian adults of either higher dose DNA ME-TRAP, or for the first time 
in The Gambia, FP9 ME-TRAP, followed by higher dose MVA ME-TRAP. 
At this point I designed a field efficacy trial with a DNA ME-TRAP/ MVA ME- 
TRAP regimen with advice from Professor Hill, Professor Brian Greenwood of the 
London School of Hygiene and Tropical Medicine and several other scientists. 
Professor Hill wrote the grant application to the Gates' Malaria Partnership. I 
wrote the trial protocol and standard operating procedures and designed the 
case report form for the field efficacy study. I conducted the field efficacy study 
between June 2002 and April 2003 as a Principal Investigator with help from 
many scientists and staff of the MRC unit particularly Tunde Imoukhuede. 
Pauline Kaye was the trial data manager. Paul Milligan analysed the data from 
the trial. Margaret Pinder gave advice on laboratory work throughout the 
Gambian trials. 
I completed the writing of this thesis in Farafenni, The Gambia and Bethesda, 
Maryland, USA. 
14 
1.2 Oxford Malaria Vaccine Trials Code Designations 
Trial Vaccine Regime No. of 
Vaccinees 
No. 
Challenged 
VAC 01 DDD, GGG 12 - 
VAC 02 MMM 6 - 
VAC 03 DDDM, DMM, DDD, MMM 16 12 
VAC 05 DDMM, GGMM 9 9 
VAC 06 DDMM, MMM In The Gambia 20 - 
VAC 10 DDDMM - higher dose DNA (2mg) + higher dose 
MVA, 
17 9 
VAC 11 MVA In children 1 to 5 In The Gambia 20 (+20 
controls) 
- 
VAC 14 FFM, DDM, DDDM (all at higher doses) in The Gambia 29 - 
VAC 20 Double-Blind Randomised Efficacy Trial of DDM with 
Rabies Controls 
372 (1: 1) - 
D-i. m. DNA ME-TRAP immunisation 
G- needleless delivery of DNA ME-TRAP 
M- MVA ME-TRAP immunization 
F- FP9 ME-TRAP immunisation 
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1.4 Detail of the role of each contributor to each project 
I had the lead role in all projects detailed below from which data are quoted for 
this thesis other than 1.4.6 (VAC 10) which was co-led by Sam McConkey and 
Daniel Webster. Sam McConkey was co-lead for VAC 05. For all UK studies 
Adrian Hill performed the process of Medicines Control Agency submission 
(MCA). 1.4.1 to 1.4.4 were funded by a Wellcome Trust project grant to Adrian 
Hill. Sarah Gilbert made the initial DNA, MVA and FP9 recombinants. Joerg 
Schneider, Carolyn Hannan and Pilar Degano performed the pre-clinical work 
necessary for MCA submission. Except where stated the data presented are my 
analyses. 
1.4.1 VAC 01 Phase I trial of DNA ME-TRAP immunisations with MVA ME-TRAP 
boosting of some volunteers 
I conducted the trial. Adrian Hill wrote the protocol, designed the studies and 
obtained OXREC approval. Mark Roberts recruited the volunteers. William Reece 
and Philip Gothard performed the ELISPOTS. 
1.4.2. VAC 02 Phase I trial of MVA ME-TRAP immunisations 
I wrote the protocol, obtained OXREC approval, recruited the volunteers and 
conducted the study. William Reece and Philip Gothard performed the 
ELISPOTS. 
1.4.3 VAC 03 First Phase Ila trial of DNA ME-TRAP and MVA ME-TRAP 
I wrote the protocol, obtained OXREC approval and conducted the study. Kate 
Watkins performed the ELISPOTS. Geoff Butcher of Imperial College and Jackie 
Williams of Walter Reed Army Institute of Research performed the falciparum 
sporozoite culture in Anopheles stephensi. 
1.4.4. VAC 05 Second Phase Ila trial of DNA ME-TRAP and MVA ME-TRAP 
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I wrote the protocol, obtained OXREC approval, recruited the volunteers and 
conducted the first part of the study. Sam McConkey co-ordinated the latter part 
of the study. Kate Watkins, William Reece and I performed the ELISPOTS. Both 
Sam McConkey and I analysed the data. Geoff Butcher of Imperial College 
performed the falciparum sporozoite culture. 
1.4.5 VAC 06 Phase I trial of DNA ME-TRAP and MVA ME-TRAP in adults living 
in Bakau, The Gambia 
I wrote the grant application to the Wellcome Trust which funded 1.4.5,1.4.7, 
1.4.8 and co-funded 1.4.9. I wrote the protocol, Gambian scientific committee 
submission and standard operating procedures, obtained OXREC and Gambian 
Government/ MRC Ethics Committee approval and conducted the study. I 
performed the ELISPOTS after cell separation. Kate Watkins performed the 
ELISPOTS on fresh cells. Sowsan Atabani performed the cell separations and 
co-staining by FACS. Carolyn Hannan performed anti-TRAP antibody ELISAs. 
1.4.6 VAC 10 Phase I trial of high dose DNA ME-TRAP and MVA ME-TRAP in 
Uk adults 
Sam McConkey wrote the protocol, obtained OXREC approval and recruited the 
volunteers. Sam McConkey and Dan Webster conducted the trial. Kate Watkins 
performed the ELISPOTS. I analysed the data 
1.4.7. VAC 11 Phase I trial of MVA ME-TRAP in children aged 1-5 living in 
Sibanor, The Gambia 
I wrote the protocol, Gambian scientific committee submission and standard 
operating procedures, obtained OXREC and Gambian Government/ MRC Ethics 
Committee approval and conducted the study. I supervised the ELISPOTS and 
analysed the data. Simone Everaere performed the ELISPOTS. Tunde 
lmoukhuede supervised the follow-ups during the study. 
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1.4.8 VAC 14 A Phase I trial of DNA ME-TRAP, FP9 ME-TRAP and MVA ME- 
TRAP in adults living in Farafenni, The Gambia 
I wrote the protocol, Gambian scientific committee submission and standard 
operating procedures, obtained OXREC and Gambian Government/ MRC Ethics 
Committee approval and conducted the study. Tunde Imoukhuede was the 
medical officer. I supervised the ELISPOTS and analysed the data. Saikou Keita 
performed the ELISPOTS. 
1.4.9 VAC 20 A Randomised Double-blind Efficacy Trial of DNA ME-TRAP 
followed by MVA ME-TRAP with Chiron Rabipur rabies vaccine as controls. 
Adrian Hill wrote the grant application to Gates Malaria Partnership at LSHTM 
which co-funded this study. I wrote the protocol, Gambian scientific committee 
submission and standard operating procedures, obtained Gambian Government/ 
MRC Ethics Committee approval, OXTREC and LSHTM ethics committee 
approval, supervised Tunde Imoukhuede, Simon Correa and Fanta Njie and co- 
ordinated the study. Tunde Imoukhuede recruited the volunteers and supervised 
immunisations, post-vaccination follow-up and the surveillance period follow-ups. 
Pauline Kaye was the data manager and supervised data entry by 4 data entry 
clerks. Paul Milligan contributed to study design and analysed the efficacy data. 
Adrian Hill, Brian Greenwood, Gijs Walraven, Margaret Pinder and Kalifa Bojang 
contributed to study design. Samba Baldeh was the supervisor of the 10 field 
assistants and 4 study nurses. Simon Correa supervised the slide reading by 4 
lab assistants. Fanta Njie supervised the haematology and biochemistry assays 
and performed the HIV antibody assays. 
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Chapter 2 
Background information on the epidemiology of 
malaria, the development of malaria vaccines and 
the Gambian study settings 
2.0 Mortality and morbidity of P. falciparum malaria 
Any visitor to a pediatric ward in a malaria-endemic sub-Saharan African country 
will be confronted with a vivid sense of the importance of malaria as a public 
health problem. If the visitor attended a primary health clinic in a village they 
would witness the scale of the problem readily. Is it therefore necessary to 
attempt to accurately estimate the mortality and morbidity of malaria in sub- 
Saharan Africa? I believe this is important for two reasons. Firstly in a competitive 
climate for provision of funding for research into interventions against diseases 
with an impact primarily on poor countries, it is a necessary pre-condition for 
advocacy. Secondly, unfortunately, there are other diseases which cause more 
deaths than malaria in some parts of some sub-Saharan African countries. 
Pneumonia and gastroenteritis are examples in low malaria transmission 
areas(Greenwood, 1999). Therefore for public health decisions to be made about 
deployment of interventions where funding can only allow prioritization, estimates 
are needed not just at a country level but also by region. Early estimates used 
data from studies in a few settings and then interpolated these with population 
densities to give figures for all Africa. These estimates were 0.5 -1 million per 
year(Sturchler, 1989). 
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More recently Snow et al. used a variety of methods to estimate disease burden 
(Snow et al., 1999). They identified 76 sources of data for annual malaria 
mortality in children in Africa between 1931 and 1997. In parallel they developed 
a fuzzy logic model of malaria transmission based on temperature and rainfall 
data. This model makes certain assumptions about parasite and vector biology in 
relation to temperature which will lead to some errors. The rainfall data as 
variables for calculation of vector abundance are underestimates as they do not 
include river/flood plain complexes as a source of breeding sites. Snow et al. 
constructed a GIS population density database from the most recent censuses of 
4000 African administrative units. They adjusted these for a common base year 
to give an interpolated 1995 population density map of Africa. By combining the 
malaria risk map and population density map they arrived at a figure of 987,466 
deaths in Africa, of whom 765,442 would have been children under the age of 5. 
These figures do not include indirect deaths due to P. falciparum particularly in 
children. Many children who are infected with, for example, a respiratory virus are 
also parasitaemic. It is very difficult to estimate the number of additional deaths 
caused by contribution of parasitaemia to other disease conditions and to 
undernutrition. Another example of an indirect effect is the number of new HIV 
infections thought to be due to malarial anaemia related blood transfusions. One 
estimate of this figure is 20,000 per year in Africa. Furthermore the above model 
does not include provision for epidemics in areas with moderate malaria 
transmission or for deaths of pregnant women. In addition malaria mortality in 
Africa is thought to be increasing for several reasons. Resistance to chloroquine 
is widespread and is increasing to the only other widely used affordable 
antimalarial, sulphadoxine/pryimethamin (Mutabingwa et al., 2001) . Pyrethroid 
resistance in west and southern Africa is decreasing the effectiveness of 
insecticide-treated bednet and residual spraying programmes(Hemingway et al., 
2002). Migration is increasing in Africa, in part due to civic instability leading to 
movement of refugee populations, which have increased malaria disease 
burdens, and also because migrant labour is increasing(Martens and Hall, 2000). 
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Construction of small dams(Ghebreyesus et al., 1999) and other environmental 
changes, possibly including global warming, (Lindblade et al., 1999) have 
increased malaria disease burden in parts of Africa. For example the el nino rains 
were followed by increased malaria mortality in Africa(Brown et al., 1998). About 
7,000 cases of imported malaria are reported in Europe each year and this figure 
is likely to increase(Muentener et al., 1999). Finally the population of endemic 
countries is rising, increasing the numbers of individuals at risk. 
The morbidity and mortality of malaria is thought to be increasing in many areas 
of Asia and South America. Multiple resistance to antimalarials in P. falciparum is 
common in parts of south-east asia(White et al., 1999) and chloroquine-resistant 
P. vivax has emerged(Fryauff et al., 1998). Some areas such as parts of the 
former Soviet Union have seen sharp economic declines leading to collapse of 
public health infrastructures and the resurgence of malaria(Pitt et al., 1998). 
When figures are obtained of decrease in mortality after the introduction of a 
successful malaria control programme, they tend to be higher than predicted by 
conventional models or malaria epidemiology(Snow et al., 1999). To conclude on 
mortality due to malaria, the consensus is that 1 million deaths a year is the 
minimum but that the true figure is up to 3 million or more. Thus an effective 
malaria vaccine might reduce overall mortality in endemic countries much more 
substantially than previously thought. 
In much of sub-Saharan Africa young children experience several attacks of 
clinical malaria a year. Estimates vary from 200 - 450 million clinical attacks a 
year in Africa(Breman, 2001). About 1-2% go on to develop severe 
malaria(Greenwood and Mutabingwa, 2002). Socioeconomic, parasite and host 
genetic factors are all likely to be involved in susceptibility(Miller et al., 2002). 
Mortality from cerebral malaria remains at about 20% with 10% suffering long- 
term neurological deficits likely to lead to long-term education and employment 
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problems(Holding and Snow, 2001). Mortality from severe anaemia is increasing 
due to drug resistance(Breman, 2001). 
Malaria in pregnant women in low transmission areas may lead to death of the 
mother or still-birth of the child. In stable transmission areas malaria in pregnancy 
is associated with heavily parasitised placentas with low birth weight babies and 
almost certainly, increased infant mortality(Miller et al., 2002). The direct 
economic costs of malaria due to loss of education and absence from work are 
very high, but the true cost is likely to be far higher than those estimated by direct 
costs alone(Sachs and Malaney, 2002). Recent research in this area has 
suggested that there is a very strong argument for large, sustained increases in 
malaria research funding on economic grounds alone(Sachs, 2002). 
2.1 The development of malaria vaccines 
An edited version of this review was published(Moorthy et at., 2004a). 
Summary 
After large reductions in malaria in the early twentieth century, its mortality has 
increased substantially over recent decades. Mortality now stands at 2-3 million 
annually. Advances in vaccine technology and immunology have transformed 
malaria subunit vaccination. Novel approaches, which might yield effective 
vaccines also for other diseases, are first being evaluated for malaria. I describe 
major progress in malaria vaccine development in the last 5 years and reasons 
for cautious optimism. I discuss what sort of vaccine might realistically be 
expected, and how this might be developed more rapidly. Timescales remain 
uncertain, but if more funding can be mobilized, a deployable effective malaria 
vaccine is a realistic medium to long term goal. 
Introduction 
In 1955 a book entitled "Man's Mastery of Malaria"(Russell, 1955) reflected the 
generally held views of that time. Half a century later 2-3 million people are dying 
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from malaria annually(World Health Organisation, 1996), mostly children under 
the age of 5 in sub-Saharan Africa. In the 21st century, an era of accelerating 
scientific progress, an African child dies from malaria every 30 seconds(World 
Health Organisation, 2000). In few other diseases has scientific optimism been 
so misplaced. With the advent of both chloroquine resistance and DDT 
resistance, malaria reemerged in many parts of the world. In recent years, the 
burden of disease and death has increased substantially in endemic 
countries(Shanks et al., 2000) and transmission has spread to new areas(le 
Sueur et al., 1996). This resurgence (described in section 2.0) in malaria 
contrasts with a background of decline in all-cause mortality in children in many 
developing countries(Snow et al., 2001). The economic prospects for endemic 
countries are closely linked to the malaria disease burden, making a strong 
economic and political case for large increases in malaria intervention 
funding(Sachs, 2002). 
Three key intermediate goals for malaria vaccinology are induction of strong, 
strain-transcending and durable immune responses; identification of protective 
antigens for stage-specific immunity; and successful combination of candidate 
immunogens. Until recently the level of malaria vaccine funding was pegged at 
the level of less than 50 million dollars worldwide. Current funding, mainly for 
human trials, has increased somewhat to 60-70 million dollars, but this is still an 
order of magnitude lower than that for HIV vaccine development, a disease which 
affects a comparable number of individuals. 
In this section I start by summarising the complex life cycle of malaria and then 
outline the differences between immunity acquired in nature and the immunity 
likely to be induced by a vaccine(Beverley, 2002), discuss the relevance of the 
recently published P. falciparum genome sequence(Gardner et al., 2002) to 
vaccine development and highlight some new vaccine candidates that have 
reached the clinical evaluation stage. 
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The history of malaria vaccines 
The history of malaria vaccine research and development has been full of 
salutary tales, good and bad science and disappointments. 1973 saw the first 
publication of human protection from malaria by vaccination(Clyde et al., 1973). 
This protection was produced by the bite of about a thousand mosquitoes 
infected with malaria parasites, which had been X-ray irradiated(Hoffman et al., 
2002). This was a demonstration of the principle that it is feasible to protect by a 
vaccine, but is obviously unlikely to be a practical means of mass vaccination. 
For about 20 years, progress occurred mainly in experimental models, not in 
human vaccine trials(Cochrane et al., 1980, Kwiatkowski and Marsh, 1997). 
Much speculation and excitement was generated by the Spf66 candidate vaccine 
championed by Pattoroyo, despite real uncertainty about how such a construct 
could work. In the end, multiple phase III efficacy trials were required to 
demonstrate that this candidate lacked efficacy(Patarroyo et al., 1992, Alonso et 
al., 1994, D'Alessandro et al., 1995, Nosten et al., 1996, Acosta et al., 1999). 
Over the last 5 years several new vaccine approaches have reached clinical trials 
(Moorthy and Hill, 2002). Numerous potential future candidate vaccines now 
warrant pre-clinical evaluation. 
The life-cycle of the P. falciparum parasite 
An infected female anopheline mosquito requires a blood meal for oviposition. 
During such a meal, she will inject perhaps 5-20 sporozoites(Rosenberg et al., 
1990, Ponnudurai et al., 1991), which invade hepatocytes within minutes. 
Sporozoites migrate through several hepatocytes before entering one to begin 
the liver-stage(Mota et al., 2001, Mota et al., 2002). The sporozoite and liver- 
stages together constitute the pre-erythrocytic stages of the life cycle. Over on 
average 6.5 days parasites develop within the liver into schizonts which rupture 
releasing 20-30,000 merozoites per original sporozoite into the hepatic venous 
circulation, from where they disseminate systemically. Each merozoite that is not 
picked up by phagocytic cells invades an erythrocyte, starting the 48 hour cycle 
of replication. This is followed by schizont rupture and invasion of new red blood 
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cells, and this is designated the blood-stage of malaria. The blood-stage 
culminates either in death of the human or control by the immune system. Some 
merozoites differentiate into male or female gametocytes which can be ingested 
by an anopheline mosquito. Fertilisation occurs within the mosquito midgut, 
leading ultimately to completion of the life cycle, with sporozoites migrating to the 
salivary glands, and becoming infective. 
Introduction to subunit vaccination 
It became clear that producing live, attenuated or killed, inactivated vaccines was 
not practical for many diseases. The concept of subunit vaccination is that partial 
or complete antigens are identified from a pathogen's proteomic complement 
which can induce protective immunity to the whole pathogen following 
immunisation. An example of an effective subunit vaccine is the hepatitis B 
vaccine(Crosnier et al., 1981). This vaccine, as with most other vaccines in 
widespread use (BCG being the notable exception), was designed to maximise 
antibody (humoral) immune responses. Unfortunately, different proteins vary 
greatly in their immunogenicity for antibody induction. Many of the vaccines 
described below embody attempts to induce antibodies having the correct avidity 
(ability to bind), specificity, biological activity and at high enough titre to result in 
blocking of infection. New understanding of antigen processing, adjuvants and 
their effects on innate immunity, genetic engineering techniques and novel 
delivery systems are gradually increasing such antibody immunogenicity. 
Duration of the induced immune responses remains a very considerable problem 
though. Moreover, such recombinant protein subunit vaccines are generally poor 
at induction of the effector T cell responses, such as CD8+ cytotoxic T 
lymphocytes (CTL), that are necessary for elimination of intracellular pathogens 
such as liver-stage malaria parasites. The newest generation of subunit vaccines 
are DNA(Ulmer et al., 1993) and improved recombinant viral vaccines(Li et al., 
1993). In the case of malaria, DNA sequences from falciparum parasites have 
been inserted into plasmid DNA molecules (DNA vaccines(Wang et al., 1998) or 
various recombinant attenuated DNA viruses (recombinant viral 
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vaccines(Schneider et al., 1998) to generate candidate vaccines. The DNA 
vaccines are taken up by host cells, protein is expressed and T cell epitopes 
bound to HLA molecules prime naive T cells to form memory T cell populations 
(Gurunathan et al., 2000). Recombinant viral vaccines work similarly but actively 
infect cells and express the recombinant malaria proteins before aborting 
infection(Miyahira et al., 1998). These vaccines provide new methods of inducing 
high levels of effector T cell immune responses(Paoletti, 1996). Methods for 
assessing T cell responses have been revolutionised by two assays - the 
enzyme linked immunospot (ELISPOT) assay and the tetramer assay. 
ELISPOT(Kabilan et al., 1990, Lalvani et al., 1997) allows highly sensitive 
quantitative detection of functional antigen-specific T cells. Tetramers allow 
detailed characterisation of antigen-specific T cells(Altman et al., 1996). These 
advances together with those of subunit vaccination in malaria raise the 
possibility of identifying antibody and T cell immune correlates of protection or, in 
other words, an understanding of how partially effective vaccines provide their 
level of protection. Such an understanding should allow tailoring of vaccine 
design around immune correlates of protection to systematically improve vaccine 
efficacy -a process dubbed iterative vaccine development. 
Naturally acquired immunity & types of vaccine-induced immunity 
Natural exposure to P. falciparum gradually elicits, in humans, relatively short- 
lived strain-specific malaria immunity first to severe disease and death and then 
to mild disease(McGregor, 1974). Repeated infections are required to maintain 
immunity. This is both antibody and T cell-based, although the clearest evidence 
for protective immunity acquired in nature is antibody-mediated immunity to blood 
stage malaria(Cohen et al., 1961, Marsh and Howard, 1986, Bouharoun-Tayoun 
et al., 1990). It is not known on which of the 5,300 antigens encoded by the P. 
falciparum parasite the key protective immune responses are focused, although 
some evidence exists for about 20 antigens. Immunity acquired in endemic areas 
is likely to be mediated by an integration of low to moderate level responses to 
many antigens. Immunity to one stage of the parasite is restricted only to that 
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stage (although sporozoite and liver-stage immunity overlap to some extent) 
increasing the complexity of vaccine design. However recent data from the 
malaria genome project call into question some of the previously held convictions 
about stage-specific expression of antigens(Florens et al., 2002); many antigens 
believed to be specific to one stage have been found at other stages of the life- 
cycle using proteomics techniques. Most vaccines aim to induce antibody and T 
cell responses to one or a few antigens but for effective vaccination these will 
need to be of greater magnitude, duration and strain-transcendence than 
naturally acquired immunity. T cell responses have been neglected to date 
particularly for blood stage vaccines; little is known or understood of the required 
T cell responses apart from the need to produce T cell help for an antibody 
response. An alternative ambitious approach for the longer term is to attempt to 
develop a vaccine using a "cocktail" of very many antigens to attempt to mimic 
natural immunity(Doolan and Hoffman, 2001) but this could lead to a product of 
considerable complexity and cost. 
A note on malaria vaccine trial terminology 
Clinical trials of new drug, vaccine or medical device products are divided into 
phase 1,2 and 3 trials. Phase 1 trials enrol small numbers of volunteers (10-60) 
and are conducted primarily to assess the safety and reactogenicity of malaria 
vaccines. Immunogenicity assessment is another important objective of phase 1 
trials. Phase 2 trials in the malaria vaccine field are divided into two quite different 
types of trial: phase 2a and phase 2b trials. Phase 2a trials are no larger than 
phase 1 trials and, in addition to safety and immunogenicity objectives, a 
preliminary efficacy measurement is obtained. In Phase 2a trials mosquitoes 
infected with P. falciparum sporozoites are allowed to bite volunteers after 
completion of the immunisation course. This deliberate infection is known as 
"challenge"; phase 2a trials are also known as challenge trials. Clones of highly 
characterised P. falciparum (either 3D7, NF54 or 7GB) are used to infect A. 
stephensi mosquitoes for challenge. Unvaccinated volunteers serve as controls 
for the infectiousness of the challenge. Phase 2b trials are medium-sized 
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randomised controlled field efficacy trials. The objectives of phase 2b trials are 
safety, immunogenicity and efficacy measurement. The primary endpoint is either 
a natural infection or a clinical disease endpoint. Between 300 - 2000 volunteers 
are required depending on the primary endpoint, the transmission setting, the 
age group of volunteers and the precision required. Infection can be measured in 
either adult or paediatric populations. Clinical disease requires paediatric 
populations. A phase 3 trial in the malaria vaccine field is a critical pre-licensure 
safety and efficacy trial. Efficacy endpoints chosen for phase 3 trials will dictate 
the indications for which the vaccine could be marketed. If efficacy is known after 
such a phase 3 trial to be correlated with an immunoassay, then further work (for 
example on dose, schedule, age groups or combination vaccines) could be 
conducted with immunogenicity as the primary endpoint. 
Pre-erythrocytic vaccines 
The ideal vaccine for this stage would induce high levels of functional antibodies 
against sporozoites to prevent all parasites entering the liver-stage and potent T 
cell immunogenicity against the liver-stage to kill infected hepatocytes (harmless 
to the human host). Much of the recent expansion in clinical trials has been using 
this type of vaccine. The lead candidate is RTS, S, a recombinant protein vaccine 
developed by GlaxoSmithKline Biologicals(Stoute et al., 1997) . At the DNA level 
hepatitis B surface antigen was fused to a large part of the best characterised 
pre-erythrocytic malaria antigen, the circumsporozoite (CS) protein(Potocnjak et 
al., 1980, Nardin et al., 1982). When expressed in yeast this fusion product (RTS) 
binds hepatitis B surface antigen (S) to form RTS, S particles. When formulated 
with a proprietary adjuvant, AS02 -a mixture of de-acylated monophosphoryl 
lipid A, QS21 and an emulsion - and given intramuscularly on 2-3 occasions 
RTS, S vaccination induces high titre antibodies to both CS and hepatitis B and 
gives 41 % protection of volunteers against challenge with parasites of the same 
strain used in the vaccine in an established sporozoite challenge model(Kester et 
al., 2001). In this challenge model vaccinees from industrialised countries (in 
America and Europe) are bitten by five mosquitoes infected with the 3D7 strain of 
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falciparum, known to be fully sensitive to chloroquine. Volunteers are closely 
monitored by malaria blood smears (or increasingly also by PCR techniques) and 
promptly treated once blood stages are detected by microscopy(Church et al., 
1997). The landmark result on the efficacy of RTS, S/AS02 in 1996-97 at the 
Walter Reed Army Institute of Research (WRAIR) , 
followed several years of 
iterative development of CS-based vaccines - trials either with no challenge, or 
with only partial protection(Ballou et al., 1987, Herrington et al., 1987, Sherwood 
et al., 1991, Vreden et al., 1991, Herrington et al., 1992, Brown et al., 1994, 
Gonzalez et al., 1994, Hoffman et al., 1994a). Notably several different 
adjuvants used with the RTS, S construct were far less protective than the AS02 
adjuvant. In a subsequent randomised controlled field trial of the efficacy of 3 
dose RTS, S in Gambian adults vaccine efficacy was 34% (p=0.014) over the 15 
week surveillance period, but with 71 % efficacy over the first 9 weeks and 0% 
over the next 6 weeks(Bojang et al., 2001). Although the duration of protective 
efficacy induced was short-lived, RTS, S is the first pre-erythrocytic vaccine to 
show clear protection against natural P. falciparum infection. Further 
development of RTS, S has been accelerated by the provision of funding by the 
Malaria Vaccine Initiative, sponsoring an efficacy trial of RTS, S in children aged 
1-5 in Mozambique, due to start in July 2003. 
Several other pre-erythrocytic candidates have reached clinical evaluation over 
the last 5 years. A pre-erythrocytic vaccine candidate known as ICC-1132, 
developed by New York University School of Medicine investigators together with 
Apovia (a biotechnology company), is currently being tested in different 
formulations in the U. S., Germany and the U. K. ICC-1132, is a hepatitis B core 
particle genetically engineered to include a region of CS for high level antibody 
induction. Very high titres of biologically active CS antibody have been seen in 
pre-clinical studies(Birkett et al., 2002) and clinical trials have recently started. 
The University of Oxford has focused in humans on the concept of heterologous 
prime-boost vaccination. Two different vaccine vectors encoding the same 
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antigen are given sequentially. Viral vectors can be given first (priming) or second 
(boosting); DNA vaccines are efficient priming vaccines but do not boost 
efficiently(Schneider et al., 1999). Three carriers have been clinically evaluated; 
DNA, MVA (modified vaccinia virus Ankara) and another attenuated poxvirus FP9 
(an attenuated fowipox virus strain once used to vaccinate chickens against' 
fowlpox). The insert in these three vaccine components includes TRAP, a well 
characterised pre-erythrocytic antigen, and a string of T cell epitopes (ME for 
multiple epitope); these ME-TRAP vaccines are given in prime-boost 
sequence(Moorthy and Hill, 2002) (DNA then MVA or FP9 then MVA). This has 
induced T cell frequencies unprecedented in the vaccination field and partial 
protection in terms of delay in time to parasitaemia in artificial challenge studies. 
A randomised controlled efficacy trial of DNA ME-TRAP followed by MVA ME- 
TRAP has been completed in The Gambia with 372 adult volunteers. MVA 
encoding the CS protein and given before or after RTS, S is also currently in 
phase I and Ila studies in Oxford. 
The US Navy's Naval Medical Research Centre has led an intensive effort to 
provide effective vaccination with DNA-based vaccines to both the liver-stage 
and blood stages. Various DNA vaccines each encoding a pre-erythrocytic 
antigen have been evaluated in Phase I studies(Doolan and Hoffman, 2001). 
Most recently a mixture of five pre-erythrocytic DNA vaccines were administered 
in phase I studies but no evidence of protection was found using sporozoite 
challenge. It has become clear that DNA vaccines require viral boosting for 
strong T cell immunogenicity in macaques(Rogers et al., 2002) as well as 
humans and that antibody induction in humans is generally very low after DNA 
vaccination(Wang et al., 1998, Wang et al., 2001), in contrast to some animal 
models. The findings on the immunogenicity and efficacy of protein adjuvant 
vaccines containing the AS02 adjuvant and the principles of prime-boost 
vaccination using non-replicating vectors identified in these malaria clinical 
studies are likely to impact on the design of vaccines for other diseases. 
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Both New York University (NYC) and the University of Lausanne have conducted 
Phase I studies, to date without challenge, of different CS-based vaccines. One 
NYU candidate vaccine is a multiple antigen peptide(Nardin et al., 2001, Nardin 
et al., 2000), a type of synthetic delivery system. It induced strong antibody 
responses but also generalised urticaria in two volunteers (Edelman et al., 2002). 
NYU also used a polyoxime construct, containing a universal T cell epitope. The 
University of Lausanne candidate, a long synthetic peptide in an oil-based 
adjuvant, induced detectable antibody, CD4+ and CD8+ T cell responses with a 
good safety profile(Lopez et al., 2001). 
Blood stage vaccines: anti-invasion and anti-complication 
There are two possible classes of blood stage vaccine: anti-invasion and anti- 
complication. A vaccine which could prevent invasion of red blood cells by the 
merozoite would prevent malaria disease. Blood-stage vaccines have been 
hampered by the lack of an established human challenge model, by the 
limitations of available animal models and by unclear immunological correlates of 
protection. A major impediment to vaccine development has been antigenic 
polymorphism of candidate vaccine antigens. Merozoite surface protein-1, MSP- 
1, is the best characterised antigen involved in invasion and the basis of several 
candidate vaccines. The existence of parallel pathways for invasion and the 
elegant demonstration that some antibodies to MSP-1 can block the activity of 
protective antibodies has alerted researchers to the difficulty of the task(Holder et 
al., 1999). A blood stage vaccine incorporating the antigen MSP-2 with two other 
blood-stage antigens reduced parasite density in vaccinees in a small efficacy 
study in Papua New Guinea(Genton et al., 2002). Vaccinees were protected 
most from infection with the vaccine strain of malaria, implying that for 
polymorphic antigens such as MSP2, a vaccine including just one allelic form of 
the antigen is not likely to be sufficient. 
WRAIR, which was primarily responsible for establishing the laboratory challenge 
model for pre-erythrocytic vaccines, developed a recombinant viral vaccine, 
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NYVAC Pf-7, encoding 7 antigens from various life-cycle stages(Ockenhouse et 
al., 1998). This showed encouraging delays in time to parasitaemia in a 
sporozoite challenge study and some antibody and CTL immunogenicity, but was 
withdrawn by the pharmaceutical company involved. WRAIR is clinically 
evaluating a blood stage candidate, FMP-1, an anti-invasion vaccine based on 
MSP-1, and has progressed quickly to an adult phase I study in western Kenya. 
Two blood stage candidates GLURP(Oeuvray et al., 2000) and MSP3(Oeuvray et 
al., 1994) have been evaluated clinically in Europe. A key issue for all such 
protein candidates is the identification of a safe, immunogenic adjuvant as the 
traditional adjuvant, alum, appears to be insufficiently immunogenic for many 
malaria proteins. In addition alum-adjuvanted vaccines induce T cell responses of 
a Th2 rather than Th1 type considered likely to be more protective for many 
antigens. Induction of biologically relevant antibodies is also a challenge and it is 
unclear how often this will require a native conformation of the recombinant 
protein. 
An alternative approach to blood-stage vaccine design has been suggested by 
the demonstration that vaccine induced T cell responses against blood-stage 
antigens can be protective in animal models(Makobongo et al., 2003) and the 
finding that human volunteers can be protected against infection by immunization 
with low doses of blood-stage parasites that do not induce detectable 
antibodies(Pombo et al., 2002). With the development of blood stage challenge 
models(Cheng et al., 1997) and numerous new antigens becoming available a 
significant expansion in clinical blood stage candidate evaluation looks set to 
occur in the next few years. 
Sequestration of P. falciparum by adherence to vascular endothelial cells in the 
brain, the kidneys and the placenta is an important cause of severe malaria. The 
PfEMP-1 antigen, known to be the main ligand for such adherence is the subject 
of intense research. However, its high degree of variability and high copy number 
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within each parasite isolate make a PfEMP-1 anti-complication vaccine highly 
problematic, although some scientists believe this possible based on a conserved 
part of the antigen. At schizont rupture inflammatory mediators are released 
which lead to many of the severe manifestations of disease. The falciparum GPI 
(glycosyl phosphatidyl inositol) molecule is a lead candidate for this mediator, 
which has been called the "malaria toxin". Immunisation with falciparum GPI 
protected mice from severe disease manifestations on malaria 
challenge(Schofield et at., 2002), although this finding was not reproducible by 
NYU investigators(Molano et at., 2000) and the pathway from this work to an 
effective clinical vaccine is unclear. . 
Sexual stage vaccines: the altruistic vaccine 
Induction of antibodies to gametocyte antigens can prevent fertilisation in the 
mosquito; the mosquito ingests antibodies with its blood meal which block 
fertilisation. As a result, efficacy evaluation of gametocyte vaccines is possible 
with a simple ex vivo assay. Mosquitoes are fed on gametocytes with or without 
the addition of human sera from vaccinated volunteers. The National Institute for 
Allergy and Infectious Disease Malaria Vaccine Development Unit plans clinical 
evaluation of a falciparum gametocyte candidate vaccine Pfs25, a recombinant 
protein. There is little commercial funding for sexual stage vaccine candidates as 
they have no market in industrialised countries. They could however contribute to 
malaria control particularly if linked with other interventions. A sexual stage 
vaccine utilizing an antigen not expressed in humans during natural infection 
would not select for escape mutants. Therefore combination of such a vaccine 
with a blood-stage or pre-erythrocytic vaccine could prevent immune selection 
that might otherwise occur. Sexual stage vaccination has been called "altruistic" 
because it would not protect vaccinees from disease but would protect 
communities from infection. 
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Vaccine development in the post-genomic era 
Whole genome sequencing indicates a likely 5,300 P. falciparum 
antigens(Gardner et al., 2002). The genome databases can be used for 
identifying hundreds of candidate antigens for vaccination. Currently the number 
of possible antigens is not rate-limiting for malaria vaccine development. 
Increasing greatly the number of available antigens does not help solve some 
key problems in malaria vaccine development i. e. how to induce strong, durable 
immune responses and how to combine multiple antigens without interference or 
competition between them. Post-genomic antigen identification should generate 
a wealth of information of long-term potential value to vaccine development but 
solving other vaccinology problems could yield an effective vaccine sooner. 
Clearly, diversion of funding from clinical development of the well-characterised 
antigens already available would be counter-productive. A distinction can be 
made here with drug development where there are likely to be shorter term 
promising applications of the genome sequence information. 
Discussion 
The clinical evaluation of malaria vaccines is accelerating. In the last 5 years the 
number of groups evaluating candidate vaccines in the clinic has increased from 
3 to 11. The number and quality of field sites with the capability to conduct field 
efficacy studies is increasing. Funding has increased and looks set to increase 
further. Progress has been facilitated by several agencies that are making 
important contributions. For example the Malaria Vaccine Initiative (MVI), at the 
Program for Appropriate Technology in Health, funded primarily by the Bill and 
Melinda Gates Foundation, has applied positive aspects of the corporate ethos to 
vaccine development undertaken by academic research groups. About nine MVI- 
funded candidate vaccines are in development (www. malariavaccine. org) and 
may reach clinical evaluation in the near future. Several other funding agencies, 
such as the NIH, the US Department of Defense, the Wellcome Trust, the 
European Commission and the European Malaria Vaccine Initiative have 
maintained and increased their commitment to this area. However funding 
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remains very inadequate for the task in hand and must increase substantially if 
an effective vaccine is to be developed in a time frame appropriate to the scale of 
global mortality and morbidity. A strong economic argument for very large 
increases in malaria intervention funding has recently been made(Sachs, 2002). 
It is vital that funding increases are allocated appropriately between vaccine and 
non-vaccine malaria researchers. The funding crisis could be addressed more 
effectively if a co-ordinated malaria advocacy community existed. Such a 
community is an important factor in the much more substantial funds available for 
HIV vaccine research. The lack of advocacy is largely due to the small number of 
"western" educated individuals who suffer severe malaria as a proportion of the 
total disease burden, although the number will probably continue to increase 
modestly. The challenge therefore is to form such advocacy effectively from a 
disparate group of researchers, non-governmental organisations and government 
officials. As malaria is a poor country disease, rich country markets offer only a 
modest incentive for development of a malaria vaccine. Therefore a significant 
scaling-up of the financing of malaria vaccine research can only occur through 
mobilisation of non-private sector funding. Company involvement in public-private 
partnerships is vital to success but on very different terms to those in private- 
sector funded initiatives. 
The urgent need for an effective vaccine should be stressed strongly. Figure 2.1 
shows a reasonable timeline for vaccine development in which a large efficacy 
trial in infants is still 8 years away. Efficacy studies will often have to progress 
through adults and children aged 1-5 before reaching their target age group of 4- 
6 months. There is a likely need for combination vaccines and therefore most 
likely a requirement for fusion of vaccine development efforts from two or more 
groups. More cooperation between vaccine groups is therefore necessary. We 
believe there is an ethical cost of pursuing a slow, linear approach to vaccine 
trials progression and propose staggered, rapid evaluation of vaccines in field 
settings, after data are available from the country of vaccine origin. At all stages 
care must be taken to ensure high quality data and the safety of study 
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participants is paramount: these are facilitated by clinical trial monitors and data 
and safety monitoring boards for each field efficacy trial. An essential component 
of field studies must be detailed immunology so that partial efficacy can be 
characterised immunologically. Although one candidate vaccine has recently 
moved from first use in humans to a phase I trial in developing countries in 
months, an additional greater challenge is speeding the progression from 
demonstrated efficacy to licensure. With current development paradigms a new 
vaccine that provided near complete efficacy against malaria infection in African 
adults might require another decade of field testing and development before 
licensure for use in young children (figure 2.1). 
Cost of vaccines should be considered from the outset, before large scale 
efficacy trials are planned. This is complicated by the unpredictable but 
anticipated decrease in price of a candidate vaccine over time. With the increase 
in field trials there will be increasing populations of study participants who should 
be followed up in the long term. Funding however rarely exists for more than 1-2 
years per trial: the best way to maintain long term follow up is to conduct 
sequential trials in the same field setting, where possible, and to include 
demographic surveillance infrastructures. A plan should be made in conjunction 
with local governments for provision of vaccine to the country or region 
participating in key pre-licensing field trials. Increasingly, ceasing vaccinations 
once such a trial is over is seen as unacceptable if the intervention has been 
shown conclusively to work. 
Informed consent is a complex issue for the conduct of field efficacy studies. In 
many rural African settings, community consent is as important as individual 
consent. The American-European-Japanese ICH-GCP (International Committee 
on Harmonisation-Good Clinical Practice) guidelines are moving towards the 
status of law in much of the industrialised world. These were drawn up by 
regulatory authorities and pharmaceutical companies with little non-industrialised 
country contribution. The issue of informed consent is often particularly complex 
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for GCP application in non-industrialised countries. GCP consent forms must be 
very detailed in part for the legal protection of sponsors. In the rural Gambian 
setting, for example, the local consensus (of lay Gambian and Gambian 
Government ethical review board members) is that ICH-GCP compliant consent 
forms are not always appropriate. It is important that complex trials are clearly 
explained to participants and local experience is that by repeated delivery of 
complex messages with reinforcement throughout the study adequate 
understanding is possible, but this undertaking is far from trivial. In particular the 
concept that the vaccine under evaluation is not known to protect against malaria 
must be stressed throughout the consent procedure and the study. 
If funding continues to increase in line with recent increases I believe that in time 
a malaria vaccine will be shown to demonstrate useful efficacy in infants. The 
next step would be the conduct of several larger trials in different epidemiological 
settings, perhaps including multiple interventions such as long term insecticide- 
treated bednets. These should be designed, with severe disease or death as an 
endpoint and sufficient sample size, so as to convince local policy makers and 
international funding organisations of the need to implement such a multiple 
intervention (figure 2.2). If vaccine development continues to be funded and to 
accelerate at current rates we can hope for a time when malaria mortality will be 
substantially reduced through multiple interventions including a vaccine. When 
an effective vaccine is developed, public sector funding needs to be provided to 
deliver the product to African infants. Organisations such as GAVI (Global 
Alliance for Vaccines and Immunisation) and the Global Fund for AIDS, 
Tuberculosis and Malaria could have sufficient funds for widespread vaccination 
in the medium term providing the cost is low (of the order of a few dollars a 
dose). The expanded programme of immunisation (EPI) infrastructure would 
need to be improved in many countries to enable adequate population coverage 
however. 
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The technology and required infrastructure now exists for development of an 
effective malaria vaccine; success or failure will depend on the mobilisation of 
financial resources and political commitment. 
2.2 The Gambia 
The Gambia was the site of studies which highlighted the T-cell based approach 
to malaria vaccine design (Hill et at., 1991, Hill et al., 1992, Aidoo et al., 1995). 
The MRC unit in The Gambia has long been a leader in the development of 
vaccines for African populations. Notable examples of vaccines which have been 
developed in The Gambia are the hepatitis B and haemophilus influenzae type b 
vaccines. Both are now part of the Gambian routine infant immunization 
programme largely as a by-product of their field efficacy evaluation by MRC 
Gambia. The MRC Laboratories possess exceptionally good laboratory and field 
trials infrastructure for sub-Saharan Africa. For these reasons we chose The 
Gambia as the site for the first African clinical trials of DNA-based malaria 
vaccines. 
The Gambia gained independence from the UK in 1965. It is a small country 
surrounded on three sides by Senegal and bordering the Atlantic ocean. The 
GDP per capita was $430 in 1994 (World Bank 1996). The Gambia was 163 out 
of 174 countries in the UNDP's human development index in 1997. The economy 
is based on subsistence farming with maize, millet and rice as the main food 
crops. Groundnuts are the most important cash crop although cotton, seafood, 
fruits and vegetables are also exported. The tourism sector is expanding with 
over 100,000 tourists visiting annually (accounting for 11% of GDP). 
The population of The Gambia was 1,411,205 in 2001 and is growing by 
approximately 3.2% each year. The population consists of 14 different ethnic 
groups including the mandinka, wollof, fula, jola, serahuli, serrer, tukulor, balanta, 
bambara, manjago and aku. These have widely differing cultures and many 
unrelated languages. The lingua franca is English although Arabic and French 
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are also spoken by some Gambian residents. In urban areas English language 
education predominates. In rural areas Arabic language education by Muslim 
scholars is more common. 
Life expectancy remains at 54 (in 2001) amongst the lowest in the world. The 
infant mortality rate was 78 per 1000 live births in 2001. Child survival is one of 
the lowest in West Africa. Maternal mortality is also high and shows a clear 
increase in rural vs. urban populations (12 vs. 6 per 1000 live births). Annual 
population growth is one of the highest in the world at 3.2% in 2001 with a very 
high fertility rate. 
The Gambia can be divided into urban and rural areas with one atypical relatively 
large conurbation known as the Kombos. The Kombos, of which Bakau is one 
part, is coastal and the population consists mostly of Gambians and West 
Africans who have moved in search of work. There is increasing contact with and 
reliance on Western tourists for revenue in this area. 
Malaria is highly seasonal in The Gambia with the bulk of infections occurring 
during the rainy season between July and November. Malaria transmission has 
been estimated in coastal Gambia, including the site of the study described in 
Chapter 8, at <1 infectious bite per year. However most adults travel regularly to 
inland areas where the transmission is up to >100 infectious bites per year. In 
The Gambia the age-incidence of malaria mortality peaks at 2-4 (van Hensbroek 
et al., 1996) and is very low after the age of 10. 
Farafenni was the site of studies described in Chapters 10 and 11 and is 170km 
inland, to the east of the Atlantic coast and part of the North Bank Division of The 
Gambia. The population of an area with a 5km radius of the center of Farafenni 
town is about 26,000. There is a district general hospital in Farafenni town. The 
regional government primary health care administrative unit, the divisional health 
team, is also based in Farafenni town. The 13 efficacy study villages comprising 
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the setting for the efficacy study are in 2 groups. 10 villages are east of Farafenni 
and three are west of Farafenni town at distances of up to 41 km. The vegetation 
in the area surrounding Farafenni is Guinea Savannah and is similar to many 
areas in West Africa for example parts of Senegal, southern Mali and northern 
Nigeria. The rural population lives in discrete village units segregated by ethnic 
group. Isolated compounds outside villages are not found in the study area. The 
extended family returns to its ancestral village for the farming season during and 
after each wet season. At the beginning of the dry season men migrate in search 
of labour to urban areas. Rainfall is restricted to between June and November 
with wide year-to-year variations, for example there was a threefold variation 
between 1998 and 1999 from 402mm to 1320mm. No data are available for 
entomological inoculation rates (EIR) for Farafenni town. However a relationship 
for village dwellers has been documented between EIR and distance from the 
flood plain. ElR varies from <10 to >50 over as little as 3km from the river in this 
area of The Gambia (Clarke, 2001). As residents of urban Farafenni, which is 
over 3km north of the river, visit villages near the river often, the volunteers in 
VAC 14 (Chapter 10) will have been intermittently exposed to high El R. The 
volunteers enrolled in the efficacy trial were residents of villages chosen for their 
proximity to the flood plain and so will have been subject to higher still cumulative 
exposure (Chapter 11). 
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Figure 2.2: Endpoints in malaria vaccine field trials 
endpoint 
MILD 
DISEASE 
SEVERE 
DISEASE 
sample size 
C300 
C1,000 
5,000 
DEATH C209000 
An extremely simplified cartoon of sample size and endpoints in malaria vaccine trials. A 
trial in adults can detect 40% efficacy against infection but not disease with only 300 
subjects even in moderate transmission settings. The higher the transmission intensity 
the smaller the necessary sample size. In children aged 1-5 about 1,000 subjects are 
needed to measure efficacy against mild malaria, whereas 5,000 such children would be 
required to measure efficacy against severe malaria and about 20,000 against death. The 
more clinically relevant the endpoint the larger and more complex the trial but the more 
likely the trial would be to change public health policy locally. 
Table 2.1: Some candidate malaria vaccines in clinical trials 
GROUP (FIELD VACCINES (TYPE) TARGET 
COLLABORATION) 
APOVIA INC., GERMANY AND ICC-1132 (PROTEIN) PRE- 
USA/ NEW YORK UNIVERSITY, ERYTHROCYTIC 
USA 
GLAXOSMITHKLINE RTS, S (PROTEIN) PRE- 
BIOLOGICALS, BELGIUM WITH ERYTHROCYTIC 
WRAIR, USA (MRC 
LABORATORIES, THE GAMBIA & 
CISM, MOZAMBIQUE) 
MALARIA VACCINE Pvs25 (PROTEIN) TRANSMISSION- 
DEVELOPMENT BRANCH, BLOCKING 
NATIONAL INSTITUTES OF 
HEALTH, USA 
NAVAL MEDICAL RESEARCH Pf-CS, Pf-SSP2/TRAP, PRE- 
CENTER, USA/ VICAL INC., USA Pf-LSA-1, Pf-EXP-1, Pf- ERYTHROCYTIC 
LSA-3 (DNA 
VACCINES) 
NEW YORK UNIVERSITY, USA CS (SYNTHETIC PRE- 
PEPTIDES, ERYTHROCYTIC 
POLYOXIMES) 
OXFORD UNIVERSITY, UK (MRC DNA ME-TRAP, MVA PRE- 
LABORATORIES, THE GAMBIA ME-TRAP, FP9 ME- ERYTHROCYTIC 
AND WELLCOME-KEMRI UNIT, TRAP, MVA-CS 
KILIFI, KENYA) (DNA & RECOMBINANT 
VIRAL) 
SSI, COPENHAGEN/ INSTITUT GLURP, MSP-3, CS PRE- 
PASTEUR, PARIS/ UNIVERSITY (SYNTHETIC PEPTIDE) ERYTHROCYTIC, 
OF LAUSANNE, SWITZERLAND BLOOD-STAGE 
WALTER AND ELIZA HALL MSP-1, MSP-2, RESA BLOOD-STAGE 
INSTITUTE OF MEDICAL (PROTEIN) 
RESEARCH, MELBOURNE/ QIMR, 
BRISBANE/ SWISS TROPICAL 
INSTITUTE/ BIOTECH AUSTRALIA 
PTY LTD (PAPUA NEW GUINEA 
INSTITUTE OF MEDICAL 
RESEARCH) 
WALTER REED ARMY INSTITUTE FMP-1 (PROTEIN) BLOOD-STAGE 
OF RESEARCH, USA (KEMRI, 
KISUMU, KENYA 
Only candidates in clinical trials as of January 2003 are listed. Similarly field 
collaborations are only listed if field trials of the candidate have begun as of 
January 2003. (see next page for abbreviations specific to this table) 
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Abbreviations for table 2.1 
SSI - Statens Serum Institut, GLURP - Glutamate Rich Protein, MSP - 
Merozoite Surface Protein, Pvs - Plasmodium vivax surface protein, CISM - 
Centro de Investigacao em Saude de Manhica, RESA - Ring Infected 
Erythrocyte Surface Antigen, CS - Circumsporozoite Protein, Pf- Plasmodium 
falciparum, SSP2 & TRAP are synonyms - sporozoite surface protein 2& 
thrombospondin-related adhesion protein, LSA - liver stage antigen, EXP - 
exported protein, KEMRI - Kenya Medical Research Institute, ME - multiple 
epitope, FMP - falciparum malaria protein. 
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Chapter 3 
Background information on the pre-clinical and 
clinical development of DNA 
and recombinant viral vaccines 
3.0 Rationale for T-cell induction based vaccine design in malaria. 
Most licensed vaccines in widespread use are thought to mediate protection by 
induction of long-lived antibody responses. In contrast development of vaccines 
that induce long-lived protective cellular immune responses has proved difficult. 
Three of the most important diseases for developing countries from a public 
health perspective, HIV, malaria and tuberculosis, require induction of cellular 
immune responses for protection against intracellular pathogens. Induction of 
CD8+ T cells has been thought to be particularly desirable for elimination of 
intracellular pathogens and cancer immunotherapy(Gurunathan et al., 2000). A 
large proportion of host cell types express HLA class I molecules and are thus 
amenable to surveillance by CD8+ T cells. Antigen-specific CD8+ T cells are able 
to secrete a variety of effector molecules which directly destroy the pesenting 
cell. Some effector cells release perforin which destroys the infected cell by lysis. 
Others induce apoptosis through the action of granzymes, fas ligand or y- 
interferon, the last of which induces nitric oxide mediated apoptosis. 
HLA class II molecules, which are necessary for interaction with antigen-specific 
CD4+ T cells, are expressed only by a small subset of cell types. In the case of 
malaria vaccination, infected hepatocytes are likely to have higher HLA class I 
expression than class Il expression. Even with good expression'of the relevant 
HLA molecules there are other prerequisites for translation of T-cell 
46 
immunogenicity to efficacy. The malaria epitopes to which vaccine-induced 
memory T cells are specific must bind to HLA molecules intracellularly and then 
be expressed on the cell surface in association with the HLA molecule. If any one 
of expression, proteolytic processing or HLA presentation is inadequate, 
inhibition of liver-stage parasites will not occur. Experiments assessing 
processing and presentation of malaria epitopes during liver-stage malaria in 
human hepatocytes in vivo are not possible currently. There is evidence that 
human T cells specific for liver-stage malaria epitopes are primed in vivo. Such T 
cells with a y-interferon effector function have been detected in the peripheral 
blood of humans living in malaria-endemic countries, but at very low 
frequency(Plebanski et al., 1997, Aidoo et al., 1995). However this may occur by 
antigen transfer to professional antigen-presenting cells and there is no direct 
evidence that such T cells have a protective effect against infected hepatocytes. 
There are conflicting data from longitudinal studies in endemic countries on the 
protective role of antibody responses to pre-erythrocytic antigens(Hoffman et al., 
1987). Limited data are available to support a protective role for T cell responses 
to pre-erythrocytic stages in naturally acquired immunity (Reece et al., submitted) 
(Kurtis et al., 1999), although this could be due to the use of inadequate T cell 
assays or a current lack of knowledge of the critical antigens for T-cell mediated 
pre-erythrocytic immunity. T cell migration may play a key role in protective 
immunity(Rodrigues et al., 1992, Renggli et al., 1995). 
There are however several persuasive types of indirect evidence for a protective 
role for T-cells specific for pre-erythrocytic P. falciparum antigens in humans. The 
first and, in my opinion most compelling evidence, stems from the irradiated 
sporozoite immunization model. Exposure of humans to the bites of P. falciparum 
infected X-ray irradiated mosquitoes allows inoculation of attenuated sporozoites. 
In the early 1970s it was discovered that exposure to >1000 such bites, in 
batches over several weeks to months, could afford sterile immunity to challenge 
with infectious sporozoites(Clyde et al., 1973). The dose of radiation must be 
such that attenuated sporozoites are able to invade hepatocytes but not complete 
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the liver-stage. They persist within hepatocytes for months in mouse 
models(Scheller and Azad, 1995). Increasing the dose of attenuation to a level at 
which sporozoites are rendered unable to invade hepatocytes abrogates 
protection. In addition chemotherapy that clears intra-hepatic parasites also 
abrogates protection. There is thus a strong implication that protection is cell- 
mediated and against infected hepatocytes in this model. Protection is species- 
specific but not strain-specific and is of up to 10 months duration(Hoffman et al., 
2002). Protected volunteers possess circulating CD8+ and CD4+ T cells specific 
for liver-stage epitopes(Malik et al., 1991, Moreno et al., 1991, Wizel et al., 1995). 
There is no immunodominance in protected humans and the consensus is that 
immunity is conferred by an integration of low to moderate level T-cell responses 
to many antigens expressed in the liver-stage, although data on characterization 
of immune responses in protected individuals are limited. 
A second line of evidence is the finding that humans who possess the B53 allele 
of the HLA-B gene are protected from severe malaria in The Gambia(Hill et at., 
1991). Further work showed that such individuals have a specific cell-mediated 
immune response to liver-stage malaria. CD8+ T cells in their peripheral blood 
are able to recognise a short peptide sequence from LSA-1, a pre-erythrocytic 
antigen(Hill et at., 1992). This finding would be strengthened by confirmation by 
other studies. 
Thirdly, some P. falciparum CD8+ epitopes are in highly polymorphic regions in 
which all nucleotide substitutions encode amino acid changes. The observation 
that no synonymous changes occur argues strongly that these regions are 
subject to selection pressure from T cells(Good et al., 1988) and the identification 
of altered peptide ligand antagonism of CTL as an immune escape mechanism 
supports this view(Gilbert et al., 1998). The evidence for T cell selection pressure 
opens up an uncertainty about whether candidates for T cell based vaccination 
should be from conserved regions of antigens or from those regions with 
demonstrated T cell selection pressure. DNA-based vaccines including 
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conserved regions would be less likely to be susceptible to T-cell escape but may 
be less likely to induce protective responses. These regions may be conserved 
because they are not processed or presented during natural infection. However 
T-cell escape is likely to occur if regions subject toT-cell selection pressure are 
used. 
The direct evidence for a protective role of T cells is from animal models. Early 
evidence that CTL induction might be relevent to protection was provided by 
analysis of the mechanisms of protection in a rodent model of irradiated 
sporozoite immunisation(Schofield et al., 1987). CTL clones induced by this 
means were found to transfer protective immunity to Plasmodium berghei 
sporozoite challenge in mice(Romero et al., 1989). CTL recognition of 
circumsporozoite protein-derived peptide on infected hepatocytes led to lysis of 
the infected cell and parasite death(Weiss et at., 1990). 
3.1 DNA vaccines. 
A major challenge in vaccine design has been the induction of CD8+ T cells. In 
the case of malaria cellular immune responses mediated by y-interferon are 
critical for protection against the liver-stage. In recent years the class of vaccines 
known as DNA vaccines has been highlighted as being of particular promise for 
induction of strong, durable cellular immune responses. 
A standard DNA vaccine consists of a plasmid DNA backbone into which gene(s) 
of interest are cloned. A promoter suitable for good mammalian expression such 
as cytomegalovirus IE1 (immediate early 1) is necessary. Polyadenylation 
termination sequences are important for mRNA transcript stability. A prokaryotic 
origin of replication allows propagation in for example E. Coli. It has been the 
norm to include an antibiotic resistance marker gene. A study in 1990 showed 
that direct intramuscular injection of plasmid DNA could induce protein 
expression in myocytes(Wolff et al., 1990). In 1993 protective CTL mediated 
immunity by DNA vaccination in mouse models was demonstrated(Ulmer et al., 
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1993). In 1994 this was demonstrated in a mouse model of malaria, confirming 
that in mice, the principle also worked for a complex parasitic pathogen(Hoffman 
et al., 1994b). 
CpG motifs have an important role in the immunogenicity of DNA 
vaccines(Klinman et al., 1999). These motifs are made up of cytosine-phosphate- 
guanosine repeats with flanking regions. These sequences are optimally 
unmethylated and 20 fold more common in prokaryotic than mammalian 
DNA(Sato et al., 1996). They induce y-interferon and IL-12 in vitro and thus may 
be important in the apparent Th1 bias of most DNA vaccines(Klinman et al., 
1996). DNA vaccination facilitates de novo synthesis of recombinant protein 
within cells for optimal antigen-presentation and priming of naive CD8+ T cells. 
Intradermal DNA vaccination by gene gun is known to transfect a proportion of 
the class of highly efficient antigen-presenting cells known as dendritic cells 
(DCs) (Corr et al., 1996). Transfected DCs prime naive CD8+ T cells directly. 
However after intramuscular DNA vaccination antigen transfer from transfected 
myocytes to DCs may be necessary for CD8+ T cell priming because significant 
DC transfection may not occur (Ulmer et al., 1996) (Fu et al., 1997). This is 
known as cross-priming. 
A study published in 1998 demonstrated for the first time induction of CTL 
responses in humans after DNA vaccination(Wang et al., 1998). The DNA 
vaccine was recombinant for Plasmodium falciparum CS and was given 
intramuscularly three times at doses up to 2.5 mg with CTL responses measured 
after the third dose. Subsequently there have been clinical trials of malaria DNA 
vaccines for CS and 4 other pre-erythrocytic vaccines with CD8+ T cell 
responses obtainable after in vitro expansion but low magnitude responses by y- 
interferon ELISPOT, no antibody induction and no protection in the Ila 
model(Wang et al., 2001) (Richie et al., 2001). Development of detectable 
antibody titres has occurred in"some individuals after challenge although this 
finding is of questionable significance. Similar poor immunogenicity has been 
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seen in HIV clinical DNA vaccine trials(MacGregor et al., 1998) (Boyer et al., 
2000) (MacGregor et al., 2002). Antibody induction through clinical DNA 
vaccination has been achieved with a Hepatitis B DNA vaccine administered by a 
needleless delivery device (also known as a gene gun) (Roy et al., 2000). It 
appears that Hepatitis B is an unusual immunogen. This result is therefore 
probably an exception. Most data indicate that antibody induction after DNA 
vaccination in man is very poor in contrast to some non-human primate models. 
3.2. Recombinant viral vaccines. 
The successful worldwide eradication of smallpox via vaccination with live 
vaccinia virus highlighted vaccinia as a candidate for recombinant use(Moss, 
1996). The prospect of recombinant viral vaccines was heralded by studies in 
1982 which described the genetic engineering of vaccinia virus to express foreign 
genes(Mackett et al., 1982) (Panicali and Paoletti, 1982). An early example of a 
successful veterinary recombinant viral vaccine is a recombinant vaccinia 
expressing a rabies virus antigen. This vaccine is licensed and has been effective 
by the oral route for control of rabies in foxes in Europe and raccoons in the 
USA(Kieny et al., 1984). Double stranded DNA viruses such as vaccinia are the 
most commonly used class of virus as candidate vectors, although there are 
methods for insertion of cDNA-derived RNA into some RNA viruses(Li et al., 
1993). However there are many viruses for which stable expression of inserted 
foreign genes has not yet proved possible. The greater part of the clinical 
experience with recombinant viral vaccines has been with recombinant 
poxviruses(Paoletti, 1996). 
Although millions of humans have been vaccinated with conventional live 
vaccinia virus with no ill effect, its small but definite risk to both researchers and 
future patients led to the development of several highly attenuated replication- 
deficient strains of vaccinia during smallpox eradication(Fenner et al. ) and more 
recently(Tartaglia et al., 1992, Paoletti et al., 1994, Paoletti, 1996, Kaplan, 1989). 
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One such strain, NYVAC, was developed as the basis for the first malaria 
recombinant viral vaccine NYVAC-Pf7 by Tine et al. (see section 2.1). As the 
immunogenicity of NYVAC and modified vaccinia virus Ankara appeared 
comparable in pre-clinical studies, this suggested that MVA recombinants could 
also be of some value as malaria vaccines, as well as being potentially more 
effective in heterologous prime-boost immunisation regimes(Schneider et al., 
1998). 
3.3 Modified vaccinia virus Ankara. 
Attenuated vaccinia virus strains were developed during the smallpox vaccination 
era to reduce possible side effects associated with using live vaccinia virus 
vaccines. In particular the host-range restricted modified vaccinia virus Ankara 
(MVA) proved to be extremely attenuated compared to wild-type(Mayr, 1976, 
Mayr et al., 1978, Werner et al., 1980). MVA was originally derived from the 
vaccinia strain Ankara by over 570 serial passages in primary chicken embryo 
fibroblasts. MVA has six major fully characterized genomic deletions compared to 
the parental genome severely compromising its ability to replicate in mammalian 
cells(Meyer et al., 1991). Deletions include host range genes and genes 
encoding cytokine receptors. Viral replication is blocked late during infection of 
cells but importantly viral and recombinant protein synthesis is unimpaired even 
during this abortive infection(Sutter and Moss, 1992), making MVA an efficient 
single round expression vector incapable of causing disseminated infection in 
mammals. The entire DNA sequence of MVA has been published(Antoine et al., 
1998). In the final stages of the smallpox eradication programme MVA was 
administered to over 120,000 individuals. No significant side-effects were 
recorded despite the deliberate vaccination of high risk groups(Stickl et al., 1974, 
Mahnel and Mayr, 1994). This safety in man is consistent with the avirulence of 
MVA in animal models(Mayr et al., 1978). Replication-deficient recombinant MVA 
has been seen as an exceptionally safe viral vector(Sutter and Moss, 1992). 
When tested in animal model studies recombinant MVAs have been shown to be 
avirulent, yet protectively immunogenic as vaccines against viral diseases and 
52 
cancer(Sutter et al., 1994, Hirsch et al., 1996, Wyatt et al., 1996, Carroll et al., 
1997, Hanke et al., 1999). 
3.4. Fowlpox strain 9. 
Some avipoxviruses have been characterised as candidate vectors, in particular 
the ALVAC strain of canarypox(Fries et al., 1996). Extensive studies of ALVAC 
have been undertaken for HIV(Clements-Mann et al., 1998). Fowlpox is an 
avipoxvirus which causes disease in chickens but not mammals. Recombinant 
attenuated fowlpox has been used as a rabies vaccine in mammals, in which it 
shows good recombinant protein expression(Taylor et al., 1988). Fowlpox strain 
9 (FP9) was derived from wild type fowlpox virus by 400 passages in tissue 
culture, leading to marked attenuation and loss of pathogenicity in chickens by all 
routes of administration to the extent of avirulence in one-day old chicks(Mayr 
and Malicki, 1966). Recombinant FP9 has been used as a vaccine in chickens 
(Mayr et al., 1971). This attenuated virus, then called PIND-AVI, was used in 
clinical studies in a variety of formulations and with various routes of 
administration in several hundred people. These studies are reported in the 
German literature and it appears that no serious adverse events occurred. In the 
UK a clone of this vector has been developed and characterised in detail as a 
candidate vector by researchers at the Institute of Animal Health in Compton 
where it was named FP9(Mockett et al., 1992). Like all avipoxviruses, FP9 does 
not replicate in mammalian cell lines in vitro. Attenuated strains of fowlpox virus, 
such as TROVAC have been used safely as recombinant viral vaccines in many 
human clinical trials and have been demonstrated to be non-virulent in a variety 
of immunosuppressed animals and human volunteers. The extensive clinical 
experience with ALVAC as a vector is relevant as this is a closely related 
avipoxvirus. FP9 ME-TRAP is the first recombinant FP9 to have been used in 
clinical trials to our knowledge. 
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3.5. Enhanced immunogenicity and efficacy by immunisation with a 
combination of delivery systems 
In order to induce immune responses against an antigen a candidate vaccine 
must present the immune system with foreign antigen, usually in the form of 
protein sequences or alternatively as DNA-based vaccines, two classes of which 
have been described above - DNA vaccines and recombinant viral vaccines. 
(Lipids and carbohydrates have also been components of some non-malaria 
vaccines, but will not be discussed here. ) Protection obtained with DNA vaccines 
and recombinant viral vaccines in animal models of malaria tended to be 
unsatisfactory. A minority of animals were protected against low dose sporozoite 
challenge. Immunisation with an influenza virus recombinant for a single P. yoelii 
CS CD8+ T cell epitope followed 3 weeks later by a vaccinia recombinant for 
whole P. yoelii CS induced complete protection of 9/15 mice against high dose 
sporozoite challenge(Li et al., 1993). The vaccination approach of using two 
delivery systems encoding the same or related constructs has been called 
heterologous prime-boost immunisation. 
The first delivery system in the combination is known as the prime and the 
second is known as the boost. DNA vaccines can prime efficiently but cannot 
boost. Poxviruses can boost efficiently. The greater the attenuation of vaccinia 
virus from replication-competent to NYVAC or MVA, the greater the 
immunogenicity of boosting(Schneider et al., 1998). FP9 and ALVAC boost 
efficiently. Both FP9 and MVA have also been shown to prime for heterologous 
boosting(Anderson et al., 2004). Recombinant protein subunit vaccines have also 
been used as part of prime-boost strategies, clinically in combination with 
ALVAC-HIV recombinants(Clements-Mann et at., 1998) and malaria DNA 
vaccines (Wang et al., 2004) or malaria MVA vaccines (S Dunachie et at., 
unpublished data). 
The experiments in our laboratory which provided the impetus for the clinical 
trials which form the basis of this thesis were as follows. In a series of 
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immunisation studies in mice various delivery systems (recombinant particles, 
peptides, plasmid DNA, numerous adjuvants and recombinant vectors such as 
recombinant BCG, Salmonella, adenovirus, MVA and FP9), encoding malaria 
epitopes and antigens, were compared. Most of these approaches induced only 
modest levels of T lymphocyte response. A priming immunisation with plasmid 
DNA encoding an entire murine malaria pre-erythrocytic antigen followed by a 
booster immunisation with MVA vector carrying the same antigen (either CS or 
TRAP) induced complete protection in strains of mice highly susceptible to 
sporozoite challenge in some experiments(Schneider et al., 1998). By 1998 the 
DNA/MVA heterologous prime boost combination had repeatedly shown very 
high immunogenicity and efficacy in mouse models(Plebanski et al., 1998) 
(Gilbert et al., 1999). Similar results for a different mouse malaria model were 
reported by an American group(Sedegah et al., 1998). Induction of CD8+ T cells 
was assessed by both conventional Cr" lysis assays after in vitro restimulation 
and fresh y-interferon ELISPOT assays. The latter assay showed the best 
association with efficacy. 
In several further studies DNA/MVA and other prime-boost regimes have been 
highly immunogenic for CD4+ and CD8+ T cell induction against Hepatitis B 
(McConkey et al. unpublished data), tuberculosis(McShane et al., 2001), 
HIV(Hanke et al., 1999), ebola(DNA/adenovirus) (Sullivan et al., 2000) and 
melanoma in both murine and non-human primate studies. DNA/MVA polyprotein 
vaccinations controlled a mucosal challenge of a highly pathogenic SIV/HIV 
chimaera and prevented AIDS in a macaque model. In this study challenge 
occurred 7 months after final vaccination(Amara et al., 2001). Interestingly two 
vaccinations with a DNA-HIV construct followed by a single adenovirus-HIV boost 
gave much higher immunogencity (about 20% vs 5% in a class I tetramer assay) 
but slightly lower efficacy than three vaccinations with the recombinant 
adenovirus without DNA priming in a macaque model (Shiver et al. 2002). 
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3.6 Mechanism of CD8+ T cell induction by heterologous prime-boost 
immunisation 
Many viral vectors, mostly poxviruses, amplify CD8+ T cell frequencies in 
heterologous prime-boost regimes. DNA vaccines are limited in their 
immunogenicity by the nanogram to picogram quantities of recombinant protein 
which can be expressed. An advantage of such immunogenicity is that it is highly 
focussed. Viral vectors produce greater quantities of recombinant protein but also 
induce polyclonal responses to many vector immunogens. If a viral vector 
immunisation is administered after a DNA immunisation, DNA vaccine-induced 
memory T cells are amplified rapidly with the kinetics of a secondary immune 
response. Although a primary immune response also occurs to vector antigens 
the tendency of the immune system to produce a few immunodominant 
responses probably leads to the high amplitude responses being directed against 
the recombinant insert. Thus the priming immunisation generates insert-specific 
T cells which are amplified strongly by the viral vector boost(Schneider et al., 
1999). 
If a viral vector boost is administered after a heterologous viral priming 
immunisation the efficiency of the boosting effect is presumably determined by 
the proportion of immunogens with cross-reactivity between vectors. The more 
cross-reactive epitopes, the smaller the likelihood that epitopes from the insert 
will be "selected" for amplification. In murine malaria experiments by several 
groups, recombinant vaccinia viruses have been particularly good for CD8+ T cell 
induction after boosting, whether after DNA(Schneider et al., 1998), recombinant 
influenza(Li et al., 1993). adenovirus(Gilbert et al., 2002), Ty-VLPs(Plebanski et 
at., 1998), fowlpox(R Anderson, unpublished data) or a recombinant protein 
particle in a murine hepatitis B model(P Gothard, unpublished data). A time 
interval is necessary before the prime-boost phenomenon can be observed. In 
the BALB/c mouse model 9 days are required after DNA immunisation before 
induced T cells are fully boostable. Not all delivery systems are able to boost T 
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cell induction as part of a combination. DNA vaccines and Ty-VLPs were unable 
to boost after MVA immunisation(Plebanski et al., 1998). So delivery systems are 
either boosting or non-boosting systems. Possible reasons for this difference are 
recombinant protein expression levels, the need for additional as yet unconfirmed 
signals for either APC maturation or T cell modulation and the relatively low rate 
of APC infection with these carriers compared to viral vectors. 
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Chapter 4 
The Candidate Malaria Vaccines DNA ME-TRAP, 
MVA ME-TRAP and FP9 ME-TRAP 
4.0 The Multiple Epitope String 
Antigens or epitopes for inclusion in a malaria vaccine should be chosen for 
induction of protective immunity. This choice has been complicated by the lack of 
both relevant animal models and immune correlates of protection for P. 
falciparum. The malarial insert, ME-TRAP, combines two complementary 
approaches. Firstly the identification of CD8+ T cell epitopes and inclusion as an 
epitope string. Secondly the inclusion of a whole antigen. 
Possession of the HLA-B53 allele confers protection against severe malaria in 
Gambian children(Hill et al., 1991). The molecular basis of this protection is 
thought to be the ability of HLA-B53 to bind Is6, a nonamer epitope from LSA-1, 
and thus induce protective CTL to infected hepatocytes(Hill et al., 1992). The 
specificity of this HLA restriction was discovered by a "reverse immunogenetics" 
approach, which was extended in later work. The DNA sequences of 6 pre- 
erythrocytic P. falciparum antigens (CS, TRAP, LSA-1, EXP-1, LSA-3 and 
STARP) were screened using allele-specific motifs for HLA-B53, HLA-B35, HLA- 
B7, HLA-B8, HLA-A2 and HLA-B17. These 6 HLA types are found in 75% of 
Gambians and 70% of caucasians. Assembly assays were used to assess the 
binding of potential epitopes thus identified to HLA molecules. CTL assays on 
Gambian adults and children were then used to confirm functional epitopes. 
Blood was obtained from children either during acute malaria or convalescence. 
14 CD8+ T cell epitopes were thus identified. More recently another HLA-B53- 
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restricted epitope was identified in another antigen expressed by liver-stage 
parasites, LSA3 (Aidoo et al., 2000) 
The ME string consists of the DNA sequences for all 14 epitopes fused to the 
following additional sequences: three CD4+ T cell epitopes from P. falciparum 
CS, BCG and tetanus toxoid; a P. falciparum CS B cell epitope; a P. falciparum 
TRAP B cell epitope and pb9, a P. berghei CD8+ mouse T cell epitope to enable 
potency testing of each clinical batch in mice. Six Ty-VLP constructs including 
various combinations of the ME string constituent epitopes were used to evaluate 
processing and presentation of single epitopes from a string(Gilbert et al., 1997). 
All 5 P. falciparum epitopes tested were processed and presented in vitro for both 
restimulation of CTL responses from malaria-exposed donors and induction of 
primary CTL responses. pb9 was processed and presented in vivo from various 
positions in a string for priming of CTL in murine experiments. A Ty-VLP 
construct including pb9 as the only murine malaria sequence was shown as part 
of a Ty-VLP/MVA immunisation regime to not only induce high level y-interferon 
effector T cell immunogenicity but also to be 100% protective in a murine 
experiment. More recently T cell responses to these epitopes have been found 
to correlate with protection from malarial anaemia in Kenyan children (Ong'echa 
et al., 2003) 
An Advanced Blast P2.0.8 search was conducted using the National Center for 
Biotechnology Information protein database in May 1999 to search for 
homologies between the multiple epitope string and all reported human protein 
sequences. This revealed the expected homologies between the TRAP AM 
peptide and members of the human thrombospondin/properdin family. As this 
peptide is not a novel sequence created by the fusion of epitopes, but is 
contained in P falciparum parasites, and has been a constituent of other malaria 
vaccines this is not believed to be a safety concern. Nucleotide homology 
searches were also undertaken. No new homologies were found which are not 
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present in the individual epitopes and to which humans are therefore exposed 
due to natural infection. 
4.1 The TRAP antigen as a vaccine candidate 
The ME string is fused in frame to the entire T9/96 strain coding sequence of 
P. falciparum TRAP to generate the 2389 base pair ME-TRAP hybrid malarial 
DNA sequence, encoding a single 789 amino acid polypeptide. The CS antigen is 
the best characterised pre-erythrocytic P. falciparum antigen. Most previous 
published work on malaria candidate vaccines has been on CS-based 
candidates. TRAP was chosen as a well-characterised pre-erythrocytic antigen 
with a homologue that is protective in rodent models and with less polymorphism 
than CS. Most T cell responses to CS are focussed on a few highly variable 
regions(Good et at., 1988). T cell responses to TRAP are broadly distributed with 
no immunodominant loci(Flanagan et al., 1999). TRAP is an abundant pre- 
erythrocytic stage antigen(Rogers et al., 1992). Human volunteers immunised 
with irradiated sporozoites and protected against malaria develop T cell 
responses against TRAP(Wizel et at., 1995), as do residents of malaria-endemic 
countries (Flanagan et al., 1999). 
4.2 DNA ME-TRAP 
The DNA vaccine DNA ME-TRAP consists of the 6773 base pair malarial 
expression vector pSG2. This includes the ME-TRAP hybrid malaria insert. 
Expression of this cloned malarial DNA sequence is regulated by a standard set 
of control elements, consisting of the human cytomegalovirus (CMV) IE1 
(immediate early 1) enhancer/promoter and intron A and the bovine growth 
hormone-derived polyadenylation signal (bGH. polyA). The polyadenylation 
serves to improve mRNA transcript stability. A kanamycin antibiotic resistance 
gene is included as a marker gene suitable for clinical use as kanamycin is no 
longer used in the clinic. A prokaryotic origin El is included for propagation within 
E. coli but not mammalian tissue. 
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4.3 MVA ME-TRAP 
MVA ME-TRAP vaccine consists of MVA, and the identical ME-TRAP hybrid 
encoded by DNA ME-TRAP. The ME-TRAP sequence was ligated into the 
vaccinia shuttle vector pSC1 1 such that it will be expressed by the vaccinia P7.5 
early/late promoter. 
This vector includes the E. coli ß-galactosidase gene expressed by the vaccinia 
P11 late promoter. The region including ME-TRAP and the ß-galactosidase gene 
is flanked by a sequence from the vaccinia thymidine kinase locus to allow 
insertion into the vaccinia genome at this locus. CEF cells infected with wild type 
MVA virus were transfected with pSC1 1 ME-TRAP and in vitro recombination 
allowed to take place. Recombinant virus was identified using ß-galactosidase 
substrate X-gal overlay of infected chicken embryo fibroblast (CEF) monolayers 
and isolated by multiple rounds of plaque picking(Chakrabarti et al., 1985). A 
stock of MVA ME-TRAP was supplied to contract manufacturer IDT (Rosslau, 
Germany) for production of the master seed virus and clinical lot, which was 
produced under cGMP manufacturing conditions. 
4.4 FP9 ME-TRAP 
The vaccine consists of the attenuated fowipox virus, FP9 and the identical ME- 
TRAP insert encoded by DNA ME-TRAP and MVA ME-TRAP. 
The ME. TRAP fusion protein sequence was ligated into the unique cloning site 
after the P7.5 promoter in the FP9 shuttle vector pEFL29 (Qingzhong et al., 
1994). This vector includes the E. coli ß-galactosidase gene expressed by the 
FPV p4b promoter, late fowlpox promoter, to allow detection of the recombinant 
virus. The region including the gene of interest driven by the Vaccinia P7.5 
promoter, and the ß-galactosidase gene is flanked by sequence from the FP9 
ORF1 locus to allow insertion into the FP9 genome at this locus. 
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Specific pathogen free CEF cells were infected with wild type FP9 supplied by 
Michael Skinner, Institute of Animal Health, Compton, UK. The infected cells 
were then transfected with the pEFL29 ME. TRAP shuttle vector and in vitro 
recombination was allowed to take place. Virus harvested from the in vitro 
recombination mixture was diluted and plated on fresh unpassaged CEF 
monolayers which were overlaid with medium containing agarose after infection 
and incubated for four days to allow viral plaques to develop. A second overlay 
containing the ß-galactosidase substrate X-gal was then added and the 
monolayers were incubated for a further 24 hours, after which time plaques 
containing recombinant virus had turned blue. 
Well isolated blue plaques were picked from the monolayer using a sterile pipette 
tip and placed in a small volume of sterile phosphate buffered saline (PBS). This 
was then frozen and thawed three times to lyse the CEF cells and release the 
virus. The resulting virus was again diluted and plated on CEF monolayers and 
the recombinant plaque picking was repeated five times in total to ensure the 
purification of the recombinant FP9 ME. TRAP away from the wild type virus 
Unpassaged CEF monolayers were then inoculated with the purified virus to 
obtain a stock of FP9 ME. TRAP. This was then titred using CEF cells. The 
infected monolayer was incubated until white plaques were visible (five days). A 
second agarose overlay containing X-gal was added. The monolayers were 
incubated for a further 24 hours and then examined to see if all plaques were 
blue. Any remaining wild-type virus would form a white plaque, but all plaques 
were found to be blue. 
The initial stock of recombinant FP9 was then inoculated into fresh CEF 
monolayers to produce a manufacturers stock which was passed through a 0.2 
micron filter to ensure absence of bacterial or fungal contamination, then supplied 
to IDT for production of the master seed virus and the clinical lot. 
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Table 4.1: Epitopes within the ME string 
Epitope Antigen Amino acid Sequence Type HLA 
restriction 
st8 STARP MINAYLDKL CTL A2.2 
Is50 LSA-1 ISKYEDEI CTL B17 
pb9 Pb CS SYIPSAEKI CTL H2-K 
Is8 LSA-1 KPNDKSLY CTL B35 
cp26 CS KPKDELDY CTL B35 
Is6 LSA-1 KPIVQYDNF CTL B53 
tr42/43 TRAP ASKNKEKALII CTL B8 
tr39 TRAP GIAGGLALL CTL A2.1 
cp6 CS MNPNDPNRNV CTL B7 
tr26 TRAP HLGNVKYLV CTL A2.1 
Is53 LSA-1 KSLYDEHI CTL B58 
tr29 TRAP LLMDCSGSI CTL A2.2 
CS CS DPNANPNVDPNANPNV T helper Universal 
38H BCG QVHFQPLPPAVVKL T helper epitopes 
F'TTp TT QFIKANSKFIGITE T helper 
cp39 CS YLNKIQNSL CTL A2.1 
1a72 LSA-3 MEKLKELEK CTL B8 
ex23 EXP-1 ATSVLAGL CTL B58 
NANP CS NANPNANPNANPNANP B cell 
AM TRAP DEWSPCSVTCGKGTRSRKRE Putative B cell 
The epitopes were encoded end to end within the ME string in the order shown above. 
The final epitope is encoded end to end with the PfTRAP sequence. 
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Figure 4.1: DNA ME-TRAP 
wndui 64sf_ 
XhoI 5941 
KanR 
Pvutt 496 
Xhoi 4777 
Sall 4771 
Xhot 4751 
Pvuil 4744 
Xbal 4439 / 
Xhoi 4427 // 
ý 
Nou 4421 
EcoRt 4394 
BamHI 4363 
PSG. ME. TRAP 
6773 bp 
CAB 
BGH polyA 
WE 
pITRAP 
1 739 
Xbal 2647 
ßamH 1 2662 
69111 2814 
Kpn1 3455 
EcoRI 3161 Oral 3104 
1 1764 
Hindill 1947 
Kpnl 1057 
Bamlil 1965 
©gIll 2242 
Schematic representation of the plasmid DNA vaccine encoding ME-TRAP. 
The MVA and FP9 vaccines expressed the same insert. KanR represents 
the kanamycin resistance gene. pCMV represents the human CMV 
immediate early 1 promoter. CAB and DHFE together represent the ME 
string. CAB represents the first 9 epitopes of the string. PfTRAP represents 
the TRAP gene. BGHpolyA represents the bovine growth hormone 
polyadenylation site. 
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Chapter 5 
General Methods 
5.0 Ex vivo y-interferon ELISPOT assay 
The vaccines were designed for maximal induction of cellular immune responses. 
Pre-clinically DNA/MVA leads to efficient induction of antigen-specific T cells with 
rapid effector function for y-interferon secretion as assayed by a y-interferon 
ELISPOT assay. Previous published antigen-specific T cell induction through 
clinical DNA vaccination was assayed in a CTL assay performed on in vitro 
restimulated cell lines(Wang et al., 1998). These assays provide high sensitivity 
for detection of antigen-specific T cells either present at very low frequency or 
without rapid effector function. However T cells able to secrete relevant effector 
molecules such as y-interferon without a requirement for cell division or 
prolonged stimulation are more likely to eliminate infected hepatocytes in vivo 
than those with such a requirement. T cells specific for influenza epitopes and 
with rapid y-interferon effector function have been shown to be present in the 
peripheral blood of humans many months to years after the most recent 
exposure to pathogen(Lalvani et al., 1997). These cells were enumerated by an 
ex vivo y-interferon ELISPOT which was modified for use in these clinical trials. 
ELISPOTs were performed on Millipore MAIP S45 96-well plates with MabTech 
human y-interferon monoclonal antibodies. Plates were coated overnight at 4°C 
with 50µI per well of 10µI/ml 1-D1 K capture antibody diluted in Sigma pH9.6 
carbonate/bicarbonate coating buffer or sterile PBS. The plates were washed 6 
times with sterile PBS and blocked for at least 1 hour at room temperature with 
Sigma RPMI-1 640 containing 10% foetal bovine serum (FBS) and with I- 
glutamine and penicillin/streptomycin supplementation (R10). Medium was Sigma 
RPMI-1640 with 10% human AB serum and 1-glutamine and 
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penicillin/streptomycin supplementation (RN10). 4x 105 PBMCs in a total volume 
of 100pl were assayed for 18-20 hours at 37°C in a humidified 5% CO2 incubator 
on the ELISPOT plates in the presence of 25 pg ml" peptides. Blood volume 
limitations precluded assaying peptides individually. 20-mer peptides overlapping 
by 10 were used in pools to span the entire T9/96 and 31D7 strain of the TRAP 
antigen. 8-mer to 17-mer epitopes from the ME string were also assayed in 
pools. Although 20-mer peptides are suboptimal for formation of the T cell-APC 
synapse, it is known that both CD8+ and CD4+ T cell responses can be detected 
with 20-mer peptides when used at high concentrations such as 25 Ng ml's. 
After the 18-20 hour incubation period, plates are flicked and washed 6 times 
with PBST (PBS with 0.05% Sigma Tween20 added). 50µI of 1 µl/ml of 7-B6-1 
detector antibody diluted in PBS is added per well and incubated at room 
temperature for 2-4 hours or overnight at 4°C. Plates are then flicked, washed 6 
times with PBST before addition of 50µI per well of 1 µI/ml of streptavidin-alkaline 
phosphatase antibody diluted in PBS. This is incubated for 1 hour at room 
temperature before flicking and washing 6 times with PBST. Development is with 
BioRad alkaline phosphatase reagents which lead to production of a blue/purple 
spot. Plates must be washed several times with tap water and left to soak in 
water preferably overnight before thorough drying. The colour of the spots fades 
gradually with time but this fading can be slowed by storage in the dark. In this 
way plates can be read without loss of data several months after the day of 
development. Ideally however plates should be read as soon as they are dry. 
5.0.1 Analysis of ex vivo ELISPOT immunogeniclty 
Means of duplicates were calculated for negative controls and test wells. A> 50 
SFC per million PBMC (spot forming cells per million peripheral blood 
mononuclear cells) level in the negative control was used to exclude plates with 
high background from the analysis. Spots were summed across relevant pools 
with the negative control subtracted the requisite number of times and values 
were adjusted to SFCs per million PBMCs. As 20-mer peptides overlapping by 
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ten were used it is possible that some responses were counted twice by this 
method. This procedure derives summed responses for T9/96 TRAP, 3D7 TRAP, 
ME peptides and all peptides in the construct (the sum of T9/96 TRAP and ME 
responses). The pre-vaccination summed responses for each volunteer were 
subtracted from the post-vaccination responses and negative induced responses 
were set to zero. By setting negative responses to zero, the sensitivity of the 
analysis was maximized and the absolute number of reactive cells is likely to 
have been slightly inflated. Biologically plausible hypotheses were made, thus 
specifying comparisons to be performed between vaccination groups or between 
T9/96 and 3D7 TRAP responses in the same group. All comparisons in the text 
are either of two groups of induced responses or an post-vaccination response 
with a pre-vaccination response. Groups of responses are positively skewed (i. e. 
to the right on a conventional graphical representation). The median is therefore 
usually smaller than the arithmetic mean. The variance of datasets is related to 
the size of the response and therefore when comparing two groups for magnitude 
of immunogenicity the variances are often markedly dissimilar. These datasets 
are often not normally distributed with or without log-transformation. Arithmetic 
means are used for visual representation of data as this has intuitive meaning to 
the reader whereas geometric means or medians with interquartile ranges are 
used in the text as these have more meaning and validity particularly for the 
purposes of significance tests. A table (table 7.2) giving comparisons within the 
UK data of geometric means and arithmetic means is provided to allow 
interpretation of the distibution of the data. Individual test responses in the ex 
vivo ELISPOT are not defined as positive or negative, rather they are summed as 
described above and then summed responses are compared between timepoints 
or between groups by the Mann-Whitney test. This statistical method was chosen 
to allow comparison of the magnitude of responses between timepoints and 
between groups. The view of our group was that negative responses do not have 
any biological meaning leading to our decision to set negative responses to zero. 
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5.0.2 Characterisation Of T cell subsets by CD4 and CD8 cell depletion. 
Cell separations were performed on PBMCs frozen in 90% Foetal Bovine 
Serum/10% Dimethylsulfoxide. Once thawed, washed and counted, the cells 
were incubated for 15 minutes at 49C with CD4 or CD8 Microbeads (Mitenyi 
Biotec), washed once in separation buffer (PBS + 0.5% human AB serum + 2mM 
EDTA) and then passed through a magnetic separation column. Undepleted, 
CD4 depleted and CD8 depleted cell populations were then assayed as above in 
ex vivo ELISPOT assays. Cell separations were checked by co-staining aliquots 
of purified populations and whole PBMC in cold PBS containing 0.5% BSA and 
0.05% sodium azide with Peridinin-chlorophyll-protein complex (PerCP)- 
conjugated mouse anti-human CD3, fluorescein isothiocyanate (FITC)- 
conjugated mouse anti-CD4, and phycoerythrin (PE)-conjugated anti-CD8 
antibodies. Cells were acquired on a FACSCalibur (Becton Dickinson, San Jose, 
CA) and analysed using CeIlQuest software (Becton Dickinson). For analysis, 
lymphocytes were gated by forward and side scatter properties and CD3+CD4+ 
& CD3+CD8+ populations were identified. 10,000 live events were collected. All 
populations shown were separated to >90% purity. 
5.1 Cultured y-interferon ELISPOT assay 
Cells are aliquotted at 2x 105 PBMCs per well into standard 96-well U-bottom 
plates with peptides at 25 , ug ml" in RN10 to make a total volume of 200/al. 
Stimulant wells are surrounded by wells containing 200pl water or PBS to reduce 
evaporative losses. On day 3 100N1 supernatant is removed and replaced with 
Lymphocult-T (BioTest) to aid cell proliferation. This is also performed on day 7. 
On day 9, the day prior to the ELISPOT, 150, ul supernatant is replaced with 
RN10 to reduce background y-interferon in the assay. On the day of the assay, 
day 10, the plates are spun at 1400 rpm for 3 minutes, 150NI supernatant 
removed and replaced with RN10. This washing procedure is repeated for 6 total 
washes. Cells are then resuspended carefully in 240/ul and transferred at 33,000 
original input cells (40/il) per well to pre-coated and blocked ELISPOT plates. 
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Further incubations and development are as described above in the ex vivo 
assay. 
5.1.1 Analysis of cultured ELISPOT immunogenicity 
Triplicate responses were obtained. These triplicates can vary substantially and 
there is a degree of variability between experiments in both test and background 
responses. In order to obtain meaningful outcomes I analysed the data with 
emphasis on high specificity rather than sensitivity. Each well containing cells 
stimulated for 10 days with ME or TRAP peptides was split after culture into 6 
wells for the overnight ELISPOT assay. One of these assay wells was a negative 
control with medium but no peptides. Therefore each test response out of the 
triplicates had a corresponding individual negative control response. An individual 
well was considered positive if the number of spots appearing in the test well was 
significantly (p <=0.05) greater than the number of spots appearing in the 
background well, assuming if the response was not positive that both responses 
were part of the same poisson distribution. Furthermore I defined as positive only 
those test responses where all three triplicates were positive in this way. 
Although this approach will tend to discard some true positives, the positive 
responses defined by this method are very likely to be true positives. 
We used definitions of positive for cultured ELISPOT assays in contrast to our 
approach for the ex vivo assay. There are two main reasons why we chose to 
use definitions of positive responses for cultured ELISPOTs but not ex vivo 
ELISPOTs. Firstly in our hands variability in the cultured ELISPOT is greater than 
the variability in the ex vivo ELISPOT. Greater variability in an assay requiring 10 
days of in vitro stimulation compared to an overnight assay is biologically 
plausible and perhaps expected. Secondly negative control responses tend to be 
slightly higher in the cultured ELISPOT. Negative control wells were almost 
always very low in the ex vivo ELISPOT assays conducted as part of this thesis. 
For these reasons in the cultured ELISPOT I was most interested in a method 
with high specificity but low sensitivity of defining positive responses. The 
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drawback of such a method is that interpretation of the size of the responses is 
more problematic when only defined positive responses are used, as most 
responses are defined as negative for the cultured ELISPOT. This cultured 
ELISPOT statistical method for defining positives therefore provides a stronger 
method, in my opinion, for defining the frequency of positive responses than for 
the magnitude of induced responses. 
5.2 Preparation and cryopreservation of PBMCs 
Venous blood is collected into BD 1 Oml lithium heparinised Vacutainers. The 
blood may be stored for up to 24 h at room temperature. The blood is transferred 
into a 50ml Falcon tube. Initially this falcon tube was centrifuged, and the plasma 
removed for storage before ficoll-hypaque layering. However in order to increase 
efficiency during the course of the studies this was modified as follows. The blood 
is transferred directly to a Leucosep 50ml Falcon tube. These tubes contain a 
filter paper horizontally fixed within the tube. 15mis of Lymphoprep, also known 
as ficoll (Nycomed technologies), is pre-added to the bottom of the tube. Blood 
could then be transferred onto the filter paper much more rapidly than when 
layering directly layered onto Lymphoprep when maintenance of good separation 
requires great care. The blood and Lymphoprep is then centrifuged at 2000 rpm 
for 20 minutes with the brake off after which aliquots of plasma are taken from 
the top plasma layer. Plasma is then either used fresh for antibody ELISA or 
clinical chemistry assays or stored at -20°C. PBMCs are then collected from the 
interface with a pasteur pipette and transferred to another 50ml Falcon tube. The 
PBMCs are diluted to 50ml with RPMI-1640 supplemented with I-glutamine and 
penicillin/streptomycin (RO). This solution is centrifuged at 1600 rpm for 10 
minutes, the supernatant poured off, the pellet flicked and one further wash 
performed in RO with the centrifuging at 1400 rpm for 7 minutes. Again the 
supernatant is poured off and the pellet flicked and resuspended in 5-10mis R0. 
If there are many red blood cells still in the pellet, these are lysed by 
resuspending in 5 ml ACK lysis buffer. After 2 minutes, the cell suspension is 
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underlaid with 5 ml heat inactivated FBS, and centrifuged at 1400 rpm for 7 
minutes without brake. Two stains are used for counting cells, Trypan Blue and 
Crystal Violet both from Sigma. The Crystal Violet is diluted 12 to 1 in water and 
filtered before use. 10/A of cells in RO are mixed 1: 1 with stain and then added to 
the counting chamber of an Improved Neubauer Haemocytometer. Whole 
numbers of chamber squares are counted until the cell count is above 200. Two 
different Crystal Violet stained counts (CV1 and CV2) are performed to count 
PBMCs which appear as nucleated purple cells. A single Trypan Blue count is 
performed to count dead cells only (TB), which stain blue throughout under this 
stain. Viable cells do not take up stain intracellularly and so appear as outlines 
only. The following calculation can then be made to calculate the number of live 
cells per litre of cell suspension. 
((CV1+CV2)/2 -TB)*(25/No Squares Counted)*(Dilution Factor)*107 cells/litre 
This number is then divided by 1000 and mutiplied by the number of mis of cell 
suspension to give the number of cells in the cell suspension. At this point the 
number of cells needed for the assay(s) are taken out into a separate container 
and the cells remaining in the 50ml Falcon are prepared for freezing. The assay 
cells are centrifuged at 1400 rpm for 7 minutes and made up to 8x106 cells/ml in 
RN10. The cells to be frozen are centrifuged at 1400 rpm for 7 minutes and 
resuspended in 0.5ml FBS for each vial to be frozen. One vial is frozen for 5-10 
million cells. The cells in FBS are kept on ice for at least 30 minutes. However 
ice supplies are not straightforward in laboratories in The Gambia and so 4 °C 
was employed when necessary. After this period the cells are mixed 1: 1 with 
80% FBS and 20% Dimethylsulfoxide (DMSO, Sigma) in 1 ml cryovials and 
immediately placed in specialised cell freezing containers (Mr. Frosty 
cryocontainers) which are placed in a -80 °C freezer overnight. The Mr. Frosty 
cryocontainers must have been filled appropriately with propanol and left at 4 °C 
at least 4 hours before this time. The vials are transferred the next day to liquid 
nitrogen. 
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5.3 Thawing of PBMCs 
Traditionally PBMCs are transferred from their liquid nitrogen cryogenic storage 
container on solid C02 during thawing. However solid C02 was not available in 
The Gambia. Therefore various modifications to the usual technique were 
employed. What was found best to work was as follows. Two scientists were 
present in the liquid nitrogen storage room. Once the correct vials were found, 
one scientist remained in this room and closed the container. The distance from 
this room to the laboratory was considerable. Therefore the vials were placed in a 
50ml Falcon tube whose lid was closed and the second scientist returned to the 
door to the laboratory as quickly as possible. Once in the laboratory the vials 
were stirred vigorously in a waterbath containing water at 37 °C watching 
carefully for thawing of the cell suspension. As soon as the 1 ml cell suspension 
had thawed they were transferred to a 15ml Falcon containing 1 Oml R10. Cells 
were centrifuged at 1400 rpm for 7 minutes and washed once further with 1 Omis 
R10 before an interval of 1-2 hours in a 37 °C 5%CO2 humidified incubator. Cells 
were then centrifuged at 1400 rpm for 7 minutes and made up to 0.5ml RN10 for 
counting as above. Recovery of about 60% of the frozen cell numbers were 
obtained by this method in The Gambia. 
5.4 Haematology 
The clinical haematology service of the John Radcliffe Hospital was used for UK 
studies. A Medonic CA620 automatic cell counter was used for all Gambian 
studies. High, normal and low controls (Mallinckrodt Baker UK) were run at least 
once a week on the Medonic. Test samples were mixed well on a roller and then 
a sample was aspirated into the Medonic. After completion of the analysis, 
results are automatically displayed on the screen. Platelets, haemoglobin, 
haematocrit (HCT) and white blood cell count (WBC) were used for analysis. 
WBC differentials were performed manually when total WBC were outside the 
normal range. 
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5.5 Biochemistry 
The clinical biochemistry service of the John Radcliffe Hospital was used for UK 
studies. A Visual (Bio-Merieux) analyser was used in The Gambia. Creatinine 
standards were used as controls for creatinine assays; zymotrol was used as 
controls for the ALT assays. Water was the negative control. ALT or creatinine 
reagents were incubated with plasma samples at 37 °C for 5 minutes before 
assaying. 
5.6 Blood Smears 
In The Gambia clinical slides were stained with Field's stain and read 
immediately. Duplicate smears were made and all slides were also stained with 
Giemsa. Slides were read to 200 fields in the Phase I studies and 100 fields in 
the Phase Ilb study (see chapter 11). Parasitaemia was calculated as /PI 
assuming 1 parasite in 1 high power field = 500 parasites/, ul. 
5.7 Anti-TRAP Antibody ELISA 
Recombinant T9/96 TRAP (PfTRAP 1.1) was obtained from Andrea Crisanti. 
Recombinant 3D7 TRAP and positive and negative control sera were obtained 
from GSK Biologicals. Antigens were coated at 4°C overnight onto Maxisorp 
immunoplates (Nunc) at a concentration of 4ug/ml in 0.05M carbonate- 
bicarbonate buffer, pH 9.6 (Sigma). Plates were washed with PBS/0.05% Tween 
20. Plasma samples from volunteers were diluted 1/100 in PBS/0.05% Tween 
containing 1% BSA and incubated in duplicate wells for 2 hours at 37°C. Plasma 
samples were also added to wells in which no TRAP had been added to the 
coating buffer. Plates were then washed and bound antibodies detected with goat 
anti-human IgG antisera conjugated to alkaline phosphatase (Promega) diluted 
1/5000 in PBS/Tween/1%BSA. After 1 hour plates were washed and developed 
using p-nitrophenyl phosphate tablets (Sigma) and the OD405 measured. 
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5.8 Anti-R32LR ELISA 
R32LR is a recombinant P. falciparum CS fragment containing 32 NANP repeats. 
This is the immunodominant B cell epitope from the CS antigen. This ELISA 
assay was developed by WRAIR and is the most widely used ELISA for antibody 
to P. falciparum CS. The antigen R32LR, which was provided by WRAIR, is 
diluted in PBS to a concentration of 0.1 Ng/50 NI. A 0.5% boiled casein (BC) 
preparation is added at 4 NI of BC per 5 ml of diluted antigen. Triplicate wells are 
coated for each dilution of serum with 50 NI of diluted antigen. Incubation is 
overnight at room temperature in a humidified box. The well contents are 
aspirated and wells are blocked with 250 pl of 99% BC/1% Tween 20 for one 
hour at room temperature. The blocking buffer is then exchanged for 50 PI of 
appropriate serum dilution per well including blanks, negative and positive 
controls. Samples are run in triplicate starting with a1 : 50 dilution and making 
two-fold dilutions down the plate. Incubation is for two hours at room 
temperature. After wells are washed four times with PBS-Tween 20,50 NI/well of 
Goat Anti-Human IgG HRP in BC/0.025% Tween 20 diluent is added and 
incubated for one hour at room temperature. Wells are washed four times with 
PBS-Tween 20 before development with HRP reagents for one hour at room 
temperature. 10 NI of 20% SIDS is used to stop the reaction. Adsorbance is read 
at 414 nm. Because the pg/ml antibody concentration of the positive control 
(DGP, Daniel Gordon Plasma) has been previously calculated, and DGP is 
available as positive control sera, antibody concentrations of test samples can be 
calculated from mean sample adsorbances. Daniel Gordon was a US Army 
researcher protected by RTS, S vaccination with high titers of NANP-specific IgG 
present in his plasma samples. 
5.9 Exclusion criteria 
Fo phase 1 trials the exclusion criteria were: 
a. Clinically significant history of skin disorder (eczema, psoriasis, etc. ), 
allergy, immunodeficiency, cardiovascular disease, respiratory disease, 
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endocrine disorder, liver disease, renal disease, gastrointestinal disease, 
neurological illness, psychiatric disorder, drug or alcohol abuse. 
b. History of splenectomy 
c. Haematocrit of less than 30% 
d. Serum creatinine concentration >130mmol/L 
e. Serum ALT concentration >42 IU/L 
f. Blood transfusion within one month of the beginning of the study 
g. History of vaccination with previous experimental malaria vaccines 
h. Administration of any other vaccine or immunoglobulin within two 
weeks before or two weeks after vaccination. 
i. Positive HIV antibody test 
j. Current participation in another clinical trial, or within 12 weeks of this 
study 
k. Any other finding which in the opinion of the investigators would 
increase the risk of an adverse outcome from participation in the trial. 
1. Likelihood of travel away from the study area for a period of 6 months 
from screening. 
m. Positive pregnancy tests for females (UK studies) 
n. Allergy to gold or previous gold therapy (UK study with needleless 
delivery device of vaccine coated to gold particles) 
o. Allergy to kanamycin for DNA vaccine studies 
p. Allergy to Fansidar for phase 2b study only. 
q. Previous rabies vaccination for phase 2b study only. 
5.10 Reactogenicity assessments 
Most adverse events whether local, systemic or unsolicited were assessed 
according to the following system. 
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0= No adverse experience 
1= An adverse experience which is easily tolerated by the subject, causing 
minimal discomfort and not interfering with everyday activities. 
2= An adverse experience which is sufficiently discomforting to interfere with 
normal everyday activities. 
3= An adverse experience which prevents normal, everyday activities. 
(In adults/ adolescents, such an adverse experience would, for example, 
prevent attendance at work/ school and would necessitate the 
administration of corrective therapy). 
Where the terms mild, moderate and severe are used for adverse events these 
generally correspond to 1,2 and 3 on this scale. Follow-up was on day 7 and day 
21 in the UK and day 1, day 2, day 7 and day 21 or day 28 in The Gambia. Local 
adverse events were discolouration, induration, blistering, pain and limited arm 
motion. Systemic adverse events were headache, nausea, malaise and objective 
fever (axillary temperature >= 37.5°C). Unsolicited adverse events were collected 
for 28 days after each vaccination and assessed for relation to vaccination. In 
The Gambia field assistants collected some reactogenicity data after appropriate 
training. 
5.11 Serious adverse events 
The following adverse events are considered "serious adverse events": 
" Death of a subject or a life threatening event. 
" Hospitalization. 
" Incapacitating disability. 
" Overdose. 
0 Cancer or congenital anomaly. 
A Safety Monitor was designated for each study and clear rules were set out for 
serious adverse event reporting. Rules were also in place for reporting to ethics 
committees and the scientific co-ordinating committee of the MRC unit in The 
Gambia. 
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5.12 Prior Approvals Sought 
All studies required ethics approval from one or more UK institutions and the 
Gambian Government/MRC Ethics Committee for the Gambian studies. Gambian 
studies all also received approval or modification by the MRC Gambia Scientific 
Coordinating Committee. Before the first Gambian study a group of UK MRC 
Ethicists convened by MRC Head Office UK considered the vaccine programme 
prior to Gambian SCC approval. UK Medicines Control Agency approval was 
obtained prior to each UK phase I study. No Gambian regulatory authority exists 
but prior UK regulatory authority approval was recognised. An independent Data 
Safety Monitoring Board gave prior approval to both the study protocol and 
reporting and analysis plan for the field efficacy study. 
5.13 Informed Consent in The Gambia 
1) Joint Gambian Government/ MRC Ethics Committee (EC) approval and other 
relevant EC approval must be obtained before any part of the study. In some 
cases general aspects of a new study design may be discussed with 
communities as a possibility for future work before formal approval is 
obtained, although none of the meetings below should be held without formal 
approval. 
2) Important community representatives and government representatives should 
be informed before volunteer recruitment commences. This may involve 
representatives from the Ministry of Health, Divisional health teams, Hospital 
Management and Chiefs of major towns (for example meetings were held with 
the Chief of Farafenni before VAC014 and VAC020). 
3) Initial meetings should be held with the Alkalo and elders of a village during 
which the study should be discussed in detail. If the elders do not feel the 
study is appropriate for the village, further general meetings should not be 
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held and volunteers from the village should not be recruited. Often it is 
possible for some women and some younger people to be present at this 
initial meeting and this should be encouraged. 
4) General village meetings should then be held at which the study should be 
described as in the information sheet and consent form. This should include a 
description of how much blood will be taken and how frequently and explicitly, 
what risks and benefits the volunteers and for benefits, the community, can 
expect from the study. 
5) Field assistants should then visit potential volunteers and conduct detailed 
individual discussions in the local languages giving out both English and 
where appropriate local language/Arabic script versions of the information 
sheet and consent forms. 
6) Further discussion should then take place at a clinic visit between a study 
physician and volunteers individually, during which consent should be sought. 
Consent forms may be signed by the field assistant on behalf of MRC and by 
the volunteer. Although not required by the MRC unit, the consenting study 
physician should sign the consent form for ICH-GCP compliance. Because of 
the very detailed nature of the consent procedure and the lack of literate 
village residents, it has not been thought appropriate to include a requirement 
for an independent witness who can witness the correct consenting 
procedure, translation and read the English consent form. This would usually 
not be possible. 
7) Investigators must understand that in a rural setting the culture of most 
Gambians is to pay a great deal of attention to the opinion of their village 
elders and their family elders. It is not the culture for all individuals to expect 
detailed individual explanation of research procedures from research staff and 
they may find the need for such detailed explanations difficult to understand, 
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given that their community and their elders have already consented. However 
it is the investigators duty to ensure that consent is as informed as possible 
on an individual basis. It is therefore incumbent on investigators to reinforce 
important messages throughout the trial in a culturally acceptable manner. In 
particular the facts that the intervention is not proven and that there is a 
control group (where applicable) should not be assumed to be understood at 
the outset. 
8) Beyond a certain length of information sheet/consent form, comprehension 
decreases for many of the village residents. Very detailed and in some 
senses, legally oriented, consent forms are increasingly being asked for by 
many sponsors. These consent forms which are sometimes stated to be 
necessary for ICH-GCP compliance and often 4 or more pages in length are 
not thought to be ideal for village settings. The important points should be 
condensed into a two page maximum information sheet and a one page 
consent form. In this way consent should focus on the critical points e. g. risks 
and benefits to individuals, randomisation, uncertain efficacy. Where ICH- 
GCP compliance and being appropriate for the target population are both 
possible they should both occur, but being appropriate for the local population 
should be the priority. 
9) It must be specifically stated that volunteers are free to leave of their own 
accord during the study as this may be not be assumed. 
10)AII villages and volunteers involved in a study must be informed of the results 
of each study in a timely manner. Culturally there is an expectation for villages 
to be informed through the mechanism of village meetings. In addition any 
promises made by researchers or field staff such as results of blood tests etc. 
must be noted and kept meticulously. 
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5.14 Quality Control, Toxicology, Potency and Stability 
Extensive pre-clinical identity, purity, biodistribution, gross pathology and 
histopathology testing was performed on samples from lots of all three vaccines 
before all clinical trials as part of MCA submissions. In addition a potency 
experiment was performed on doses of vaccines from the clinical lots prior to 
start of each clinical trial. Three groups of 4 female BALB/c mice were immunised 
on day 0 with either 50, ug of DNA ME-TRAP intramuscularly, 2Ng of DNA ME- 
TRAP by gene gun or 1x106 pfu of MVA ME-TRAP or FP9 ME-TRAP 
intradermally. Those that received DNA ME-TRAP receive a further 50Ng or 2Ng 
respectively on day 14. The number of y-interferon secreting pb9-specific CD8+ 
T cells in freshly prepared mouse splenocytes was determined by the ex vivo 
ELISPOT(Schneider et al., 1998). These assays were repeated 3 monthly for 
each clinical lot to ensure vaccines did not degrade during storage. 
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Chapter 6 
Safety of DNA ME-TRAP and MVA ME-TRAP 
in Malaria-naive Adults 
This phase 1 trial has been reported (Moorthy et al., 2003a). 
6.0 Introduction 
This series of UK Phase I trials provides, to my knowledge, the first data on 
immunisation with a recombinant MVA malaria vaccine, the first data on DNA 
prime-recombinant viral boost malaria immunisation in humans and the first data 
on administration of a polyepitope infectious disease vaccine in humans. 
In this section, I evaluate the safety and tolerability of intramuscular DNA priming 
followed by intradermal MVA boosting. In addition I evaluate the safety and 
tolerability of priming by DNA delivered intradermally by a needleless delivery 
system followed by intradermal MVA boosting. 
6.1. Methods 
6.1.1 Volunteers 
Forty-three healthy, male or female volunteers aged 18-55 were recruited from 
the communities surrounding the clinical trial site in Oxford, UK. Recruitment was 
by placement of posters in designated sites and advertisements in the local 
press. Each volunteer received a detailed information sheet by post concerning 
the study. The potential risks were discussed with the volunteers. The research 
protocol and appended submissions were reviewed and approved by OXREC 
and MCA. All volunteers gave written informed consent. 
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Volunteers were screened by clinical evaluation for good physical and mental 
health. Screening consisted of a medical history, physical examination, urinalysis, 
complete blood count, anti-nuclear antibody, anti-double stranded DNA antibody, 
HIV-1 antibody, hepatitis B serology and a biochemistry screen including 
measurement of liver enzymes and creatinine. For females a urine beta-HCG 
pregnancy test was performed on the day of the first vaccination and prior to 
each vaccination. 
Exclusion criteria included positive pregnancy testing, serological evidence of 
HIV or hepatitis B infection, clinically significant haematological, hepatic, renal, 
cardiac, respiratory, dermatological, gastrointestinal, autoimmune, neurological or 
psychiatric disorder and drug or alcohol abuse. Allergy to gold or previous gold 
therapy were exclusion criteria for vaccination by needless delivery. 
6.1.2 Vaccines 
The study vaccines were DNA ME-TRAP and MVA ME-TRAP as described (see 
chapter 4). The clinical lot of DNA ME-TRAP for intramuscular administration 
consisted of vials containing 1 mg DNA ME-TRAP in 1 ml of phosphate-buffered 
saline. DNA ME-TRAP was stored at -20 4C and thawed for 30 minutes at room 
temperature prior to administration. The DNA vaccine was administered through 
a 23-gauge needle intramuscularly. 
MVA ME-TRAP was stored at -80 4C and vials were thawed for 30 minutes at 
room temperature prior to vaccination. The clinical lot consisted of 0.2ml vials 
containing 1x108 pfu. The MVA vaccine was administered intradermally through a 
27 gauge needle in a volume of 0.1 ml. 
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6.1.3 Administration of DNA vaccine by gene gun 
The Powderject Pharmaceuticals XR1 needleless delivery device has previously 
been used to administer a hepatitis B DNA vaccine to 19 volunteers in the 
USA(Tacket et al., 1999). The Powderject Pharmaceuticals device is the version 
of the device (sometimes called a "gene gun") for which there has been the 
greatest experience in clinical trial use. Gene gun technology uses a gas-driven 
ballistic bombardment device that propels gold particles coated with plasmid DNA 
into the skin. These gold particles are propelled directly into the cytosol of 
epidermal dendritic cells, improving delivery of plasmid DNA to the nucleus for 
transcription. This results in transgene expression levels higher than those 
obtained by comparable doses of "naked DNA". This mode of immunisation 
produces protective immunity in several animal models(Fynan et al., 1993, Han 
et al., 2000). DNA ME-TRAP was precipitated onto microscopic gold beads under 
GMP conditions. The gold beads carrying DNA were helically coated onto the 
internal surface of a 74 cm length of tefzel tubing, which was dried and cut into 
one-half inch segments. A coated segment, or `cartridge', is inserted into a 
polycarbonate nozzle, approximately the size of a 12 ml syringe, and the 
cartridge/nozzle unit is sealed with vacuum in a pouch. Each cartridge carried 1 
pg of DNA on 500 pg of gold particles. Prior to vaccination the skin of the 
proximal, posterior upper arm was prepared with alcohol. Each dose of vaccine 
consisted of a total of 4 pg of DNA ME-TRAP on 2mg of gold particles, given as 4 
administrations of one cartridge each to 4 adjacent sites. The helium delivery 
pressure was 500 psi. 
6.1.4 Study design 
This is an open-label, dose-ranging, route-finding series of phase I clinical trials 
in healthy adult volunteers. Intramuscular DNA ME-TRAP and intradermal MVA 
ME-TRAP were administered to the non-dominant deltoid region and then to 
alternate arms for booster doses. Scheduled vaccination intervals were 3 weeks, 
although exceptionally an interval of up to 4 weeks occurred. Table 6.1 details 
vaccination regimes by groups. Note that three individuals in group 1 and two in 
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group 2 went on to received 2-3 intradermal MVA immunisations 2-6 months after 
their final DNA immunisation. Ascending group number corresponds to 
chronology such that assessment of safety and tolerability was made before 
increasing the dose of intramuscular DNA ME-TRAP. 
6.1.5 Assessment of safety and tolerability 
Volunteers in groups 1,2 and 3 were observed for 3 hours after each 
immunisation with vital signs monitored. Volunteers in groups 4 to 9 were 
observed for 1 hour after immunisation. They were then seen for assessment at 
day 7 and 28 and again 6 months (or 4 months for groups 4 to 9) after final 
immunisation. At each of the follow-up visits detailed history and physical 
examination, including vital signs were done. All symptoms and signs were 
considered adverse events and graded as follows: mild if no limitation of activities 
of daily living (ADL); moderate if limitation but not prevention of ADL; severe if 
prevention of ADL. On the day of each immunisation and seven days after each 
immunisation, blood was obtained for full blood count, anti-nuclear antibodies 
and anti-double stranded DNA antibodies and the following plasma biochemistry: 
sodium, potassium, urea, creatinine, alanine aminotransferase, aspartate 
aminotransferase, albumin, total bilirubin, y-glutamyl transferase, calcium, 
magnesium, phosphate, urate and amylase. These investigations were also 
performed on venous blood obtained 4 weeks and 6 (or 4) months after final 
immunisation. 
6.2 Results 
6.2.1 Study population 
Forty-three volunteers were enrolled and assigned to groups 1-9 sequentially. 
Thirty-three men and ten women participated in the study. Median age was 27 
(range 21-54). All volunteers were Caucasian. One of the volunteers had spent 
some time in a falciparum-endemic region. This volunteer was in group 2 and 
had spent 1 month in Uganda in 1998. He had not had clinical malaria. Six 
volunteers had vaccinia scars. The participants were either students, biomedical 
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researchers, clinicians, nurses or other hospital staff or employees of other non- 
biomedical University of Oxford Departments. All of the volunteers in groups 1 
and 2 received their 3 vaccinations, but 3 of those in group 1 were not traceable 
for the final 6 month follow-up. One volunteer in group 3 was withdrawn after first 
vaccination because he travelled to a falciparum-endemic country during the 
study. All volunteers in groups 4 to 9 received all planned vaccinations and 
completed the study. 
6.2.2 Safety Overview 
All doses of both vaccines were well tolerated when given by all three routes in 
all volunteers. No changes occurred in vital signs during the observation period 
and during the follow-up period. Most adverse events were mild (table 6.2). There 
were 10 moderate adverse events as follows. 4 episodes of mild flu-like episodes 
consisting of headache, myalgia and malaise. 3 of these episodes occurred the 
day after the volunteer's first MVA immunisation. During 2 of these 3 episodes, 
pyrexias were documented of 37.5 °C and 37.8 4C. We have therefore 
documented 3 mild flu-like reactions of duration less than 24 hours to MVA 
immunisations out of 40 total MVA immunisations in this series of trials. The 
fourth episode occurred two days after the volunteer's first DNA immunisation. In 
all 4 cases, the volunteers experienced only mild limitation of activity (still being 
able to attend work) and were entirely well the day after the episode began. 
There were 3 episodes of moderate headache the day after each MVA 
immunisation in the same volunteer, always of duration of less than 1 day. There 
was 1 episode of painful lymphadenopathy 2 days after first MVA immunisation in 
a volunteer who had received three previous DNA immunisations. On 
examination during the episode two tender 1.5cm right supraclavicular lymph 
nodes were palpable. There was no restriction of arm movement and no other 
symptoms or signs. The lymph nodes were no longer palpable on the seventh 
day after immunisation. There was 1 episode of lethargy from the first to the fifth 
day after first DNA immunisation. On the fourth day this volunteer was marching 
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as part of a military training exercise and suffered a brief vaso-vagal episode with 
loss of consciousness for a few seconds. On clinical assessment including 
laboratory testing there were no abnormalities on the seventh day. This episode 
was classified as unrelated to vaccination. There was 1 episode of intermittent 
nausea, weakness and leg myalgia with groin pain in a male volunteer lasting for 
6-8 hours on the third, sixth and ninth day after his first MVA immunisation 
following one previous DNA immunisation. On clinical assessment on the ninth 
day the volunteer was well, pyrexial at 38.0 sC with no other clinical signs and 
normal genital and inguinal examination. By the tenth day he was entirely well 
and remained so. This episode was classified as unrelated to vaccination. 
There were no significant laboratory abnormalities attributable to vaccination 
including anti-nuclear antibodies and anti-double stranded DNA antibodies. 
Swabs taken from MVA sites 3 hours after injection and fluid withdrawn 
from a blister on the third day after a MVA immunisation were assayed 
for presence of infectious MVA ME-TRAP by culture in chicken embryo 
fibroblasts which are permissive for MVA replication. No MVA ME-TRAP was 
detected. This suggests that there is no or minimal risk of persistence of the 
recombinant organism in the environment. 
6.2.3. Local reactions to MVA ME-TRAP administered intradermally 
A total of 52 doses were given to 22 volunteers in groups 1-7. All sites showed 
absorption of the intradermal fluid within 30 minutes and onset of redness at the 
site by 1 hour. Redness, sometimes with induration, developed to maximal size 
at 48 to 72 hours from vaccination. These were either mildly tender on firm 
pressure or, in most cases, non-tender. There was little or no warmth. There was 
no limitation of arm movement. The maximum diameter of the redness on the 
seventh day after vaccination varied from 5 mm to 21 mm. The redness faded to 
a faint erythema, which rarely was visible four weeks post vaccination. 33% 
(17/52) of vaccinations were associated with mild pain at some time during the 
first seven days after vaccination. 32% (16/52) were associated with mild pruritus 
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during this period. A1 to 2 mm blister occurred at 15% of sites (8/52) by the 
seventh day. Blisters healed without complication over three weeks in all cases: 
6.2.4 Local reactions to DNA ME-TRAP administered by Powderject needleless 
delivery device. 
A total of 30 doses of 4 pg DNA ME-TRAP were given to 12 volunteers. 
Therefore a total of 120 cartridges were administered. Erythema sometimes with 
a sensation of mild tingling or burning developed within minutes at all sites. The 
erythema was of maximal diameter between 30 minutes and 3 hours. The range 
for maximal diameter was 17-28 mm. The erythema resolved over 4-7 days 
leaving hyperpigmentation. This hyperpigmentation was rarely still visible at day 
70, in one case co-existing with a faint erythema. In this one case there was 
hyperpigmentation and faint erythema at up to 10mm diameter at all 12 sites, 
which has persisted to day 224. Mild dermal oedema is seen within 30 minutes 
and resolved by day 7. Mild pruritus was experienced after 27% (8/30) of doses. 
6.3. Discussion of safety and reactogenicity data 
Two specific safety concerns have been raised with reference to DNA 
immunisation: integration oncogenesis and potential induction of 
autoimmunity(Mor et al., 1997). Several pre-clinical studies have measured the 
number of copies of plasmid DNA covalently linked to genomic DNA after 
intramuscular plasmid DNA injection in mice. It is unknown whether this linked 
DNA represents integration but if it is assumed that all bound DNA integrates, 
one arrives at a figure of integration 1000 times less than the spontaneous 
mutation rate(Ledwith et al., 2000). Whilst this issue now seems extremely 
unlikely to be a risk to volunteers, it will be necessary to encourage reporting of 
any possible long-term adverse events once DNA vaccines have been given in 
larger scale trials and post-licensing. The possibility of autoimmunity now looks 
similarly remote. Anti-double stranded DNA antibodies are often associated in 
clinical practice with the connective tissue disorder systemic lupus erythematosis, 
a multi-system autoimmune condition with a variable clinical course which can 
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result in death. In mouse studies it has been very difficult to raise anti-DNA 
antibodies through administration of plasmid DNA preparations(Parker et al., 
1999). After injection of crude E. coli denatured DNA preparations in a very 
strong adjuvant, Freund's adjuvant, antibodies can be raised but these are to 
single-stranded DNA. Such antibodies are not associated with clinical disease in 
humans. In clinical trials to date no double-stranded anti-DNA antibodies have 
been induced after DNA immunisations with up to 2.5mg of plasmid DNA. This 
chapter adds to the negative body of data in this area. 
We show that intradermal administration of a malaria DNA vaccine by needleless 
delivery device has an acceptable safety profile. Currently, however, there are 
greater limits to the quantity of DNA which can be delivered intradermally than 
intramuscularly. 
We report the safety profile of recombinant MVA in humans either with or without 
prior DNA immunisations. The small number of acceptable adverse events is 
comparable with viral vaccines in general use. Indeed there is scope for 
increasing the dose of MVA. 
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Table 6.1. Composition of vaccination groups 
Group Trial Regime DNA Interval 
to 
MVA No. 
Code Dose Dose Dose 
Ng pg pg 
boost x1x107 x107 
pfu pfu pfu 
1 VA0001 DDD(0.5) 500 500 500 6 
2 VA0001 GGG 4 4 4 6 
3 VA0002 MMM(3) 3 3 3 6 
4 VA0003 MMM(3) 3 3 3 5 
5 VA0003 DDD(1)M(3) 1000 1000 1000 3 3 3 
6 VA0003 D(1)MM(3) 1000 3 3 3 3 
7 VA0003 DDD(1) 1000 1000 1000 5 
8 VA0005 DD(1)MM(3) 1000 1000 3 3 3 3 
9 VA0005 GGMM(3) 4 4 3 3 3 6 
10* VAC010 MM(15) 15 15 8 
11* VAC010 DDD_MM(15) 2000 2000 2000 8 15 15 5 
12* VAC010 DDDMM(15) 2000 2000 2000 3 15 15 4 
D- intramuscular DNA ME-TRAP vaccination 
G- gene gun DNA ME-TRAP vaccination 
M- intradermal MVA ME-TRAP vaccination 
Interval between prime and boose shown above; all other intervals were 3 weeks. 
Numbers in brackers refer to the dose administered at each vaccination; in mg for 
DNA and in x107 pfu for MVA. As examples: 
DDD(O. 5) indicates three intramuscular DNA ME-TRAP vaccinations given at 
weeks 0,3 and 6; each at a dose of 500pg. 
DD(1)MM(3) indicates the group who received two 1mg DNA ME-TRAP 
vaccinations at weeks 0 and 3 followed by two 3x107 pfu MVA ME-TRAP 
vaccinations at weeks 6 and 9. 
The 
- symbol 
in DDD_MM(15) indicates an interval of 8 weeks between third 
immunization and fourth immunization, rather than the 3 week intervals between 
all other immunizations. Hence DDD_MM(15) indicates a group who received 
three 2mg DNA ME-TRAP immunizations at weeks 0,3 and 6 followed by two 
15 x107 pfu (or 1.5 x108 pfu) MVA ME-TRAP immunizations at weeks 14 and 17. 
*safety data not presented 
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Table 6.2. Solicited local adverse events over 7 days after immunisation. 
Local 
Pain 
Pruritus Redness Induration Blister Other 
Group 1 DDD(0.5) -6 individuals 
Inj 1 (D) 0 0 0 0 0 1 
Inj 2 (D) 0 0 0 0 0 0 
Inj 3 (D) 0 0 0 0 0 0 
Group 2 GGG -6 individuals 
Inj 1 (G) 3 4 6 0 1 0 
Inj 2 (G) 2 4 6 0 0 0 
Inj 3 (G) 3 2 6 0 0 0 
Group 3 MMM(3) -6 individuals 
Inj 1 (M) 3 2 6 4 3 1 
Inj 2 (M) 1 1 6 0 0 0 
Inj 3 (M) 0 0 6 0 0 0 
Group 4 MMM(3) -5 individuals 
Inj 1 (M) 4 3 5 5 1 1 
Inj 2 (M) 0 1 5 1 0 1 
Inj 3 (M) 0 1 5 0 0 1 
Group 5 DDD(1)M(3) -3 individuals 
Inj 1 (D) 0 0 0 0 0 0 
Inj 2 (D) 0 0 0 0 0 0 
Inj 3 (D) 0 0 0 0 0 0 
Inj 4 (M) 3 1 3 1 0 2 
Group 6 D(1)MM(3) -3 individuals 
Inj 1 (D) 0 0 0 0 0 2 
Inj 2 (M) 3 1 3 1 1 1 
Inj 3 (M) 1 1 3 1 0 0 
Group 7 DDD(1) -5 individuals 
Inj 1 (D) 0 0 0 0 0 0 
Inj 2 (D) 0 0 0 0 0 0 
Inj 3 (D) 0 0 0 0 0 0 
Numbers refer to the number of volunteers positive for the symptom or sign. 
D- intramuscular DNA ME-TRAP vaccination 
G- gene gun DNA ME-TRAP vaccination 
M- intradermal MVA ME-TRAP vaccination 
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Chapter 7 
Immunogenicity and Efficacy 
of DNA ME-TRAP and MVA ME-TRAP 
in Malaria-naive Adults 
The data for this chapter published in Nature Medicine (McConkey et al., 2003: 3 
joint first authors; McConkey, Reece, Moorthy). 
7.1 Methods 
7.1.1 Study Population and Procedures 
All volunteers whose safety profiles were outlined in Chapter 6 are included in the 
immunogenicity and efficacy measurements. In addition three further groups of 
volunteers are included. The dose, route and order of immunizations in these 
groups is described in table 1, chapter 6. All immunization intervals were 3 weeks 
other than the interval between final DNA and first MVA immunization in group 11 
which was 8 weeks (this timepoint is abbreviated as DDD_M(15), whereas 
DDDM(15) represents the same immunization regimen with a3 week interval in 
group 12). Blood was drawn pre-vaccination (sometimes referred to as day 0 or 
baseline), 7 days after each immunization and 28 and 150-300 days after final 
vaccination. Ex vivo y-interferon ELISPOT assays, anti-TRAP and anti-R32LR 
antibody ELISAs were performed as described in Chapter 5. Cell separations 
were performed on frozen/thawed cells using Miltenyi Biotech MACS beads and 
columns according to the manufacturer's instructions. Separated and 
unseparated populations were co-stained with BD anti-CD3, anti-CD4 and anti- 
CD8 antibodies to allow checking of the purity of the separations. 
7.1.2 Analysis of Immunogenicity 
See section 5.0.1 
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7.1.3 Challenge with P. falciparum Sporozoites 
Asexual blood-stage P. falciparum parasites of the well characterized 3D7 clone 
of the NF54 strain were provided to Geoff Butcher by David Walliker of Edinburgh 
University. NF54 was derived from a sample taken from a Caucasian female who 
was infected near to an airport in the Netherlands by a mosquito thought to have 
originated in West Africa. The 3D7 parasites were expanded in vitro and enriched 
for the gametocyte fraction. Laboratory reared A. stephensi mosquitoes were 
membrane fed 3D7 gametocytes and seven days later a sample of the 
mosquitoes' mid guts were dissected and oocyst counts performed. 14-21 
(typically 19-21) days after the membrane feeding groups of mosquitoes thought 
to be infected were allowed to feed for 5 minutes on unvaccinated control 
volunteers and vaccinees. Mosquitoes were dissected to check for feeding and 
salivary gland infection. This process was repeated until 5 mosquitoes each with 
102-104 sporozoites per salivary gland were known to have fed on each volunteer. 
These challenges took place 14-37 days after final vaccination (see table 7.1). 
From the sixth day after challenge volunteers were monitored twice daily with 
microscopy of thick smears for blood-stage infection. Smears were read to 200 
fields (or more if volunteers were symptomatic) before being declared negative. 
Subjects were given a standard adult treatment course of chloroquine after the 
first positive blood smear. There was no significant difference in time to infection 
between the controls in the three challenges using the log-rank test. 
7.2 Results 
7.2.1 Homologous vaccination induces low but detectable effector T cell 
responses 
Repeated vaccination with either DNA ME-TRAP (p value = 0.07 for all peptides 
in construct) induces responses by ex vivo ELISPOT above pre-vaccination 
values. These are comparable to those seen with DNA vaccine recombinant for 
Pf CS previously(Wang et al., 2001). The amplitude of these responses is given 
in table 7.2. Some of these responses are barely detectable and tend to be 
towards the minimum threshold for detection by ex vivo ELISPOT which is 
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approximately 10 SFCs per million PBMCs (K Flanaghan DPhil Thesis 2000). 
Repeated MVA ME-TRAP immunizations induce comparable low levels of 
effector T cells (p=0.04 for all peptides comparison with pre-vaccination values). 
7.2.2. Heterologous prime-boost vaccination induces higher effector T cell 
frequencies than homologous vaccination 
A single MVA ME-TRAP immunization at 3x 10' pfu induces increases in T cell 
response, most markedly after gene gun DNA immunization (see figure 7.1). A 
single 1.5 x 108 pfu MVA ME-TRAP immunization after three 2mg i. m. DNA ME- 
TRAP immunizations induces very large increases in effector T cell responses (p 
value = 0.0003, all peptides). The responses are strongest to T9/96 peptides but 
strong 3D7 responses and weaker ME string responses (p value = 0.01) are also 
seen. 
7.2.3 Dose, route and interval affect Immunogenicity 
Delivery of DNA ME-TRAP by gene gun at 4µg is more immunogenic as a 
priming immunization for subsequent 3x10' pfu MVA ME-TRAP boosting than 
i. m. DNA at 1 mg (p value = 0.01). The peak induced responses in the 9 
volunteers who received three 2mg i. m. DNA immunizations followed by MVA at 
1.5 x 108 pfu were higher than those in the 9 individuals who received either one, 
two or three DNA immunizations at 1 mg followed by MVA at 3x 10' pfu (p value 
= 0.02). No statistically significant difference in response magnitude was 
observed in comparison of intervals between DNA and MVA (8 weeks vs 3 
weeks). 
7.2.4 Breadth of the induced effector T cell response 
Responses were induced to all peptide pools (see figure 7.4 and 7.5). Strongest 
responses for one donor at one timepoint after boosting were generally seen in 
one or two T9/96 peptide pools with subdominant responses in other T9/96 
pools, generally weaker responses in 3D7 pools and to CD4+ T cell epitopes in 
the ME string and weakest to CD8+ T cell epitopes in the ME string. Tissue 
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typing was performed and on average each volunteer possessed HLA alleles 
allowing recognition of 1 CD8+ T cell epitope from the ME string. The results are 
consistent with the ability of volunteers to recognize several epitopes from within 
the whole TRAP antigen leading to immunodominance of this region over the 
CD8+ T cell epitope(s) recognized from the ME string. 
7.2.5 The T cell responses persist for several months 
In the GGMM group in whom the longest follow-up has been documented the T 
cell response was 38% of the peak at 5-11 months and 61 % of the plateau level 
(day 21-28) at the 5-11 month timepoint (figure 7.2). In the high dose DDDMM 
groups the response was 86% of the peak response at 6 months (156 geometric 
mean SFCs per million PBMCs) 
7.2.6 Both CD4+ and CD8+ T cells were induced by prime-boost vaccination 
Depletion assays on cells cryopreserved 7 days after first MVA immunization in 
the GGMM group showed that both CD4+ and CD8+ T cell dependent responses 
were induced by this vaccination regimen (figure 7.3). 4 of the group had CD4+ T 
cell responses and 2 had CD8+ T cell responses. In the DDDMM groups 
depletions showed that the responses were mainly CD4+ T cell dependent. 
7.2.7 Delay in time to parasitaemia in the highest immunogenicity prime-boost 
groups 
Volunteers in the GGMM and the two high dose DDDMM groups, but not those 
receiving lower dose or homologous regimens had a significant delay in time to 
parasitaemia (p=0.013, log rank test). 
7.2.8 Limited antibody induction by DNA/MVA vaccination in humans 
Many vaccinees had no detectable anti-CS or anti-TRAP antibodies after 
vaccination. One vaccinated subject had a four-fold rise in antibody titre, and two 
others had a two-fold rise in titre (see table 7.3). Four subjects developed low- 
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titre antibody responses to the NANP repeat epitope in the vaccine. These low 
titre antibody responses did not correlate with protection. 
7.3 Discussion 
When the studies detailed in this chapter were designed, the aim was to identify 
a candidate vaccination regimen for efficacy evaluation including DNA ME-TRAP 
and MVA ME-TRAP within a time frame appropriate to the scale of the disease 
burden. The following parameters all required evaluation: dose of DNA, route of 
DNA, number of DNA vaccinations, dose of MVA, number of MVA vaccinations, 
intervals between homologous vaccination and the interval between heterologous 
vaccination. The tensions in the choices for study design were: duration to 
completion of each study; the need to choose from many possibly protective 
regimens; group size as a statistical consideration. We decided to use a study 
design with many small groups (n=3-6). This allowed us to rapidly screen 
potential regimens and enabled identification of large differences in 
immunogenicity or protection at the expense of inadequate sample size to show 
statistical significance for smaller differences. With this scheme we arrived at the 
very high immunogenicity DDDMM(15) regimen within 18 months of the start of 
the first phase I trial. Even with the small group size the results provide very 
strong support for the hypothesis that heterologous DNA prime MVA boost (HP- 
B) immunization is more immunogenic for effector T cell induction than 
homologous immunization (the HP-B hypothesis). 
Gene gun DNA immunization at 4µg is more immunogenic than 1 mg DNA i. m. for 
subsequent MVA boosting (p=0.01 in small group comparison). If it were possible 
to increase the dose of gene gun delivery it may be that T cell frequencies even 
greater than those seen in the DDDMM(15) group could arise. Unfortunately this 
is not possible with current technology and the pharmaceutical firm have 
withdrawn their interest in the malaria DNA vaccine. If however conventional 
liquid DNA vaccine preparations could be concentrated, then evaluation of high 
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dose needle-administered i. d. DNA vaccination would be desirable. Currently it is 
not feasible to administer mg DNA quantities i. d. 
Effector T cell frequencies are lower after second than first MVA immunizations in 
the DDDMM(15) (p=0.06 in group n=4). The same finding is seen in all other 
groups with two or more MVA immunizations. This drop is most likely to be due to 
the normal decline in T cell frequency over 28 days and indicates no boosting of 
second MVA immunization with a3 week interval. I believe that this is due to a 
human immune response to MVA vector antigens which prevents infection of 
cells and recombinant protein expression for second MVA immunizations with 
this interval. The timecourse of this vector immunity is unknown. 
DDDM(15) and DDD_M(15) were not statistically significantly different in their 
immunogenicity. Data in two primate models, DNA/adenovirus in a macaque 
model of Ebola virus (Sullivan et at., 2000) and DNA/MVA (Amara et al., 2000) in 
a macaque model of HIV infection, had suggested that a longer interval between 
DNA and MVA may be more immunogenic. Further studies with larger sample 
size are necessary to resolve the question of the optimum prime-boost interval in 
humans. 
Our data also confirm the fact that dose titrations in humans are empirical and 
where reactogenicity and clinical considerations allow dose increases they are 
desirable for maximal Immunogenicity. 2mg of DNA followed by 1.5 x 108 pfu of 
MVA are more immunogenic than 1mg and 3x 107 respectively. We have now 
reached the highest dose feasible with current formulations. Higher doses of 
MVA as well as DNA may be practical, safe and desirable if newer formulations 
can increase the concentration. 1x 109 pfu MVA has been administered to 
macaques immunocompromised by total body irradiation, anti-thymocyte globulin 
administration or measles virus infection. No clinical, haematological or 
pathological abnormalities were detected during a 13-day follow up(Stittelaar et 
al., 2001). No replication-competent MVA was isolated from the macaques after 
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inoculation. Therefore higher doses are likely to be safe even in 
immunocompromised individuals. 
However I should state which questions remain unanswered by our approach. 
The data do not allow us to state with certainty how many DNA priming 
immunizations (one, two or three) are most immunogenic for subsequent MVA 
boosting. Although there is an indication that a longer interval is less 
immunogenic than a shorter interval between DNA prime and MVA boost this has 
not been shown beyond doubt. 
Some interpretation of the delay in time to parasitaemia with HP-B immunisation 
is necessary. Calculation of the likely reduction in parasite load required to cause 
a2 day delay in parasitaemia suggests a >70% reduction in merozoites 
emerging from the liver in the HP-B vaccinees. If blood-stage multiplication is 8- 
fold over 48 hours (Simpson et al. 2002) then a 48 hour delay corresponds to a 
8-fold reduction (or 87.5%) in parasites leaving the exo-erythrocytic stage. A 75% 
reduction in sporozoite inoculation leads to a2 day prolongation of the pre-patent 
period in the P. berghei BALB/c model (RJ Anderson and AV Hill, unpublished 
data). These data suggest that the three highest immunogenicity groups 
developed partially effective immune responses against liver-stage Pf parasites. 
However this theoretical interpretation requires validation against natural infection 
in a field efficacy study (see chapter 11). 
Could the delay in time to parasitaemia be a non-antigen specific effect? No 
delay is seen in homologous DNA or MVA vaccination groups. A non-specific 
effect of DNA followed by MVA immunization cannot be excluded although the 
biological basis for this is difficult to conceive. Ideally empty vectors would be 
available for mock immunization of controls, as commonly occurs in animal 
models. The cost of manufacture of empty vectors to cGMP precludes this at the 
moment. The final unlikely possibility for a spurious result is that the lack of 
formal blinding confounded the results. The physician investigators are aware of 
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vaccine allocation and interact with slide readers often. It is therefore conceivable 
that there could be some effect of unblinding on the results for delay in time to 
parasitaemia. Unblinding could not affect complete protection. It would be 
preferable if a formal single-blinding system were introduced for slide readers. 
The ex vivo y-interferon assay was strongly associated with protection in the 
BALB/c P. berghei model. Irradiated sporozoite-immunised and malaria-exposed 
adults possess T cells specific for liver-stage parasites with a y-interferon 
phenotype. Such T cells are known to be able to bring about the apoptosis of 
infected hepatocytes in murine models by induction of reactive nitrogen 
intermediates(Mellouk et al., 1994) (Tsuji et al., 1995). However it is also possible 
that other effector T cell phenotypes such as perforin-mediated lysis and fas or 
granzyme A or B mediated apoptosis may be important. To date we have not 
ascertained whether or not P. falciparum liver-stage specific T cells from HP-B 
immunized volunteers are able to exhibit these phenotypes. In future HP-B 
studies in humans these other effector mechanisms could be assessed to 
exclude the possibility that a clear protective response of one of these alternative 
phentotypes is missed. However pragmatically there is a tension between how 
detailed the immunological studies are and how rapidly alternative regimens or 
constructs can be screened for efficacy in the Ila model. I believe the highest 
utility derives from identification of an optimally protective regime followed by 
characterization of the protective responses exhaustively. 
The antibody induction presented is very weak and highly unlikely to account for 
the delay seen. Anti-CS titres (to the NANP repeat epitope) have been 
associated with protection after RTS, S/AS02 vaccination(Bojang et al., 2001) at 
several logs higher than titres seen in the few volunteers who seroconverted to 
TRAP or CS in the studies presented here. There are also several studies which 
show no association between antibody titres to CS and protection against 
infection or disease in field settings(Hoffman et al., 1987, Riley et al., 1990). 
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The interval between DNA and between MVA immunizations has been 3 weeks 
in all but one group, but with an acceptable window of up to 3 extra days. 
Ultimately a regimen with no more than 3 doses and intervals of 4 weeks would 
be desirable for incorporation into the WHO/UNICEF EPI infrastructure through 
which routine immunizations are administered to infants in many sub-Saharan 
countries. Although this infrastructure would need to be expanded in many 
countries, it would likely form the basis of delivery of an effective malaria vaccine 
to infants in Africa. 4 week intervals for HP-B regimens are likely to be as 
effective as 3 week intervals but this needs to be evaluated in future studies. 
There are various methods under exploration for increasing immunogenicity of 
DNA vaccines through adjuvants. Co-administration of plasmids containing IL-2 
or GM-CSF; delivery as PLG particles and various other techniques are under 
trial. MVA and other viral vectors will be improved as vectors through 
recombinant DNA manipulation. The intellectual property issues involved with 
developing a regimen involving several different patents is complex. For example 
some very desirable regimens could involve patents over individual optimized 
vectors, for vector combinations, for epitopes within constructs, for antigens, and 
for novel adjuvant, formulation and medical device technologies. In addition to 
intellectual property, development of these combinations may be slowed by 
complex regulatory pathways. Once a potential product is highlighted through 
what has been called "the proof of principle" it should be possible to perform a 
series of studies aimed at licensure even with complex combination regimens. 
Avoiding these complex regimens would speed licensure, but sufficient efficacy 
may not be possible with more simple regimens. 
The data presented above represent an early body of data of heterologous DNA- 
based prime-boost vaccination in humans, which can form a basis for further 
work. The first hypothesis of this thesis (the HP-B hypothesis) is validated by the 
data presented or more accurately the repeated failure to falsify the hypothesis 
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provides strong grounds to believe it is true. The work presented in Chapters 8 
and 9 address the second hypothesis. 
Regimen Interval to 
challenge 
(weeks) 
Number 
challenged 
MMM(3) 2-3 4 
D(1)MM(3) 2-3 3 
DDD(1) 2-3 5 
DD(1)MM(3) 2-3 3 
GGMM(3) 5-6 6 
DDD_MM(15) 2-3 4 
DDDMM(15) 3 4 
Table 7.1: Interval between final vaccination and sporozoite challenge. See table 
6.1 for clarification of nomenclature for vaccination regimen. 
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Figure 7.2 Geometric mean (standard error) y-interferon ELISPOT time 
course after vaccination is shown at seven, 28 and 150 - 350 days after 
final vaccination for the six subjects in group GGMM(3). This group 
received two 4pg DNA ME-TRAP immunizations by gene gun at weeks 0 
and 3 followed by two 3 x107 pfu MVA ME-TRAP immunizations at weeks 
6 and 9. 
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Figure 7.3 CD4+ and CD8+ T cell depletion 
experiments from DDD_MM(15) and DDDMM(15) 
groups seven days after the last vaccination. 
Cryopreserved and then thawed PBMCs were used. 
Negatively selected and unseparated populations 
were assayed in overnight y-interferon ELISPOT 
assays. 
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Figure 7.4 The breadth of the 
20-mer TRAP peptide 
response in the GGMM(3) 
group. This group received two 
4pg DNA ME-TRAP 
immunizations by gene gun at 
weeks 0 and 3 followed by two 
3 x107 pfu MVA ME-TRAP 
immunizations at weeks 6 and 
9. 
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3D7 x-y refers to a pool of 10 
overlapping 20-mer peptides of 
the 3D7 strain of TRAP spanning 
110 amino acids beginning at 
(x`10) -10 and ending at the 
(y*10)+10 amino acids. T9/96 x-y 
correspondingly refers to T9/96 
TRAP 20-mer peptides. 
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Figure 7.5 The breadth of response across 
the whole ME-TRAP construct seven days 
after the first MVA immunization in the 
DDDMM(15) group. See figure 7.4 for 3D7 x- 
y and T9/96 x-y explanations. See table 4.1 
for FTTp, 38H BCG and NANP. ME pool 1 
consists of the first 7 peptides listed in table 
4.1; ME pool 2 is the other 7 peptides 
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Table 7.2 (see pages 105-6) 
y-Interferon ELISPOT responses, shown as spot forming cells per million 
PBMCs, in peripheral blood seven days after the vaccination regimens shown 
in the left hand column (see table 6.1 for description of nomenclature). For 
some time points the data are missing due to subjects unavailability, errors in 
performing the assay or background responses more than 50 spots/million 
PBMC which were not included in the analysis. The number of subjects in 
each arm and their vaccination schedule is shown in Table 6.1. Some 
subjects are included more than once as the results indicate their time course 
through the trials. For example, a subject who had three doses of 2mg of DNA 
ME-TRAP followed 3 weeks later by two doses of 1.5 x 108 pfu of MVA ME- 
TRAP is included in the DDD(2) regimen seven days after the first three 
vaccinations, in the DDDM(1 5) regimen seven days after the first MVA ME- 
TRAP and in the DDDMM(1 5) regimen seven days after the second MVA ME- 
TRAP. Arithmetic and geometric means and standard error (SE) are shown 
for three sets of peptide pools: the summed net responses to all the epitopes 
in the vaccines, the summed net responses to all peptide pools from T9/96 
strain of TRAP and the summed net responses to all peptide pools from 3D7 
strain of TRAP. 
Table 7.3 Responders by antibody ELISA. Titres shown 
are greatest dilution which produced an OD of >0.20 in 
the relevant assay 
Volunteer 
number 
Vaccination 
regimen 
Pre-vaccination Final vaccination 
+7 days 
TRAP IgG ELISA (see section 5.7) 
111 DDD_MM(15) 1/800 1/3200 
112 DDD_MM(15) 1/1000 1/2000 
121 DDDMM(15) 1/1400 1/3000 
R32LR CS IgG ELISA (see section 5.8) 
111 DDD_MM(15) 1/400 1/600 
112 DDD_MM(15) 1/1400 1/3000 
118 DDD_MM(15) 1/1000 1/3200 
121 DDDMM(15) 1/1200 1/1500 
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Chapter 8 
Safety and Immunogenicity of 
DNA ME-TRAP and MVA ME-TRAP 
in Gambian adults 
8.0 Introduction 
There has been a publication reporting this phase 1 trial (Moorthy et at., 
2003b) 
In my view one of the most interesting observations made in murine malaria 
studies of DNA and recombinant viral vaccines related to the effects of prior 
exposure to sporozoite infection on vaccine immunogenicity. Inoculation of a 
few hundred sporozoites led to only a minimal CD8 T cell response, but this 
could be boosted very substantially to protective levels (>1000 peptide- 
specific CD8+ T cells) by a single subsequent immunisation with either the 
MVA vaccine or, surprisingly, the plasmid DNA vaccine each encoding the P. 
berghei circumsporozoite antigen (Schneider et al. unpublished data). Similar 
observations were reported by a New York group using a different replicating 
strain of recombinant vaccinia virus encoding a P. falciparum antigen(Miyahira 
et al., 1998). These results suggest that in individuals primed by natural 
exposure to sporozoites only one of the vaccines might be needed to induce a 
substantial immune response. Once promising safety and immunogenicity 
data from Oxford of DNA ME-TRAP and MVA ME-TRAP at 1 mg and 3x 107 
pfu doses were obtained, we decided to plan a phase I trial evaluating 
whether MVA alone and DNA/MVA would be more immunogenic in malaria- 
exposed compared to malaria-naive adults, as the animal model data 
suggested. This trial was also designed to provide data which would 
accelerate conduct of a field efficacy trial if subsequent UK Ila efficacy data 
warranted one. 
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8.1 Methods 
8.1.1 Study setting and volunteers 
Volunteers were recruited from the perl-urban community of Bakau, on the 
coast of The Gambia. Approval was obtained from the Joint Gambian 
Government/ Medical Research Council Ethics Committee and the Central 
Oxford Research Ethics Committee. Written informed consent was obtained 
from all volunteers after initial community consent, discussion with volunteers 
in the local languages and dissemination of information sheets and consent 
forms translated into local languages in arabic script. The trial was conducted 
according to the principles of the Declaration of Helsinki. 
Potential volunteers underwent thorough clinical evaluation and were 
screened for haematological (full blood count), renal (plasma creatinine, 
urinalysis) and hepatic (plasma alanine aminotransferase (ALT)) dysfunction. 
20 semi-immune healthy adults aged 18-45 were enrolled. An independent 
safety monitor based in The Gambia monitored the study. 
For comparison between malaria-exposed and malaria-naive individuals, 
ELISPOT data from assays performed on UK volunteers are included in the 
analysis. The UK DNA/MVA group consists of 9 volunteers (3 volunteers in 
each group) who received either one, two or three 1 mg DNA ME-TRAP 
immunisations followed by one 3x 107 plaque forming units (pfu) MVA ME- 
TRAP immunization (groups 5,6 and 8 in table 6.1). The UK MVA alone group 
consists of 5 volunteers who received three 3x 107 pfu MVA ME-TRAP 
immunizations (group 4 in table 6.1). See chapter 6 for details of recruitment 
and vaccination of these volunteers. 
8.1.2 Vaccines 
The two study vaccines were DNA ME-TRAP and MVA ME-TRAP. Regulatory 
approval for prior U. K. phase I studies with these vaccines was obtained from 
the U. K. Medicines Control Agency (MCA). The Gambian Government 
accepted MCA approval in the absence of a Gambian regulatory authority. 
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8.1.3 Study design 
This was a phase I open-label trial designated as trial VA0006 in the Oxford 
malaria vaccine programme. All Gambian volunteers received a standard 
treatment with sulphadoxine/pyrimethamine two weeks prior to first 
vaccination. All vaccinations in both UK and Gambian groups were 
administered at 3 week intervals. Twelve Gambian volunteers received two 
1 mg doses of DNA ME-TRAP intramuscularly followed by two 3x 10' pfu 
doses of MVA ME-TRAP intradermally. Eight Gambian volunteers received 
three 3x 107 pfu doses of MVA ME-TRAP intradermally. Eligible volunteers 
were allocated to each of these two groups alternately in order of enrolment. 
Each volunteer was observed for at least one hour after vaccination. Study 
visits were scheduled for day 1,2,3,7 and 28 days after each vaccination 
and 8-10 weeks after final vaccination. Six screened, healthy unvaccinated 
volunteers were bled three times at day 0,56-84 and 140-156 to assess 
background variation in effector T cell responses over the study period in the 
Gambian population. 
8.1.4. Laboratory analysis 
Each Gambian volunteer had 30mls venous blood drawn from an ante-cubital 
vein on five occasions as follows: screening (day -28 to day -7); one week 
after first vaccination in MVA group only (day 7); one week after second 
vaccination in both groups (day 28); one week after third vaccination in both 
groups (day 49); one week after fourth vaccination in the DNA/MVA group 
only (day 70) and 8-10 weeks (day 142-156) after final vaccination. Full blood 
counts and ALT and creatinine assays were performed according to the 
standard operating procedures of the unit (see section 5.4 and 5.5). Normal 
ranges were as follows: Haemoglobin = 13-16 gm/dl(men). WBC Total = 4-11 
x 109/L. Diff count = Neutrophils - 40-55%, Lymphoctyes - 25-45%, 
Monocytes - 3-7%, Eosinophils - 1-5%, Basophils - 0-1 %. RBC = 4-6.5 x 
1012/L. PCV = 36-54%. MCV= 76-96. Platelets = 150-400 x 109/L. ALT<=42 
iu/L. Creatinine <=130 mmol/L. Clinically non-significant neutropaenia is 
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common in Gambians - neutrophil counts of >= 1.0 x 109/L were considered 
normal in asymptomatic subjects. 
Ex vivo Enzyme-Linked Immunospot (ELISPOT) Assay: Detection of Antigen- 
Specific Effector T cells. (see 5.0) ELISPOTs were performed on Millipore 
MAIP S45 plates with MabTech antibodies according to the manufacturer's 
instructions. 4x 105 freshly isolated peripheral blood mononuclear cells 
(PBMCs) were incubated for 18-20 hours on the ELISPOT plates in the 
presence of 25 Ng ml's peptides, before being developed. The number of spot 
forming cells (SFCs) were counted by the Autoimmun Diagnostika system. 
Individual 8-mer to 17-mer epitopes were used for epitopes from the ME 
string, whereas 20-mers overlapping by 10 were used to span TRAP with both 
T9/96 and 3D7 strains of TRAP spanned in their entirety. Peptides were 
assayed in pools due to cell number limitations and cells were assayed in 
duplicate for each pool. Cell separations were performed on frozen cells with 
Miltenyi Biotech MACS beads and checked by co-staining and FACS analysis. 
Anti-TRAP Antibody ELISA. (see 5.7) 
Recombinant T9/96 TRAP and 3D7 TRAP were coated at 4°C overnight onto 
Nunc immunoplates at a concentration of 4ug/ml. Standard ELISA assays 
were performed with incubations of 2 hours at 37°C. 
8.1.5 Statistical Analysis 
The plate layout was changed slightly from the UK studies. Peptide pools 5-9 
spanned 3D7 TRAP and 10-13 spanned T9/96 TRAP (figure 8.1). Spots were 
summed across relevant pools and the "no peptide" negative control spot 
counts subtracted the requisite number of times (figure 8.3a-d). Arithmetic 
means, geometric means, medians and interquartile ranges were derived. All 
four are provided for initial immunogenicity values presented in the text to 
allow evaluation of the distribution of these summed response data. Two- 
tailed Mann-Whitney tests were performed on groups of individual summed 
responses. 
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8.2 Results 
8.2.1 Safety and reactogenicity 
Two volunteers had asymptomatic P. falciparum parasitaemia (55 and 32 
parasites in 200 high power fields respectively) on screening and had 
subsequent negative blood smears prior to vaccination. Eighteen of 20 
vaccinees completed the study protocol. Two withdrew their consent after 
second DNA immunisation; neither had experienced any adverse events. Two 
volunteers experienced an episode of clinical malaria (13 and 9 asexual 
parasites per high power field) between screening and first dose in one case 
and between first and second doses in another case. One volunteer was in 
the DNA/MVA group and the other was in the MVA group. In both instances, 
parasitaemia and symptoms resolved entirely after standard treatment 
courses of chioroquine and sulphadoxine/pyrimethamine. No other episodes 
of clinical malaria occurred during the study. 
There were no severe or serious adverse events. There were no local or 
systemic adverse events after a total of 24 DNA ME-TRAP immunisations. 
The MVA vaccine was well-tolerated (table 8.1). All the tabulated adverse 
events were mild (no interference with activities of daily living). The one 
moderate adverse event was transient limitation of arm abduction after MVA 
vaccination. MVA causes a characteristic local reaction after intradermal 
administration with redness and induration peaking at 48-72 hours. In 5/18 
MVA ME-TRAP first doses, there was a blister < 2mm at the centre of the 
indurated lesion, which healed without complications over 1-3 weeks in all 
cases. Analysis of the haematology and biochemistry safety assays 
performed reveal no adverse events. 
8.2.2 High-frequency induction of effector T cells specific for T9/96 TRAP 
The six unvaccinated volunteers had geometric mean effector T cell 
frequencies of 5.3,7.2 and 6.6 SFCs per million PBMCs at the beginning, 
middle and end of the study. Effector T cells were induced in vaccinees with 
specificity for all peptide pools; TRAP-specific frequencies were higher than 
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ME-specific frequencies (figure 8.1). Following DNA ME-TRAP immunisation 
there was no statistically significant increase in effector T cell frequency. MVA 
ME-TRAP immunisation induced much greater effector T cell frequencies. 
Immunogenicity of MVA ME-TRAP following preceding DNA ME-TRAP (in 
terms of vaccine-induced T9/96 TRAP-specific effectors) was over three-fold 
higher in Gambian than in UK volunteers (figure 8.3a vs 8.3c, arithmetic mean 
175.4 vs 51.4, geometric mean 69.8 vs 19.8, median 172.0 vs. 31.2, 
interquartile range 23.4 - 239.4 vs 15.6 - 131.0 spot forming cells (SFCs) per 
million PBMCs, p value = 0.03). Enhanced immunogenicity was also observed 
in Gambians who received MVA ME-TRAP immunisation without prior DNA 
ME-TRAP compared to UK adults who received the same regime (figure 8.3b 
vs 8.3d, arithmetic mean 55.4 vs 17.2, geometric mean 23.0 vs 11.0, median 
28.8 vs 15.2, interquartile range 10.6-105.6 vs 3.4 - 40.7, SFCs per million 
PBMCs, p value = 0.10). Prior DNA ME-TRAP increased T9/96 TRAP effector 
T cell frequency after MVA boosting in Gambians compared to Gambians who 
received MVA without prior DNA (figure 8.3a vs 8.3b, geometric mean 69.8 vs 
23.0 SFCs per million PBMCs, p value = 0.07). After second MVA 
immunisation in the Gambian DNA/MVA group effector T cell frequency was 
geometric mean 63.3 SFCs per million PBMCs compared with 69.8 after first 
MVA immunisation. In both UK DNA/MVA (see table 7.2) and Gambian MVA 
alone (figure 8.3b) groups effector T cell frequency kinetics showed a decay 
from 7 days after first MVA to 7 days after second MVA. Geometric mean 
effector frequencies at the 8-10 week follow-up in the group with the strongest 
responses (DNA/MVA vaccinated Gambian adults) were 70.6% of the peak 
frequencies. 
8.2.3 Enhanced cross-recognition by effector cells for 3D7 TRAP 
To assess the ability of a malaria vaccine to induce a cross-reactive T cell 
response we evaluated the effector response to the 3D7 strain of TRAP, a 
heterologous strain with 6% sequence variance at the amino acid level 
compared to T9/96. Cross-recognition of responses induced in Gambians was 
far in excess of that seen in UK volunteers (vaccine-induced response to 3D7 
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after DNA then MVA immunisation in Gambian vs UK adults - geometric 
mean 65.1 vs 5.5 SFCs per million PBMCs, p value 0.01, figure 8.3a vs 8.3c). 
Prior to vaccination T cell responses in the group of Gambians who received 
MVA without prior DNA were higher to 3D7 than T9/96. In this group 
immunogenicity was correspondingly greater for 3D7 than T9/96 (figure 8.3b, 
vaccine-induced responses of geometric mean 25.9 vs 15.0 SFCs per million 
PBMCs, p value = 0.16). 
8.2.4 Characterisation of vaccine-induced effectors 
The induced effectors are of both CD4+ and CD8+ T cell subsets (figure 8.2). 
Most responses were CD4+ or mixed CD4+ and CD8+ but pure CD8+ 
responses were also seen. 
8.2.5 Anti-TRAP antibodies 
12 out of 20 Gambian volunteers had titres of anti-TRAP antibodies (to either 
or both of T9/96 and 3D7 strains) that are statistically significantly above titres 
in malaria-naives. There was no statistically significant rise or fall of antibody 
titres after vaccination (figure 8.4). 
8.3 Discussion 
Most vaccines in widespread use have been developed and formulated for 
optimal antibody induction. The prime-boost approach outlined here is an 
example of a new approach targeted at maximisation of T cell 
immunogenicity. Potent T cell induction is likely to be necessary to vaccinate 
effectively against intracellular organisms such as HIV, M. tuberculosis and 
liver-stage P. falciparum, and for cancer immunotherapy. 
The ability of MVA vaccines to amplify pre-existing T cell responses induced 
by priming with DNA vaccines in animal models suggested that they may be 
more immunogenic in African volunteers who have been previously primed by 
natural exposure to malaria. Previously in a mouse model, it has been shown 
that immunogenicity of a single dose of a recombinant vaccinia vaccine is not 
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protective but prior exposure to malaria sporozoites boosts this 
immunogenicity to protective levels (Miyahira et al., 1998), protection which is 
T-cell mediated. Our findings confirm this prediction. The immunogenicity of a 
MVA malaria vaccine (with or without DNA priming) was of greater magnitude 
in previously exposed Gambian individuals than in malaria-naive British 
individuals. There are genetic and environmental differences between the 
malaria-naive and malaria-exposed individuals in this study other than their 
malaria exposure, but we feel these are unlikely to account for the reported 
altered immunogenicity. Interestingly even with sporozoite priming, further 
priming by DNA immunisation is still necessary for maximal T cell induction by 
MVA immunisation. It is unclear whether infants aged less than 6 months will 
display enhanced immunogenicity as in the adults in this study. Although they 
are protected from severe disease to some extent by maternal IgG antibodies, 
some exposure to liver-stage parasites still occurs in high transmission 
settings in the first few months of life. It may be that such exposure with 
covering antibody-mediated blood stage immunity would prime for 
recombinant viral boosting with a liver-stage malaria vaccine. Another 
unknown is the necessity of immune maturation for immunogenicity of T-cell 
based vaccines. The little available evidence suggests that B-cell function 
may be more impaired than T-cell function in early life. BCG affords 
protection, which is thought to be T-cell mediated, against TB meningitis even 
when administered at birth. But measles vaccine is known to provide less 
efficacy below 9 months of age. This effect is only partially due to interference 
with maternal measles antibody. 
It is unclear why MVA ME-TRAP but not DNA ME-TRAP shows enhanced 
immunogenicity in malaria-experienced adults compared to malaria-naives. 
This is presumably the same immunological mechanism which causes the 
failure of DNA (or Ty-virus like particles) to boost in pre-clinical heterologous 
prime-boost regimens. Perhaps there is insufficient recombinant protein 
expression or APC transfection for boosting. 
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The greatly increased cross-recognition demonstrated in Africans in this study 
provides encouragement for further work with T-cell inducing DNA and 
recombinant viral vaccines. Lack of strain-transcendence has long been 
viewed a potential obstacle to malaria vaccination (Genton et al., 2002). The 
volunteers who received MVA without prior DNA vaccination in The Gambia 
(figure 8.3b) had higher pre-vaccination effector T cell frequencies to 3D7 
strain of TRAP than the vaccine strain, T9/96. After immunisation frequencies 
of T cells specific for 3D7 TRAP rose more than those to T9/96, consistent 
with the well-recognised immunological phenomenon termed original antigenic 
sin (Klenerman and Zinkernagel, 1998). 
Not only CD8+ T cells, but also high frequencies of CD4+ T cells, were 
induced by DNA/MVA and MVA immunisation. Whilst CD4+ T cells have 
traditionally been considered helper T cells for either antibody production or 
CD8+ T cell cytotoxicity, it is now clear that many CD4+ T cells have effector 
activity. Directly cytotoxic CD4+ T cell clones confer protection in murine 
adoptive transfer experiments(Tsuji et al., 1990), and such CD4+ cytotoxic T 
cell clones are present in attenuated-sporozoite immunised protected 
humans(Moreno et al., 1993). 
In mouse models, contraction of approximately 90-95% of the effector T-cell 
pool by apoptosis occurs after infectious challenge over 2 weeks (for CD8+ T 
cells) or 7 weeks (for CD4+ T cells) in one model(Homann et al., 2001). We 
examined the kinetics of such contraction in humans. We demonstrated the 
persistence of a residual memory pool with rapid effector function 8-10 weeks 
after final vaccination with frequencies at this time greater than 50% of the 
peak frequencies. 
In all groups studies second MVA immunisations 3 weeks after first MVA 
immunisations show no increase in immunogenicity. In fact, effector T cell 
frequencies show a reduction consistent with natural decay kinetics from the 
peak frequency 7 days after first MVA immunisation. This may be because a 
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host immune response to the highly immunogenic MVA vector prevents 
infection of host cells and recombinant protein expression after second MVA 
immunisation at this interval. A study is underway to evaluate immunogenicity 
of second MVA immunisation after a 12 month interval. 
It has been difficult to induce strong effector T cell immune responses through 
vaccination. We present a safe strategy which is immunogenic for effector T 
cell induction in malaria and is likely to be applicable to other fields. Prime- 
boost approaches with viral vector boosts have been seen as an excellent 
option for improving the efficacy of prophylactic DNA vaccines in diseases 
where T cell responses are protective. The confirmation of the ability of MVA 
to boost pre-existing T cell responses in humans implies that MVA and the 
DNA/MVA combination may also be effective for immunotherapy of chronic 
infections and tumours. Examples which may merit evaluation are 
tuberculosis infection prior to onset of disease, hepatitis B-virus infected 
individuals at risk of disease progression and immunotherapy of HIV-positive 
and melanoma patients. 
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Local Adverse Events Dose 1 (n=18) Dose 2 (n=1 8) Dose 3 (n=7) 
Discolouration 9(6-18) 7(4-11) 7(5-9) 
Itching 7 3 1 
Pain 5 0 0 
Blisters 5 0 0 
Systemic Adverse Total PB Total PB Total PB 
Events 
Temperature 2 37.5°C 1 1 0 0 0 0 
Headache 2 1 1 1 2 1 
Malaise 1 1 0 0 1 0 
Myalgia 0 0 1 0 0 0 
Arthalgia 1 1 0 0 0 0 
Nausea 0 0 0 0 0 0 
Table 8.1: Reactogenicity after each dose of MVA ME-TRAP In VA0006 
Data for discolouration are median (range) in mm measured on day 2. PB = 
probably related. Data for other fields are numbers of volunteers experiencing 
adverse event during 3-day follow-up. n is the number of volunteers who 
received each dose for whom diary cards were completed. 
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Figure 8.1: Breadth of effector T cell responses by ex vivo ELISPOT 
A timecourse for one Gambian volunteer in VA0006.13 peptide pools are 
shown along the x-axis. Pool 1 is the negative control (cells, no peptide). 
Pools 2-4 span the ME string. Pools 5-9 span 3D7 TRAP. Pools 10-13 span 
T9/96 TRAP. Pools 5-9 each consisted of ten 20-mer 3D7 TRAP peptides; 
pools 10 and 12, ten 20-mer T9/96 TRAP peptides; pool 11, thirty 20-mer 
T9/96 TRAP peptides and pool 13, seven 20-mer peptides which cover the 
N-terminal region completely conserved between T9/96 and 3D7 TRAP 
strains. Y-axis units are SFCs per million PBMCs. Post-DNA indicates the 
timepoint seven days after second DNA immunisation. Post-DNA/MVA 
indicates the timepoint seven days after first MVA immunisation. 
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Figure 8.2: Subset distribution of effector T cell responses. 
T cell subsets for DNA/MVA vaccinated volunteers from VA0006(a) and 
MVA vaccinated volunteers also from VA0006(b); each set of three bars 
represents ELISPOT response to a single pool of peptides (various pools 
from 5-13 in figure 1 a) at the maximal timepoint (usually 7 days after first 
MVA immunisation). Assays were performed on frozen/thawed cells on 
unseparated, CD4 depleted and CD8 depleted cell populations. The x axis 
numbers are volunteer numbers. Two different pooled responses were 
assayed from both volunteers 95 and 84. 
120 
'0 
_w 
a0 
<w 
ýc 
CI 
ö 
z r 
äý 
C) 
WU 
äý 
z 
f- 
0. 
öz 
aA 
WU 
äý 
_Q 
W 
Q> 
22 
U 
äýYa0 
ERZ 
cvü ýN 
<Ö c- 
(d 0E 
öE 0 0< 
.> 
(n 
N-? (, g 
JZ«u 
W c2c'º=° 
0 0). 0 aD C N E 
>A-- 
`C 
d ö2 8=E 
c cv >- 
ü3 E> 
(Z7 (Dr- 
0"_°C 
y0M, 
E2 
Ü 
v Cýýrte-' N 
tD 
CÖ N-'C 
V Co U0 cu CL c3 U .. E> 
>C u) 
00 d-a, o3ýaýc 
doC,. 
d 
c0 C) ' 
Ö 0], cd 
:3 äo0ý < CL 
> 
COE 
tu CL 
aý. 00 tu 
16. C 
Ni >Ev8 
10 c0> Co c: - n2 ö Z- cd 
Z0r0 
`- ýVý iý 
CCy N 
ZN0M 'A 
N 
ßNg> 
CM'-<V 
k-- 
atu ao IM r- '2 
C) 
o 
px% 
moo ýý`výv(D 
cý c cgaQ ;> O> O 
>c ca n 
9) aý z' ,_p UL CL Eo a 
1.4 
N 
. -. 4 
ýý8ý° 
Anti-TRAP IgG in MVA Vaccinees 
0.8 
0.6 
° 0.4 
0 0.2 
0 
  T9/96 
ý3D7 
Anti-TRAP IgG in DNA/MVA vaccinees 
1.2 
1 
E 0.8 
Ln 
'2 0.6 
0 
0 0.4 
0.2 
0 O co O4oO CO OCOOCO Coo CO O co (D CO I_) LO a C\l a <v <v a <v -ZD 01 a 01 a C\, a (1, a Cv (\, 
++++++++++ 
Figure 8.4: Anti-TRAP IgG in MVA and DNA/MVA vaccinated Gambians in VA0006 pre- 
vaccination and four weeks after final vaccination 
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Chapter 9 
A randomised controlled dose-escalating Phase 
I trial of the safety and immunogenicity of MVA 
ME-TRAP in Gambian children aged 1-5 
9.0 Introduction 
As described in chapter 8, MVA ME-TRAP immunisation with or without prior 
DNA ME-TRAP immunisation induces higher frequencies of effector T cells 
with a y-interferon phenotype in malaria-exposed Gambian adults than in 
malaria-naive adults at a dose of 3x 107 pfu. If such enhanced 
immunogenicity occurred in children perhaps efficacy in children would also 
be superior to that seen in malaria-naive adults. With the findings in Chapter 8 
and the fact that children under the age of 5 in sub-Saharan Africa are the 
most important target population for a malaria vaccine it was important to 
assess the MVA ME-TRAP malaria vaccine for safety and immunogenicity in 
a paediatric population. We therefore conducted a randomised controlled 
phase I trial of MVA ME-TRAP with dose-escalation and with controls who 
received meningococcal A, C vaccine. To my knowledge this is the first 
paediatric trial of a recombinant viral vaccine for any disease. 
9.1 Methods 
9.1.1 Study setting and volunteers 
Mothers and children were recruited from the rural Mandinka community of 
Sibanor, about 100 km inland in The Gambia. EIRs are substantially higher 
than at the coast and have been estimated as >10 and <30 per person per 
year. Approval was obtained from the Joint Gambian Government/ Medical 
Research Council Ethics Committee and the Central Oxford Research Ethics 
Committee. Written informed consent was obtained from all mothers after 
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initial community consent, discussion with mothers and fathers in the local 
languages and dissemination of information sheets and consent forms. 
Wherever possible fathers were consulted prior to seeking of consent from the 
mother. An indication by either parent that they did not wish their child to 
participate was sufficient to exclude the child. The trial was conducted 
according to the principles of the Declaration of Helsinki. 
Potential study participants underwent thorough clinical evaluation and were 
screened for haematological (full blood count), renal (plasma creatinine, 
urinalysis) and hepatic (plasma alanine aminotransferase (ALT)) dysfunction. 
After pre-test counseling of mothers HIV-1 and HIV-2 antibody rapid tests 
were performed with confirmation of positives by ELISA. 40 healthy children 
aged 1-5 were enrolled. An independent safety monitor based in The Gambia 
monitored the study. 
9.1.2 Vaccines 
The two study vaccines were MVA ME-TRAP and Mencevax (a licensed 
meningococcal polysaccharide A, C vaccine manufactured by 
GlaxoSmithKline). 
9.1.3 Study design 
This was a controlled phase I trial with partial blinding and random allocation 
to vaccine group. All children received single dose immunisation only. Ten 
children received a6x 106 pfu dose of MVA ME-TRAP i. d. and ten children 
received 0.5ml Mencevax i. m. during the same week. Twenty further children 
were immunized after review of safety and reactogenicity data; ten received a 
3x 107 pfu dose of MVA ME-TRAP i. d. and ten received 0.5ml Mencevax i. m. 
I generated the randomisation code with stratification by age and performed 
the vaccinations. All other study staff, including the medical officer and field 
workers who assessed systemic reactogenicity and lab staff who conducted 
safety and immunology assays, were blinded to vaccine allocation as were 
mothers and children. Mothers may have been aware that the two vaccines 
were given by different routes, but they could not have known which group 
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received the candidate malaria vaccine. Each child was observed for at least 
one hour after vaccination. Study visits were scheduled for day 1,2,7 and 28 
days after vaccination and 6 months after vaccination. 
9.1.4. Laboratory analysis 
Each child had 5mis venous blood drawn on three occasions as follows: 
screening (day -28 to day -7); one and four weeks after vaccination(day 7, day 
28). Full blood counts, ALT and creatinine assays were performed according 
to the standard operating procedures of the unit (see sections 5.4 and 5.5). 
ELISPOT Assays: Detection of Antigen-Specific Effector and Memory T cells. 
ex vivo ELISPOTs were performed as described in section 5.0 and 8.1.4. 
Cultured ELISPOTS were performed as described in section 5.1 with addition 
of Lymphocult-T on day 3 and day 7 and the y-interferon ELISPOT assay on 
day 10. Due to extreme blood volume limitations very large pools of peptides 
were used in these experiments. In ex vivo assays three pools were assayed 
in duplicate containing all ME, 3D7 TRAP and T9/96 TRAP peptides 
respectively (up to 57 peptides in one pool). Identical pools were used for 
setting up short term cultures with smaller pools of 7-20 used for the cultured 
ELISPOT assay. 
Analysis of cultured ELISPOT data 
See Section 5.1.1. Cultured ELISPOT assays were conducted in the UK study 
VA0005 and the three Gambian studies VA0006, VAC011, VAC014. The 
same SOP was used, only differing in the size of the peptide pools and hence 
the number of test responses per individual due to blood volume restrictions in 
The Gambia and in children for VAC011. 
9.2 Results 
9.2.1 Safety and reactogenicity 
56 children aged 1-5 were screened. 11 were excluded; 8 with a PCV of less 
than 30% and 3 with various medical conditions (1 with malnutrition, 2 with 
respiratory infections). 40 of the remaining eligible children were enrolled. The 
median age of the 20 MVA vaccinees was 37.8 months (range 12.5 - 70.1 
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months) compared to 36.0 months for the control group (range 14.3 - 66.4 
months). There were 11 boys and 9 girls in the MVA groups and 14 boys and 
6 girls in the control group. 
At screening 12 of the 40 enrolled children had asexual P. falciparum 
parasites on thick malaria smears. 3 had clinical P. falciparum malaria, were 
treated with suiphadoxine/pyrimethamine and chloroquine and subsequently 
enrolled and vaccinated. Six parasitaemic volunteers received control vaccine, 
four received low dose MVA ME-TRAP and two received high dose MVA ME- 
TRAP. There were 7 episodes of clinical P. falciparum malaria during the four 
weeks after study vaccination, 3 and 1 in the low and high dose MVA ME- 
TRAP groups respectively and 3 in the control group. All of these children 
responded clinically and parasitologically to oral sulphadoxine/pyrimethamine 
and chloroquine treatment. One child with clinical malaria in the control group 
required admission to hospital for parenteral treatment due to persistent 
vomiting and recovered entirely over one week. There were no severe or 
serious adverse events related to vaccination during the 6 month follow-up 
period. 38 vaccinees completed the study protocol. 2 children in the control 
group left the study area between the day 28 and 6 month follow-ups. 
The MVA ME-TRAP vaccine was well-tolerated at both doses. The mean PCV 
in the 2 MVA groups and control group were 32.9 (standard deviation 1.9) and 
33.7 (2.1). The mean PCV at day 7 for these groups were 26.7 (4.1) and 28.9 
(3.8). At day 28 the mean PCV were 27.2 (5.2) and 27.7 (4.3). There were no 
abnormalities of laboratory safety assays related to vaccination. There were 
similar frequencies of systemic adverse events in both MVA ME-TRAP groups 
and the control group (see table 9.1). Of the 7 episodes of axillary 
temperature >= 37.5°C during the 7 days after vaccination, 5 were associated 
with clinical malaria and one with a gluteal abscess unrelated to vaccination. 
The one remaining episode of fever occurred on the second day after 
vaccination with no apparent cause or associated symptoms or signs in a low 
dose MVA ME-TRAP vaccinee. The fever had resolved by day 3 and was 
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assessed as possibly related to vaccination. Discolouration and induration 
were seen most frequently in the higher dose MVA ME-TRAP vaccines, 3 of 
whom also developed blisters. These blisters were 1-5 mm in diameter and 
usually maximal size on day 2 after vaccination. They healed over 1-3 weeks 
without complications. Blisters were protected by non-adherent occlusive 
dressings and replaced daily until they were healing. 4/10 of the higher dose 
MVA vaccinees had visible faint marks at 6 months; none of the lower dose 
MVA vaccinees or the control vaccinees had visible marks at this time. 
9.2.2 Ex vivo ELISPOT assays 
There was no evidence of induction of antigen-specific T cells to 20-mers 
spanning either 3D7 or T9/96 TRAP after vaccination as assayed by ex vivo 
ELISPOT. There were no statistically significant changes in summed 
responses (geometric or arithmetic means or medians) to ME, 3D7 or T9/96 
peptides in either MVA dose group between values at screening and at day 7. 
9.2.3 Cultured ELISPOT assays 
There were more positive y-interferon responses in cultured ELISPOT 28 days 
after MVA vaccination than prior to vaccination (10/90 vs 2/90, p value = 0.04, 
x2 test) (Table 9.3). Similar increases were seen in malaria-naive and malaria- 
exposed adults vaccinated with the same dose of MVA ME-TRAP. The 
analysis method renders questionable the value of magnitude in the 
responses defined as positive and magnitude is therefore not quoted . 
9.3 Discussion 
Ex vivo ELISPOT data presented indicate no induction of effector T cells as 
enumerated by this assay. One caveat is that much larger pools were used in 
this paediatric study than in adult studies. The size of these pools did not 
prevent cultured ELISPOT responses. This study demonstrates one of the 
applications of ELISPOT assays conducted on short-term cell lines. Cultured 
ELISPOT assays provided greater sensitivity to detect an induced immune 
response than ex vivo assays in this trial. A similar finding occurred during 
127 
description of both naturally acquired and RTS, S/AS02 induced immune 
responses to CS peptides in a field efficacy trial conducted in The Gambia in 
1998. Indeed a cultured ELISPOT response to a CS peptide predicted 
protection from malaria infection in this study, whereas no responses in ex 
vivo assays were protective (Reece et al., 2004). The disadvantageous 
variability of cultured ELISPOT assays was minimized by using a robust, 
specific analysis method in the trial described in this chapter. A similar 
timecourse is seen in the groups vaccinated with MVA or DNA/MVA regimens 
in The Gambia and UK (table 9.3). Cultured ELISPOT responses increased 
from day 7 after MVA vaccination to day 28 in contrast to ex vivo responses 
which when induced (see chapters 7 and 8) contract considerably after day 7. 
Therefore based on this limited dataset for vaccination with ME-TRAP it 
appears that peripheral memory non-effector T cells as enumerated by the 
cultured ELISPOT assay have a more extended kinetic than the effector T 
cells enumerated by the ex vivo ELISPOT assay. Unfortunately cultured 
ELISPOT data are not available at higher doses of DNA or MVA ME-TRAP or 
at later timepoints, both of which may be informative. If the memory T cells 
assayed in the cultured assay were found to persist in the long term, duration 
of immunogenicity would be longer than previously seen in clinical trials of 
malaria subunit vaccines. Furthermore if the vaccine construct could be 
iteratively optimized to induce memory T cells that afforded protection against 
liver-stage malaria, long-lasting efficacy may be obtained. 
Safety and reactogenicity of MVA ME-TRAP at doses of up to 3x 107 pfu 
intradermally in Gambian children aged 1-5 is acceptable. The blisters seen 
will need to be carefully assessed in larger scale trials of MVA vaccines 
particularly at higher doses. However no infection-related complications of 
these blisters have been documented with MVA ME-TRAP. This study 
confirms the value of controls in phase I trials in endemic trials in populations 
in which the background rate of adverse events is high. Only 1 of the 7 
documented febrile episodes during 7 days after vaccination was possibly 
related to vaccination and without the inclusion of control vaccines it would 
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have been difficult to determine whether or not MVA vaccination had 
contributed to these episodes. 3 of the 7 episodes occurred in control 
vaccinees and there is therefore little evidence that MVA ME-TRAP 
vaccination is associated with febrile episodes in this study. 
The data in this study are consistent with the falsity of our hypothesis that 
enhanced immunogenicity seen in malaria-exposed Gambian adults would 
transfer to malaria-exposed Gambian children aged 1-5. It is not possible to 
determine the mean number of sporozoite inoculations the children in this 
study had received over their lifetime. However it is certain that they will have 
received less cumulative exposure than the Gambian adults described in 
chapter 8. Another factor is the relative lack of immune maturation in this 
paediatric population compared to adults, although there is little evidence that 
significant qualitative or quantitative immune maturation occurs beyond the 
age of 24 months. 
As DNA/MVA proved more immunogenic than MVA alone in Gambian and UK 
adults why did we did not conduct a phase I trial of DNA/MVA in children? The 
theoretical risk of oncogenesis needed to be taken into account in the 
risk/benefit evaluation. No paediatric DNA vaccine trials have occurred for any 
disease and it could be argued that with such a theoretical risk for DNA 
vaccinations, as unlikely as it is that this will translate into adverse events, 
with the problem of consent for children and the lack of an expectation for an 
overriding medical benefit to study participant children, it would be preferable 
to await clear indication of efficacy prior to starting a paediatric DNA vaccine 
trial. This was my opinion, although not that of many malaria researchers. 
This study provides encouragement for further work in paediatric populations 
with recombinant viral vaccines. Although enhanced immunogenicity was not 
observed, induction of T cell responses with a comparatively low dose of MVA 
ME-TRAP occurred in children aged 1-5. Use of higher doses and DNA-based 
prime-boost combinations will be likely to improve on the immunogenicity 
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seen. The results presented in this chapter are consistent with the expectation 
of broadly equivalent immunogenicity in children aged 1-5 in endemic 
countries and malaria-naive adults and inform study progression of future 
candidate vaccine regimens. 
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Local Adverse Events 6x 10 MVA (n=10) 3x 10 MVA (n=10) Men A, C (n=20) 
Discolouration 7 9 0 
Induration 5 8 0 
Pain 0 2 2 
Blisters 1 3 0 
Systemic Adverse Total PB Total PB Total PB 
Events 
Temperature >_ 37.5°C 202030 
Headache 201010 
Malaise 302030 
Vomiting 001000 
Table 9.1: Reactogenicity during the 7 days after MVA ME-TRAP or meningococcal 
A, C vaccination in VAC011. PB - probably related to vaccination. 
3x 10ý fu MVA n=10 6x 10 fu MVA n=10 Controls n_20 
ME 3D7 T/96 ME 3D7 T/96 ME 3D7 T/96 
Screenin 10.5 1.5 3.1 3.6 1.2 4.5 8.7 3.7 6.6 
pa X7 6.9 3.2 2.7 8.7 2.2 3.7 4.4 4.5 3.7 
Day 28 20.3 2 3.6 6.2 1.7 2.2 7.0 2.6 4.7 
Table 9.2: Arithmetic mean summed ex vivo ELISPOT responses at screening and 7 and 
28 days after vaccination in Gambian children receiving MVA ME-TRAP at one of two 
doses or controls receiving meningococcal polysaccharide vaccine. Trial code VAC011. 
ME - summed response to all ME string peptides. 3D7 - summed response to all 3D7 
TRAP 20-mers. T9/96 - summed response to all T9/96 peptides. Units are SFCs per 
million PBMCs. The mean+/- standard error overlapped in all cases when comparing 
timepoints for a response within a group or when comparing between groups. 
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Regimen UK or G Time point Age Volunteers Pos Responses Pos XZ 
VA0006 
DDMM G Pre-vac 18-45 10 3(30) 180 3(1.7) 
DDMM G DDM+7 18-45 10 4(40) 180 14(7.8) 
DDMM G DDM+28 18-45 10 7(70) 180 25 13.9 <0.001 
VA0006 
MMM G Pre-vac 18-45 8 3(37.5) 144 5(3.47) 
MMM G M+7 18-45 8 3(37.5) 144 10(6.9) 
MMM G M+28 18-45 8 6(75) 144 12(8.3) 0.13 
VACO11 
MMM L G Pre-vac 1-5 10 2(20) 90 2(2.2) 
MMM L G M+7 1-5 10 2(20) 90 2(2.2) 
MMM L G M+28 1-5 10 2(20) 90 6(6.6) - 
VACO11 
MMM G Pre-vac 1-5 10 2(20) 90 
-2(2.2) 
MMM G M+7 1-5 10 2(20) 90 5(5.5) 
MMM G M+28 1-5 10 5(50) 90 10(11) 0.04 
VA0005 
GGMM UK Pre-vac 18-55 6 5(83.3) 90 10 11.1 
GGMM UK GGM+7 18-55 6 16(100) , 90 16 17.8 
GGMM UK GGM+28 18-55 6 16(100) 1 90 24 (26.7) 0.01 
Table 9.3: Proportion of volunteers and of responses positive in cultured 
ELISPOT in adults in the UK and Gambia and Gambian children. Regimen: D 
-1 mg i. m. DNA ME-TRAP immunization, M-3x 10e7 pfu MVA ME-TRAP 
immunization, M(L) -6x 10e6 pfu MVA ME-TRAP immunization, G-4 ug 
DNA ME-TRAP by needleless delivery. UK or G: UK - malaria-naive British 
residents, G- malaria-exposed Gambian residents. Timepoint: + followed by a 
number indicates the number of days following immunization, hence DDM+28 
indicates 28 days after a single MVA immunization which was given after two 
DNA immunizations. Age in years. Volunteers - number of volunteers per 
group. Responses - number of peptide pool responses assayed for the group. 
The two pos columns give the proportion of firstly volunteers and secondly 
responses which were positive as defined in section 9.1.4. X2 test values 
quoted include Yates' corrections and are comparisons between pre-vac and 
+28 proportions of positive responses. 
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Chapter 10 
Higher Doses of DNA ME-TRAP and MVA ME- 
TRAP and a comparison of FP9 ME-TRAP with 
DNA ME-TRAP for priming in Gambian adults 
10.0 Introduction 
Priming with two 1 mg i. m. DNA ME-TRAP immunisations followed by boosting 
with two 3x 107 pfu i. d. MVA ME-TRAP, all at 3 week intervals, produced 
strong CD4+ and CD8+ T cell responses in the Gambian phase I study 
detailed in Chapter 8. Subsequent UK Phase I/Ila studies showed that 
increasing the dose of DNA ME-TRAP to 2mg and MVA ME-TRAP to 1.5 x 
108 pfu dramatically increased the induced effector T cell frequency (Chapter 
7). Another outcome of UK studies was the demonstration that DNA could be 
replaced by FP9 for priming with slightly lower immunogenicity but equivalent 
or perhaps somewhat higher efficacy as evidenced by partial protection 
against high-dose heterologous sporozoite challenge (D Webster, 
unpublished data). 
Fowlpox is an avian poxvirus which causes disease in chickens but not 
mammals. Recombinant attenuated fowlpox has been used as a rabies 
vaccine in mammals, in which it shows good recombinant protein 
expression(Taylor et al., 1988). FP9 was derived from wild type fowlpox by 
400 passages in tissue culture, leading to marked attenuation and loss of 
pathogenicity in chickens by all routes of administration to the extent of 
avirulence in one-day old chicks(Mayr and Malicki, 1966). Like all 
avipoxviruses, FP9 and FP9 ME-TRAP cannot replicate in mammalian cells. 
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Attenuated strains of fowipox virus, such as TROVAC, and of another 
avipoxvirus, canarypox, named ALVAC, have been used safely as 
recombinant viral vaccines in many human clinical trials(Fries et al., 1996, 
Clements-Mann et al., 1998) and have been demonstrated to be non-virulent 
in a variety of immunosuppressed animals and human volunteers. 
This Phase I study was designed to assess three issues: safety and 
immunogenicity of FP9 ME-TRAP priming followed by MVA ME-TRAP 
boosting in Gambian adults; safety and immunogenicity of the higher dose 
DNA ME-TRAP / MVA ME-TRAP regimen used in the UK; provision of data 
for two and three priming DNA ME-TRAP immunisations for subsequent MVA 
ME-TRAP boosting. 
10.1 Methods 
10.1.1 Study setting and volunteers 
Volunteers were recruited from the town of Farafenni in The Gambia. The 
study occurred during the dry season when the background rate of adverse 
events in the study population is low. Approval was obtained from the Joint 
Gambian Government/ Medical Research Council Ethics Committee and the 
Oxfordshire Research Ethics Committee. Men living in Farafenni were 
recruited as follows. A general meeting was held in Farafenni during which the 
study was discussed in detail. Information sheets and consent forms were 
distributed. Field workers then held individual discussions with potential 
volunteers. A third discussion was then held with a study physician at least 
one week after first contact between study physician and volunteer. Written 
informed consent was obtained by a study physician from all volunteers during 
this third discussion. Potential volunteers underwent clinical evaluation 
including a full medical history and clinical examination and were screened for 
haematological (full blood count), renal (plasma creatinine) and hepatic 
(plasma alanine aminotransf erase (ALT)) dysfunction. Of the 38 adults 
screened, five were excluded (1 with raised ALT, 2 with raised creatinine and 
2 with low PCV). 29 healthy adults aged 18-45 were enrolled. The study was 
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monitored throughout by an independent safety monitor and was conducted 
according to the ethical priniciples of the Declaration of Helsinki and MRC 
clinical trial guidelines. 
10.1.2 Vaccines 
The three study vaccines were DNA ME-TRAP, FP9 ME-TRAP and MVA ME- 
TRAP. DNA ME-TRAP was prepared in vials of 2mg in 2ml. MVA ME-TRAP 
was prepared in vials of 108 pfu in 200 µl. FP9 ME-TRAP was prepared in 
vials of 108 pfu in 200 µl. The cold chain was maintained and monitored until 
vaccine administration. 
10.1.3. Study Design 
This was a phase I open-label study. All vaccinations were administered at 3 
week intervals. Allocation to each of the three groups was by order of 
enrolment. The doses and routes were: 1x108 pfu i. d. for FP9 ME-TRAP; 2mg 
i. m. for DNA ME-TRAP and 1.5x108 pfu i. d. for MVA ME-TRAP. A group of 16 
received FP9 ME-TRAP at weeks 0 and 3 followed by MVA ME-TRAP at 
week 6; a group of 8 received DNA ME-TRAP at weeks 0,3 and 6 followed by 
MVA ME-TRAP at week 9 and a group of 5 received DNA ME-TRAP at weeks 
0 and 3 followed by MVA ME-TRAP at week 6. Volunteers were observed for 
at least one hour after immunisation. Follow-up visits occurred on day 1,2,7, 
21 for non-final immunisations and 1,2,7,28 and 56 for final immunisations. 
10.1.4 Laboratory Analysis 
Each volunteer had 30ml venous blood drawn pre-vaccination, 7 days after 
penultimate vaccination and 7,28 and 56 days after final vaccination. Full 
blood counts, plasma ALT and creatinine were performed according to the 
standard operating procedures of the unit. Ex vivo y-interferon ELISPOT 
assays were performed as described in section 5.0. A single pool contained 
all ME peptides. 4 pools of 20-mer peptides spanned T9/96 and 3D7 strains of 
the entire TRAP antigen. Antibody and HLA typing data are not presented 
135 
from these volunteers. ELISPOT data were analysed as described in section 
5.0.1. All values quoted in the text are geometric means. 
10.2 Results 
10.2.1 Safety and reactogenicity 
Twenty five of 29 volunteers completed the protocol. Three volunteers 
migrated from the study area during the study period. One volunteer withdrew 
his consent. There were no laboratory abnormalities attributable to 
vaccination. The tabulated adverse events (table 10.2 and 10.3) are all mild or 
moderate. There were no severe or serious adverse events. Reactogenicity of 
DNA ME-TRAP was minimal, similar to that seen at lower doses. First dose 
FP9 ME-TRAP had slightly greater reactogenicity than MVA ME-TRAP with a 
proportion of volunteers experiencing mild to moderate malaise, headache 
and local pain of onset during the evening of vaccination with resolution during 
the two days after vaccination. In no cases did these episodes prevent the 
volunteers attending work or performing other activities of daily living. Second 
dose FP9 ME-TRAP was markedly less reactogenic than first dose FP9 ME- 
TRAP. There was induration, maximal at day 1, at the site of FP9 ME-TRAP 
and MVA ME-TRAP immunisations with range 1-9mm and 1-10mm and 
median 4mm and 5mm respectively. Discolouration was visible, maximal at 
day 2, and faded to a faint shiny plaque. The blisters were median 2mm, 
maximal on day 2 and resolved by day 21 without complication. 
10.2.2. Optimised T9/96 TRAP-specific y-interferon effector T cell induction 
after prime-boost immunisation with DNA/MVA 
Pre-vaccination summed responses to T9/96 TRAP in volunteers from all 3 
groups was geometric mean 8.6 SFCs per million PBMCs (range 2.5 - 80). 
There was a small increase after two or three DNA ME-TRAP immunisations 
(p values for increase above pre-vaccination - not significant). A single MVA 
immunisation after two DNA ME-TRAP immunisations (DDM group) induced a 
very large increase in effector T cell frequency to geometric mean 211.7 SFCs 
per 106 PBMCs (figure 10.1 a). A single MVA boost after three DNA ME-TRAP 
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immunisations (DDDM group) induced a frequency of 331.0 SFCs per 106 
PBMCs (figure 10.1b, p value for difference from two DNA immunisations - 
not significant). Geometric mean effector T cell frequency 4 weeks after final 
MVA ME-TRAP immunisation was 142.0 and 119.1 SFCs per 106 PBMCs for 
DDM and DDDM groups (figure 10.1 a and b, 42.9% and 56.2% of the peak 
value). The corresponding values for 8 weeks after final immunization are 
113.8 and 98.3 (34.4% and 46.4% of the peak value at the final timepoint in 
this study). Merging the DDM and DDDM groups to evaluate the decay during 
the plateau phase from 4 weeks to 8 weeks after final immunization, we find 
that the geometric mean at 8 weeks is 80.7% of the 4 week value (132.0 vs. 
106.5). 
10.2.3 Efficient priming and boosting with two recombinant viruses, FP9 ME- 
TRAP and MVA ME-TRAP 
Effector T cell frequencies in this group increased after two FP9 ME-TRAP 
immunisations to 46.7 SFCs per 106 PBMCs. After a single MVA ME-TRAP 
boost frequencies had risen to a 156.3 SFCs per 106 PBMCs (figure 10.1 c). At 
4 and 8 weeks after the MVA immunisation geometric mean frequencies were 
79.9 and 79.4 SFCs per 106 PBMCs (51.1% and 50.8% of the peak value). 
The decay kinetics for this group during the plateau phase are flat with 
geometric mean frequency at 8 weeks after final immunization being 99.4% of 
the 4 week value. Due to venesection limitations in this population no 
comparison is available between immunogenicity of first and second FP9 ME- 
TRAP immunisations. 
10.2.4 T9/96 ME-TRAP prime-boost immunisation induces effector T cells 
cross-reactive for 3D7 TRAP 
In order to assess the ability of induced T cells to recognise a non-vaccine 
strain of TRAP, cells were assayed with peptides encoding the 3D7 sequence 
for TRAP. 3D7 has 6% variance at the amino acid level with T9/96. In the 
DDM, DDDM and FFM groups, at the peak timepoint after MVA boosting the 
3D7 TRAP-specific effector T cell frequencies were 274.6,197.0 and 197.8 
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SFCs per 106 PBMCs (83.0,93.1 and 126.5% of the T9/96-specific values, 
figure 10.1a-c). There is no statistical significance to the apparent difference 
between T9/96 and 3D7-specific frequencies, consistent with near to complete 
cross-reactivity. In all three groups both T9/96 and 3D7 specific frequencies 
are statistically significantly greater after MVA immunization compared to pre 
MVA immunization (p values<0.01). 
10.2.5 Induction of effector T cells specific for epitopes from the polyepitope 
string 
Responses to epitopes from the polyepitope string were present in many 
volunteers at lower frequencies than those to 20-mer peptides spanning 
TRAP. 4 of the 29 volunteers had frequencies greater than 50 SFCs per 106 
PBMCs above the pre-vaccination values. The highest induced response to 
the ME string was 106.2 SFCs per 106 PBMCs (to the tetanus toxoid epitope). 
The geometric mean ME-specific frequency merging all groups at the peak 
timepoint (7 days after MVA immunization) was 13.4 SFCs per 106 PBMCs (p 
value <0.001 for increase above baseline). 
10.2.6 Dose may affect immunogenicity in malaria-exposed adults 
Increasing the dose of DNA to 2mg i. m. from 1 mg i. m. and the dose of MVA 
from 3x 107 pfu to 1.5 x 108 pfu i. d. increased geometric mean peak 
frequency from 69.8 to 211.7 SFCs per million PBMCs. A Mann-Whitney test 
returns ap value of 0.09 but it is likely that significance would be greater with 
larger numbers. Statistical significance is not seen for this comparison of dose 
increases between two groups of malaria-exposed individuals in contrast to 
the statistically significant difference seen for dose increases in malaria-naive 
adults. There is also no statistical significance in the difference between the 
high dose DNA/MVA regimens in malaria-exposed and malaria-naive 
individuals in contrast to the difference described in Chapter 8 for lower dose 
DNA/MVA in Gambians vs. UK volunteers. 
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10.3 Discussion 
DNA has previously been administered at up to 2.5 mg doses in humans(Le et 
al., 2000); the safety of 2mg doses of DNA ME-TRAP is therefore 
unsurprising. We add to the body of data indicating that DNA has excellent 
safety profiles even at high doses. We have previously reported the safety of 
MVA at 3x 107 pfu. Here we show that a fivefold increase in dose in malaria- 
exposed adults presents few safety issues. MVA ME-TRAP is more 
reactogenic at 1.5 x 108 pfu than at 3x 107 pfu with local pain, headache and 
malaise being fairly common amongst volunteers over the 24-48 hour period 
after vaccination, but the safety profile is acceptable. The blisters seen were 
similar with FP9 and MVA and healed without complications in all cases over 
1-3 weeks. These small blisters seen in a minority of volunteers would need to 
be assessed carefully in a paediatric population. The first FP9 ME-TRAP 
vaccinations were slightly more reactogenic than these higher dose MVA 
immunizations as detailed in table 10.2 but all MVA and FP9 related adverse 
events were mild to moderate in this study. Interestingly local adverse events 
were not only less frequent but resolved more quickly after second than first 
FP9 immunisation, possibly a manifestation of a host immune response to the 
FP9 vector (table 10.3). It may be possible to increase doses further if 
necessary for efficacy with these and other recombinant DNA, FP9 and MVA 
vaccines, although concentrations would need to be higher to make this 
practical. 
DNA/MVA delivery of ME-TRAP is more immunogenic in Gambian adults at 
2mg/ 1.5x108 pf u doses than 1 mg/ 3x10' pfu doses although the increased 
immunogenicity is less marked than the same comparison in UK adults. There 
are several possible reasons for this. The high immunogenicity seen in UK 
individuals was in a single group of 4 volunteers (the DDDMM(1 5) group in 
chapter 7 in whom immunogenicity was greater than in the DDDM group in 
this chapter). Results from such a small group should be treated with caution. 
It is most likely that the enhanced immunogenicity seen at the lower 1 mg/ 
3x10' pfu doses in Gambian compared to UK adults only occurs at this lower 
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dose. At higher doses the available data suggest that the enhancement is lost 
because maximal effector T cell frequencies are reached whether malaria- 
naive or malaria-exposed. It is conceivable that the prior exposure of 
Gambian adults to the many malaria antigens (and other genetic and 
environmental differences) could reduce the maximum immunogenicity 
possible compared to malaria-naive adults but there are insufficient available 
data to address this question. 
It is not possible to state whether two or three priming DNA immunizations 
offer greater immunogenicity for MVA boosting from this data. Any difference 
between the two regimens is highly unlikely to be significant for efficacy. We 
did not state limits for equivalence prior to onset of the study and this should 
be done prior to any future attempt to evaluate equivalence. High dose DDM 
delivery of ME-TRAP has not been evaluated in the UK and once this occurs 
further data for the comparison between two and three DNA primes will be 
available. 
As a three dose regimen is far more practical for use in a non-research setting 
I believe DDM is preferable. The data in this thesis are consistent with high 
dose DDM being the best "real world" regimen for enhanced induction of 
effector T cells in humans and this finding should be applicable to other 
malaria constructs and vaccines for other infectious diseases and cancer 
immunotherapy. Most practical would be a three dose, four week interval 
regimen and future work will need to evaluate my belief that four rather than 
three weeks is unlikely to reduce immunogenicity or efficacy. This three dose, 
four week interval DDM regimen would allow administration at expanded 
programmes of immunisation (EPI) timepoints and therefore maximise the 
prospects for implementation of an effective vaccine within existing African 
public health frameworks. 
Somewhat surprisingly FFM immunization is less immunogenic than 
DNA/MVA regimens in this study. This has also been seen in UK studies with 
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the ME-TRAP construct (D Webster, unpublished data). A possible reason is 
that there could be some cross-reactivity in the host immune responses to 
FP9 and MVA such that some MVA is neutralized before infection of cells and 
recombinant protein expression. Although FP9 and MVA are only distantly 
related phylogenetically, and so this was not expected to occur, the two 
poxviruses have moderate sequence homology. If the targets of the cross- 
reactive immunity could be characterized and removed from MVA by 
recombinant DNA techniques, the immunogenicity of FP9/MVA regimens 
could be increased substantially - in theory to greater frequencies than 
DNA/MVA regimens because of relative recombinant protein expression 
levels. This work would be a major undertaking however. 
There are encouraging data from this study about the kinetics of induced T 
cell responses. As expected we see a substantial and rapid decline in 
frequency from 7 days to 4 weeks as apoptosis of effector T cells occurs but 
from 4 weeks to 8 weeks the decline is very gradual and flat in one group (the 
FFM group). I believe that an effective T-cell based malaria vaccine will not be 
developed until a relevant T cell response can be induced which is protective 
against natural infection at the frequencies induced during the plateau phase 
from 4 weeks onwards. It will be important to explore the kinetics of frequency 
decay further from 8 weeks to 12 months. 
Our collaboration between the University of Oxford, UK and the Medical 
Research Council laboratories, The Gambia has facilitated the conduct of a 
series of phase I studies in the UK and The Gambia. Within an appropriately 
short timeframe, and therefore with the necessity of using small group sizes, 
we have optimised the following parameters: dose, route, interval, number of 
priming immunisations and choice of priming agent in terms of acceptable 
safety and reactogenicity and the highest possible immunogenicity. Prime- 
boost regimens showed a statistically significant delay in time to parasitaemia 
(figure 7.6) and this has been interpreted as possibly sufficient efficacy for 
complete protection in the field setting. We obtained funding for, designed and 
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conducted a field efficacy trial of high dose DDM delivery of ME-TRAP in The 
Gambia (see chapter 11). 
It has been unclear whether it is possible to induce higher levels of immune 
responses through vaccination than occurs through natural infection. The 
requirement for such supra-natural immunogenicity is a key one for effective 
liver-stage malaria subunit vaccination. T cell responses to liver-stage 
antigens in semi-immune adults from sub-Saharan Africa in contrasting 
epidemiological settings are low(Lalvani et al., 1996, Plebanski et al., 1997). 
The pre-vaccination geometric mean effector T cell frequency to T9/96 TRAP 
in 43 healthy adult semi-immune volunteers enrolled into this study and the 
study described in chapter 8 is 6.1 SFCs per 106 PBMCs. Therefore the most 
immunogenic regime in this study induces responses fifty-fold higher than 
natural immunity. 
Preliminary plans have been made to scale up recombinant MVA manufacture 
once a product is highlighted for licensure and widespread use. Currently 
DNA vaccines are considerably more expensive than recombinant poxviruses, 
but there are many examples of vaccines' costs coming down to affordable 
levels during the development process (notably the Hepatitis B vaccine now 
licensed and part of routine immunisations in the Gambian EPI). The 
technologies which the study vaccines represent are scaleable and suitable 
for licensure. 
This study confirms that the increasing body of promising pre-clinical data with 
DNA/MVA vaccines translate into human immunity with a malaria antigen -a 
translation which has not held for several other approaches which were 
promising in pre-clinical studies(Doolan and Hoffman, 2001). The study 
provides strong rationale for further clinical evaluation of both DNA/MVA and 
FP9/MVA for diseases caused by intracellular pathogens. It provides hope 
that effective vaccines for liver-stage malaria, HIV and tuberculosis can be 
developed with heterologous DNA-based prime-boost combinations. 
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Table 10.1: Descriptive statistics for timecourses in the three 
vaccination groups in VAC14 
Screening POST 
DNA+7 
FF+7 DDM+7 DDDM+7 FFM+7 
AM 14.8 18.9 78.9 671.0 627.5 289.7 
GM 8.6 11.9 46.7 211.7 331.0 156.3 
Median 10 14.4 57.5 101.25 458.75 165.6 
IQR 2.5-13.75 3.4-31.2 29.4- 
128.4 
55.6- 
1571.3 
113.75- 
1053.8 
120.3- 
450.9 
Table 10.1: Summed ex vivo ELISPOT responses to T9/96 TRAP in Gambian 
adult males receiving three prime-boost malaria vaccination regimens. Units are 
SFCs per million PBMCs. The responses presented are the sum of the four 
T9/96 TRAP peptide pools presented in figure 10.2 with the negative control 
subtracted four times. Trial code VAC014. AM - Arithmetic mean. GM - 
geometric mean. IQR - interquartile range. POST DNA+7 includes volunteers in 
DDM group and DDDM group at 7 days after their final DNA ME-TRAP 
vaccination. FF+7 indicates volunteers in the FFM group at 7 days after their 
second and final FP9 ME-TRAP vaccination. DDM+7, DDDM+7 and FFM+7 
indicates 7 days after final vaccination in the DDM, DDDM and FFM groups. 
Table 10.2: Local and systemic adverse events with ME-TRAP vaccines in VAC14 
DNA FP9 dose 1 FP9 dose 2 MVA after MVA after 
N=13 N=16 N=16 DNA N=12 FP9 N=14 
Headache 15535 
Malaise 7434 
Nausea/Vomiting 01000 
Local Adverse Events 
Pain 16173 
Itching 5622 
Blister 06132 
This table is a comparison of DNA, FP9 and MVA carriers and shows solicited 
adverse events over 7 days after immunisation. All adverse events were mild or 
moderate. 
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Table 10.3: Timecourse for local solicited adverse events after first and 
second FP9 and after MVA immunizations in VAC14. 
FP9one day l day 2 day 7 day 21 Size 
Indurat" 13 15 0 0 
Itching 5 6 1 0 
Pain 6 4 0 0 
blister 3 5 1 0 2-8 on day 2 
LAM 0 0 0 0 
FP9two dayl day 2 day 7 day2l Size 
Indurat" 7 2 0 0 
Itching 6 0 0 0 
Pain 1 0 0 0 
Blister 1 1 0 0 4 on day2 
LAM 0 0 0 0 
MVA day l day 2 day 7 day 21 Size 
Indurat" 13 10 3 0 
Itching 4 3 8 0 
Pain 10 8 0 0 
Blister 6 8 0 0 1-10 on day 2 
LAM 1 1 0 0 
n=16 for first and second FP9 immunisations. n=25 for MVA 
immunizations. Indurat"- induration measured by palpation. Blister in 
either or both arms. LAM - limited arm motion. Size was measured in 
mm. 
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Figure 10.1 Timecourses for the three vaccination groups by ex vivo y- 
interferon ELISPOT assay. (see page 146 below for legend) 
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Figure 10.1 Magnitude, duration and 3D7 cross reactivity of y-interferon responses by ex 
vivo ELISPOT. A) Group who received DNA immunizations at weeks 0 and 3 followed by an 
MVA immunization at week 6. B) Group who received DNA at weeks 0,3 and 6 and MVA at 
week 9. C) Group who received FP9 at weeks 0 and 3 followed by MVA at week 6. Each point 
represents the arithmetic mean (standard error) of the summed ex vivo ELISPOT responses to 
T9/96 (or 3D7) TRAP. D and F are the first pre-vaccination timepoints. D- DNA ME-TRAP 
immunisation. M- MVA ME-TRAP immunisation. F- FP9 ME-TRAP immunisation. Numbers 
after plus signs represent the number of days after the most recent vaccination that blood was 
obtained. For example DDM+7 indicates the group of volunteers who received two DNA ME- 
TRAP immunisations followed by a MVA ME-TRAP immunisation with blood drawn seven days 
after the MVA immunisation. Y axis units are SFCs per million PBMCs. Trial code VAC14. 
Figure 10.2 The breadth of responses across the ME-TRAP construct at 
seven days after MVA immunization in the three groups in VAC14 
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Figure 10.2 Arithmetic mean ex vivo ELISPOT responses at seven days after first 
MVA immunization in VAC14. ME - pool of all ME peptides. TD - 31D7 TRAP 20-mer 
peptides. TT - T9/96 TRAP 20-mer peptides.. 1-10 - pool of ten 20-mers spanning 
amino acids 1-110.11-20 - pool spanning amino acids 100-210 etc. 51-57 pool 
completely conserved between 3D7 and T9/96 
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Chapter 11 
Randomised, controlled, double-blind efficacy 
trial of DNA ME-TRAP in combination with MVA 
ME-TRAP in semi-immune males aged 15-45 in 
The Gambia 
11.0 Introduction 
Priming with two 2mg i. m. DNA ME-TRAP vaccinations followed by boosting 
with one 1.5 x 108 plaque forming units (pfu) i. d. MVA ME-TRAP vaccination, 
at 3 week intervals, produced very strong vaccine-induced CD4+ and CD8+ T 
cell responses in previous phase I studies in the UK(see Chapter 7) and The 
Gambia (see Chapter 10). DNA and MVA's excellent profiles as candidate 
vectors for human use have been discussed previously (see Chapter 6,8 and 
10). DNA ME-TRAP/ MVA ME-TRAP regimens led to a delay in time to 
parasitaemia compared to unvaccinated controls after high dose heterologous 
sporozoite challenge of malaria-naive volunteers (Chapter 7). Based on these 
encouraging preliminary findings we have undertaken a randomised controlled 
trial of DNA ME-TRAP/ MVA ME-TRAP in a rural part of The Gambia to 
explore whether this vaccine combination could provide protection against 
natural P. falciparum infection. 
11.1 Methods 
11.1.1 Study Setting and Volunteers 
Volunteers were recruited from 13 villages in the North Bank Division of The 
Gambia in July 2002 with follow-up to December 2002. Malaria incidence is 
highly seasonal in The Gambia with most infections occurring between August 
and December. In 2002, the malaria transmission season was delayed with 
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few disease episodes before October. The Entomological Inoculation Rate 
(EIR) varies between <1 and >100 in The Gambia(Hay et al., 2000). The 
villages were chosen for proximity to the alluvial flood plain .A strong 
association between distance from the flood plain and EIR has been seen in 
this part of The Gambia(Clarke et al., 2002) and thus the EIR in the study area 
is likely to have been in the range of 10 - 30 infectious bites during the period 
of follow-up surveillance. 
Approval was obtained from the Joint Gambian Government/Medical 
Research Council Ethics Committee, the Oxford Tropical Research Ethics 
Committee, the London School of Hygiene and Tropical Medicine Ethics 
Committee and an independent data safety monitoring committee. 
Independent clinical trial monitors monitored for adherence to International 
Committee of Harmonisation Good Clinical Practice guidelines. 
Before recruitment, meetings were held with village chiefs and elders followed 
by general village meetings at which the study was explained. Volunteers 
received information sheets and consent forms translated into the three local 
languages in Arabic script as well as in English. After written informed consent 
was obtained by a study physician, age and identity were checked, pre-test 
HIV counselling occurred and potential volunteers underwent clinical 
evaluation including a full medical history and clinical examination. They were 
screened for haematological (full blood count), renal (plasma creatinine) and 
hepatic (plasma alanine aminotransf erase (ALT)) dysfunction and duplicate 
malaria smears were made. Exclusion criteria included clinically significant 
disease, ALT>42 (iu/I), creatinine>130 (µmol/I), PCV<30%, positive antibody 
ELISA to HIV-1 or HIV-2, simultaneous participation in another clinical trial, 
blood transfusion in the month prior to vaccination, previous experimental 
malaria vaccination, administration of another vaccine within 2 weeks of 
vaccination, previous rabies vaccination, allergy to any previous vaccine or to 
sulphadoxine/pyrimethamine, history of splenectomy and any treatment with 
immunosuppressive drugs. Eligible volunteers were given a unique study 
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number and a photographic identity card. Parental written informed consent 
was obtained for volunteers aged 15-17 years. 
11.1.2 Procedures 
Volunteers were randomly assigned to receive either two, 2mg doses of DNA 
ME-TRAP followed by a single 1.5 x 108 pfu dose of MVA ME-TRAP or three 
doses of rabies vaccine which were given on days 0,21 and 42 timed to 
coincide with the start of the rainy season. A member of the data safety 
monitoring committee generated the randomisation list in London. A block 
procedure was used and whole villages were enrolled with sequential study 
numbers to ensure balanced numbers in each group. Local investigators did 
not know the size of the blocks. Non-translucent sealed envelopes were used 
for vaccine allocation. Study numbers were not pre-printed on vials but were 
written on vials at vaccination. Used vials were checked for correct allocation 
off-site. Vaccination was performed by nurses who played no other part in the 
trial. The first two doses of vaccine consisted of two intramuscular injections, 
one into each deltoid muscle. DNA ME-TRAP was given as 1 ml and rabies 
vaccine as 0.5ml into each arm. The third dose of vaccine was given as four 
intradermal injections into the skin overlying the deltoid muscle; two injections 
into each arm. The malaria vaccine group received MVA ME-TRAP as four 
0.1 ml injections, two into each arm, whereas the control group received four 
0.05ml injections of rabies vaccine. Two weeks before administration of the 
third dose all volunteers received three tablets of sulphadoxine/ 
pyrimethamine to clear blood-stage P. falciparum infections. 
The individual epitopes making up the ME string are described in detail 
elsewhere(Gilbert et al., 1997). The strain of TRAP included in the vaccine 
construct is T9/96. The candidate malaria vaccines were manufactured to 
Good Manufacturing Practice by contract manufacturers (DNA ME-TRAP by 
Qiagen, Hilden, Germany and MVA ME-TRAP by IDT, Rosslau, Germany). 
DNA ME-TRAP was supplied as single dose 2mg in 2ml vials. MVA ME-TRAP 
was supplied as two dose vials each containing 3x 108 pfu in 0.8ml. The 
149 
rabies vaccine (Chiron Behring GmbH, Marburg, Germany) was supplied as a 
lyophilised single dose vial with accompanying diluent and syringe. This 
vaccine was chosen because of its public health benefit in The Gambia. 
After each vaccination, volunteers were observed for one hour and visited at 
home on the first, second and seventh day post-vaccination for assessment of 
local adverse events (discolouration, induration, blister formation, pain, 
limitation of arm motion), systemic adverse events (headache, nausea, 
malaise, axillary temperature) and unsolicited adverse events. One week and 
13 weeks after the third vaccination venous blood was collected for 
measurement of full blood count, ALT and creatinine. 
The local reactogenicity during the seven days after MVA vaccination could 
conceivably have unblinded its assessors. Therefore, we deployed different 
field workers to assess reactogenicity after dose 3 and to perform surveillance 
during the remaining period of follow-up. In this way we ensured that field 
workers making morbidity observations and taking blood smears after the 
period of vaccination were blind to the vaccine code. All slide readers had no 
contact with volunteers and were blind to the vaccine code. 
During the surveillance period, starting two weeks after the third dose of 
vaccine, volunteers were visited twice weekly and asked whether they had 
attended a health centre. At the weekly visits, blood smears and axillary 
temperatures were taken. At midweek visits, blood smears and temperature 
were taken if symptoms compatible with malaria were present. Investigators 
and field supervisors did random visits to ensure accurate data collection. This 
active case detection was supplemented by passive case detection by study 
nurses to whom volunteers had 24 hour access at 3 of the study villages and 
by a clinic at MRC Farafenni (20km from the study villages). When blood 
smears were obtained, two sets of duplicate blood smears (four smears in 
total) were made. For possible clinical episodes an immediate Field's stain 
was performed and read. Two further smears ("A" and "B" slides) were stained 
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with Giemsa after overnight drying and 100 high power fields were read by 
different slide readers before being declared negative. P. falciparum parasites 
were confirmed by a supervisor before a slide was declared positive. The 
arithmetic mean of the A and B slides was used to determine parasite density 
and a volunteer was declared positive for asexual P. falciparum parasitaemia 
if either slide was positive. If A and B slides were markedly discrepant, a third 
read was performed by the supervisor and this read was used for analysis. 
Parasite density was expressed per µl (assuming one parasite per high power 
field = 500 parasites/µl). Full blood counts including packed cell volume were 
measured in a CA620 cell analyser (Medonic). ALT (iu/I) and creatinine 
(gmol/I) were measured in a Visual analyser (Biomerieux). 
Effector T cell responses were assessed in ex vivo y-interferon ELISPOT 
(enzyme-linked immunospot) assays for 98 volunteers randomly selected from 
a substudy list containing a3 to 1 ratio of malaria vaccinees to control 
subjects. 4x 105 peripheral blood mononuclear cells (PBMCs) were assayed 
as described(Moorthy et al., 2003) using Millipore MAIP S45 plates for 18-20 
hours before being developed. Mabtech antibodies were used and counting of 
spots was performed blinded to vaccine allocation with the Autolmmun 
Diagnostika computerised system. All peptides were at 25 µg/ml 
concentration. A single pool contained all ME peptides. 4 pools each were 
used of 20-mer peptides, overlapping by 10, to span T9/96 and 3D7 strains of 
the entire TRAP antigen. 
11.1.3 Statistical analysis 
The primary endpoint was time to first infection with asexual P. falciparum, 
defined as the number of days from the start of the surveillance period to the 
date of the first positive slide. Vaccine efficacy was calculated from the hazard 
ratio estimated by Cox's regression, adjusting for the effects of prognostic 
variables. An analysis plan, written before unblinding, specified exclusion 
criteria, statistical methods and important covariates (age, village of residence 
and bednet use defined as sleeping nightly under an intact bednet). Ethnic 
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group, though not specified as a covariate in the analysis plan, was found on 
analysis to be associated with the risk of infection, and was included as a 
covariate. Because of small numbers in some villages and for presentation 
purposes only we describe village of residence as three groups of villages, 
divided geographically (see tables 10.1 and 10.4). There was no stratification 
by village. Volunteers who received fewer than three doses or who were 
parasitaemic both pre-vaccination and at the beginning of surveillance without 
an intervening negative blood smear were excluded from the primary analysis 
but included in a secondary analysis. Observations on individuals who were 
lost to follow-up or were missing from trial data for >3 weeks were censored. 
The incidence of P. falciparum infection varies substantially within the study 
area from year to year. Based on data obtained over a period of 10 years it 
was calculated that the trial would have >80% power (with a=0.05) to detect a 
difference in the hazard of infection if vaccine efficacy was 40%. Symptomatic 
malaria was defined as presence of asexual P. falciparum parasites at any 
parasitaemia with either an axillary temperature of >= 37.5 °C or one or more 
of the following symptoms: headache, myalgia, arthralgia, malaise, nausea, 
dizziness or abdominal pain: Analyses were done with Stata version 7 (Stata 
Corporation, College Station, TX Station, USA). 
ELISPOT responses were analysed as follows. After subtraction of medium 
alone values from each pooled peptide response, they were summed across 
T9/96 and 3D7 pools. Geometric means were calculated for T9/96 TRAP, 3D7 
TRAPand ME string responses. Responses in the two groups were compared 
with the Mann-Whitney test. 
11.2 Results 
11.2.1 Safety and reactogenicity 
489 volunteers aged 15-45 were screened of whom 113 were excluded. 46 
could not be found on the day of vaccination, 40 were not eligible because of 
anaemia, an abnormal ALT or creatinine result, HIV, various medical 
conditions or because they were too young or too old and 27 withdrew 
consent. 372 were enrolled. 335 men (90%) received their second dose of 
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vaccine and 320 of these received the third dose. 52 who were randomised 
did not receive three doses (2 men received the wrong vaccine at dose 2,26 
left the study area, 23 withdrew consent and 1 was withdrawn because he 
developed pneumonia between dose 1 and dose 2). 296 (141 malaria, 155 
rabies) received three doses and were followed up of whom 277 (74% of 
those initially enrolled) completed 11 weeks of surveillance. Additional data 
were available for 14 volunteers who did not receive all three vaccine doses 
(all 14 received dose 1 and dose 3), 2 (in the malaria vaccine group) who 
received the wrong vaccine at dose 2, and for 18 volunteers who were 
parasitaemic both before vaccination and at the start of surveillance. These 
individuals were included in a secondary analysis. Losses to follow-up were 
similar in the two groups. Prognostic variables were similarly distributed in the 
two groups at the start of surveillance (table 11.1). 
11.2.2 Adverse events 
No clinically significant differences in packed cell volume, ALT or creatinine 
were seen in either vaccine group. One volunteer who received rabies vaccine 
had a history of breathlessness and chest pain several years prior to 
enrolment, experienced a relapse of symptoms and deteriorated and died of 
likely cardiac pathology 3 months after the last vaccine dose. This event was 
regarded as unrelated to vaccination. There were no other serious adverse 
events. Adverse events were rare after first and second doses and were not 
increased in the DNA ME-TRAP group compared to the rabies vaccine group 
(data not shown). Injection site pain, limited arm motion, headache and 
malaise in the first 24 hours after vaccination were more common after MVA 
ME-TRAP vaccination than after rabies vaccination (table 11.2). Most 
volunteers developed an injection site blister 1-2 days after MVA ME-TRAP 
vaccination which healed over 1-3 weeks without complications. Induration 
(for 1-2 days) and discolouration (faint, shiny macular appearance for several 
weeks) was common after MVA ME-TRAP vaccination. There were severe 
adverse events in three individuals causally related to MVA ME-TRAP 
vaccination. These individuals experienced one or more of severe malaise, 
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headache, local pain or limited arm motion during the 24 hours after 
vaccination. 
11.2.3 Effector T cell induction 
Sixty-three and 30 volunteers from malaria and rabies vaccine groups 
respectively were tested for T cell responses 7 days after final vaccination 
(table 10.3). In the rabies vaccine group, geometric mean effector T cell 
responses to TRAP were 3.1,3.9 and 1.4 spot forming cells (SFCs) per 
million PBMCs for T9/96 and 3D7 strains of TRAP and the ME string 
respectively (table 10.3). In the malaria vaccine group, the effector T cell 
frequency to the vaccine strain of the TRAP antigen, T9/96, was geometric 
mean 251.1 SFCs per million PBMCs (80-fold increase above control group, p 
value <0.001). 3D7 is a strain with 6% amino acid variance to T9/96 and is 
thought to have greater homology to locally circulating strains. The cross- 
reactive response to 3D7 TRAP was 197.5 SFCs per million PBMCs (50-fold 
increase above control group, p value <0.001). The ME string response in the 
malaria vaccine group was 4.7 SFCs per million PBMCs (3 fold increase, p 
value 0.03). 
11.2.4. Time to first P. falciparum infection 
171 subjects developed parasitaemia at least once during the surveillance 
period, 80/141 (57%) in DNA/MVA group and 91/155 (59%) in the rabies 
group. The distribution of time to first infection was similar in the two groups 
as seen in the graphical representation of the Kaplan Meier Survival curve 
(Fig 2). Vaccine efficacy among subjects in the according to protocol group 
who received 3 doses, adjusted for age, bednet use, ethnic group and village 
of residence was 10.3% (95%Cl -22% to +34%) p=0.49. Similar results were 
obtained when all subjects who received at least one dose of vaccine were 
included in the analysis (efficacy 0.95% (95%Cl -32% to +25%) p=0.95. 
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Geometric mean P. falciparum densities in first infections were similar in the 
two groups (31 (IQR 5-154)/µI in the malaria vaccine group compared to 24 
(IQR 5-69)/µI in the rabies group, p=0.79 (Mann-Whitney test)). 
During surveillance there were 10 episodes of symptomatic malaria in the 
malaria vaccine group and 13 in the rabies group. The risk of malaria-related 
symptoms during an episode of parasitaemia was similar in both vaccine 
groups. 
Within the ELISPOT substudy group, the risk of developing parasitaemia was 
not associated with the magnitude of the summed effector T cell response by 
ex vivo ELISPOT to the 3D7 strain of TRAP. The 80 men from the substudy 
group who received 3 doses of either malaria vaccine (55 men) or rabies 
vaccine (25 men), completed 11 weeks of surveillance, and had complete 
ELISPOT data after dose 3, were divided into four quartiles according to the 
magnitude of their summed response to 3D7 TRAP 20-mer peptides. Men 
with the highest effector T cell responses had similar hazard ratios for 
incidence of patent blood stage infection, as estimated by Cox's regression, 
compared to those with the lowest effector T cell responses after adjustment 
for age, bednet use and village of residence. However, the small numbers 
limits the power of this analysis. 
The incidence of parasitaemia decreased with increasing age, and was 
decreased in those of Fula ethnicity compared to Mandinka and Wollof ethnic 
groups (Table 11.4). 
11.3 Discussion 
This trial demonstrates that vaccination with two doses of DNA ME-TRAP 
followed by a single dose of MVA ME-TRAP is safe and highly immunogenic 
for effector T cell induction but is unlikely to protect against natural P. 
falciparum infection. This provides a second comparison between protection 
in malaria-naive and malaria-experienced adults. RTS, S/AS02 provides 30- 
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60% complete protection in the artificial challenge model and 71% short-term 
protection against natural infection(Bojang et al., 2001). The lack of field 
efficacy in this paper suggests the use of complete, not partial, protection in 
the artificial challenge model as a screening measure for candidate pre- 
erythrocytic vaccines. However some vaccines are known to prevent disease 
but not infection, as is also the case for naturally acquired immunity to 
malaria. This study does not exclude the possibility that the candidate regimen 
could provide significant anti-disease immunity. Paediatric study designs may 
be required to show this. 
The candidate regimen represents a new method for induction of very high 
effector T cell frequencies, which are about 50 fold higher than those induced 
by lifelong natural exposure. The failure of these effector T cells to kill infected 
hepatocytes is intriguing. Perhaps in infected hepatocytes in vivo ME-TRAP 
epitopes are not expressed, processed or presented adequately for the 
required T cell-hepatocyte synapse formation. The predominance of CD4+ 
over CD8+ T cells in the induced responses was unexpected and could be 
relevant for efficacy(McConkey et al., 2003, Moorthy et al., 2003). Both 
considerations may be addressed by altering the malarial construct to include 
different antigen(s) or epitopes. For example DNA/MVA delivery of a 
circumsporozoite (CS) antigen based construct may allow translation of the 
strong effector T cell responses now possible through vaccination to 
protection against natural P. falciparum infection. Other heterologous 
combinations (for example replacement of DNA priming with another 
attenuated viral vector) may be necessary for efficacy. 
DNA/MVA vaccination has not to date induced significant antibody titres in 
humans(McConkey et al., 2003); trials are underway of combination with 
recombinant protein vaccines for dual antibody/effector T cell induction. 
Combination with protectively immunogenic blood-stage candidates is also 
desirable. Determining methods for the successful combining of different 
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candidate vaccine regimens (whether within or between parasite stages) will 
be one of the important challenges of coming years. 
Even for an adult population, the incidence of clinical disease was lower than 
expected. Sulphadoxine/pyrimethamine was administered four weeks before 
the start of surveillance in this study and in an RTS, S field efficacy 
study(Bojang et al., 2001). There is some evidence that pre-treatment with 
this antimalarial reduces incidence of clinical malaria for longer than four 
weeks(Genton et al., 2000, Coulibaly et al., 2002). However there was also 
less clinical disease than in recent years in paediatric cohorts recruited for 
other studies in 2002 at the study setting and so there may have been a 
general reduction for climatic reasons. 
This study highlights North Bank Division in The Gambia as an excellent 
malaria vaccine field trial site both for adults and by extrapolation for children. 
In a low transmission year cumulative incidence overall in men aged 15-45 
was 72% over 11 weeks, higher than expected, compliance was good despite 
a demanding study design and migration from the study area was acceptable. 
This paper adds to the body of data detailing the very gradual acquisition of 
anti-infection immunity in adults resident in sub-Saharan Africa. While 
substantial immunity to severe malaria is acquired after only a few infections 
and anti-disease immunity is acquired in childhood, we saw statistically 
significant decreases in incidence of infection with increasing age in the 15-45 
age range (table 4) as was observed in the previous Gambian RTS, S adult 
efficacy trial(Bojang et al., 2001). The protection against infection for those 
with Fula ethnicity in this trial is consistent with a report from Burkina 
Faso(Modiano et al., 1996) and with an earlier study in the Farafenni area 
(Greenwood et al., 1987). 
Effector T cell induction 50 fold above that induced by natural infection is now 
possible through DNA-based prime boost vaccination. Further candidate 
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vaccine evaluation is required to assess which candidate immunogens will 
confer efficacy in this system and to identify methods for dual high frequency 
induction of CD8+ T cells and antibody-producing plasma cells. 
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Table 11.1: Characteristics of the trial cohorts at the start of surveillance in VAC20 (296 
subjects who received 3 doses of vaccine and were followed up). 
Malaria vaccine (n=141) Rabies vaccine (n=155) 
Median age (years) (interquartile range) 20 (17-32) 21 (18-30) 
Village group 1 (Alkali Kunda, Chamen, 
Yallal) 
26 (18%) 29 (19%) 
Village group 2* 79 (56%) 93 (60%) 
Village group 3 (Bambali) 36 (26%) 33 (21%) 
Ethnic group: Fula 12 (9%) 19 (12%) 
Mandinka 81(57%) 82 (53%) 
Wollof 48 (34%) 54 (35%) 
Sleeps nightly under intact bednet 76 (54%) 83 (54%) 
*Village group 2 consisted of 9 closely situated villages 
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Table 11.2: Frequency of solicited symptoms during the 7 days after the third dose of vaccine 
in VAC20. 
i. d. AIVA NIE-TRAP i. d. RABIES VACCINE 
N % 95% CI N % 95% CI 
Local symptoms 
Limited arm motion 28/152 18% (13-26) 2/158 1.3% (0.2-4.5) 
Pain 103/152 68% (60-75) 19/157 12% (7.4-18) 
Discolouration 116/151 77% (69-83) 26/156 17% (11-23) 
Induration 138/152 91% (85-94) 86/158 54% (46-62) 
Blister 89/151 59% (51-67) 14/156 9.0% (5.0-15) 
General symptoms 
Headache 45/161 28% (21-36) 19/168 11% (6.9-17) 
Objective Fever 6/161 3.7% (1.4-7.9) 0/168 0% (0-2.0) 
Malaise 40/161 25% (18-32) 14/168 8.3% (4.6-14) 
Nausea 3/161 1.9% (0.4-5.3) 1/168 0.6% (0-3.3) 
Notes: N= total number of subjects who received the third dose. n (%) = number (percentage) 
of subjects who had at least one report of the symptom. 
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Table 11.3: Effector T cell responses one week after the third vaccination in VAC20* 
Malaria vaccine (n=55) Rabies vaccine (n=25) 
Stimulant Geometric mean SFCs per 
million PBMCs 
Geometric mean SFCs per 
million PBMCs 
P value 
ME peptides 4.70 1.39 0.10 
3D7 TRAP peptides 198 3.91 <0.001 
T9/96 TRAP peptides 251 3.30 <0.001 
*80 of the 93 individuals identified for testing T cell responses received three doses of vaccine according to 
protocol and gave analysable responses. Groups of summed responses were compared by the Mann- 
Whitney test in order to obtain p values. 
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Table 11.4: Results of Cox proportional hazards regression analysis for the risk of developing 
parasitaemia after 3 doses of vaccine in VAC20 
Variable No. developing 
arasitaemia/total 
Crude hazard ratio Adjusted hazard ratio 
Vaccine Group 
Malaria vaccine 80/141 (57%) 1 1 
Control 91/155 (59%) 1.07 (0.79-1.45) 1.12 (0.82-1.52) 
Village group 
1 29/55 (53%) 1 1 
2 109/172 (63%) 1.18 (0.78-1.78) 0.92 (0.54-1.55) 
3 33/69 (48%) 0.93 (0.56-1.54) 0.94 (0.54-1.66) 
Age at enrolment (ears) 
15-17 48/69(70%) 1 1 
18-20 39/72 (54%) 0.66 (0.43-1.01) 0.56 (0.36-0.87) 
21-29 41/71 (58%) 0.74 (0.49-1.13) 0.61 (0.39-0.95) 
30-45 43/84 (51%) 0.56 (0.37-0.85) 0.46 (0.29-0.73) 
Bednet use 
Yes 89/159 (56%) 0.93 (0.69-1.26) 1.07 (0.75-1.53) 
No 82/137 (60%) 1 1 
Ethnic group 
Fula 15/31(48%) 1 1 
Mandinka 86/163 (53%) 1.20 (0.69-2.07) 1.16 (0.65-2.1) 
Wollof 70/102 (69%) 1.60 (0.91-2.79) 1.92 (1.02-3.60) 
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Figure 11.1 Trial Profile for VAC20 
489 screened 
117 excluded 
186 randomly assigned to 186 randomly assigned 
receive malaria vaccine to receive rabies vaccine, 
and received dose 1 and received dose 1 
7 lost to follow- 
14 lost to follow-up, 
10 up, 5 missed 
dose 2 9 missed dose 2,2 
received wrong 
vaccine IF IF 
161 received dose 2 174 received dose 2 
7 lost to follow-up 
1 4 
- 
8 lost to follow-up 
154 received dose 3 166 received dose 3 
(149 of these received (162 of these received 
Fansidar) Fansidar) 
2 lost to follow up 
4 lost to follow-uo 
152 bled at the start of 162 bled at the start of 
surveillance surveillance 
11 excluded .4 -1 i 110 7 excluded 
141 followed up in 2002 11 155 followed up in 2002 
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Figure 11.2: Kaplan-Meier survival curves showing the probability of remaining free of P. 
falciparum infection during the 11 weeks of surveillance in VAC20. Week 0 of surveillance began 
in October 2002,14 days after dose 3 of vaccine was administered. 
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t468 10 
Weeks of surveillance 
Figure 11.3: Local reactogenicity two days after injection of MVA ME-TRAP in VAC20. Two 
areas of induration are seen at the two adjacent injection sites. Note a 3mm blister at the centre 
of one injection site. The topmost lesion is an unrelated old scar. 
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Chapter 12 
Conclusions 
This thesis describes a series of studies culminating in a field efficacy trial. 
Although the intervention evaluated in the efficacy trial did not succeed in 
preventing natural P. falciparum blood-stage infection there were several notable 
findings. Some of these findings will have applications to development of 
candidate vaccine regimens by other groups both against liver-stage malaria and 
other infectious diseases. The thesis will therefore conclude by discussing the 
implications of these results for future vaccine research and development. 
Some possible reasons for the failure of the intervention are described'in Chaper 
11. An important consideration is the apparent predominance of CD4+ T cell 
responses over CD8+ T cell responses with DNA/MVA ME-TRAP vaccination. 
There is a difficulty in determining the true magnitude of CD8+ T cell responses 
to a whole antigen, in this case TRAP, in an outbred human population. As the 
spectrum of CD8+ T cell epitopes to which volunteers will respond cannot be 
predicted precisely it is not possible to assay with selected CD8+ T cell epitopes. 
We used 20-mers overlapping by ten to span the whole protein. The high 
concentration used should have maximized the ability to detect CD8+ T cells but 
there is a possibility that some populations of such cells are not enumerated by 
this approach. In our laboratory experiments using recombinant viruses to infect 
presenters as an alternative way of providing MHC classl/epitope complexes for 
T cell activation have occurred. However the frequency of non-specific activation 
of T cells by non-recombinant virus has been problematic to date using human 
cells even though this method works adequately in murine cell assays. 
Optimisation of such a system should enable improvements in CD8+ T cell 
detection above current assays used. 
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Another possibility for the low CD8+ T cell frequencies seen to date is that 
insufficient APC transfection occurs with DNA/MVA vaccination. In this scenario 
antigen transfer from transfected cells to APCs occurs with bias towards the HLA 
class II presentation pathway. De novo synthesis within APCs is likely to be 
necessary for sufficient entry into the HLA class I presentation pathway. A third 
possibility is that processing of expressed antigen does not lead to generation of 
HLA class I epitopes after vaccination. 
If there are sufficient CD8+ T cells, but the assays described in this thesis have 
not enumerated them, there are several reasons why they may not have been 
protective. Frequencies of effector T cells at the time of exposure may have been 
inadequate and a population of non-effector T cells with a memory phenotype 
may have been unable to expand and differentiate to a population with effector 
function within the timeframe required by the expression profile of TRAP. Locally 
circulating strains may have been sufficiently different to T9/96 strain to prevent 
T-cell synapse formation or activation. TRAP may not be expressed in vivo 
sufficiently in infected hepatocytes. Induced memory or effector T cells may not 
have the necessary migration phenotypes to be able to survey infected 
hepatocytes. 
Because there is no satisfactory method of distinguishing between these reasons 
for failure using in vitro systems, the reason will not be known until a related 
DNA-based regimen is shown to protect against malaria. At this point detailed 
comparisons between protective and non-protective T-cell responses should 
determine the immune correlates of protection not induced by DNA ME-TRAP in 
combination by MVA ME-TRAP vaccination. If human hepatocytes could be 
maintained in culture this would allow characterization of vaccine-induced T 
cell/infected hepatocyte interactions. 
How should we design a construct which will induce protective CD8+ T cell 
responses? The next pragmatic step is to attain the very high immunogenicity 
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seen to ME-TRAP by prime boost delivery of another antigen. If CD8+ T cell 
frequencies are higher with DNA/MVA delivery of for example CS then it could 
simply be that processing and/or presentation of TRAP within the ME-TRAP 
construct favours CD4+ T cell induction in a construct specific manner. It may 
also be the case, however, that a bias towards CD4+ T cell induction is a general 
feature of DNA/MVA vaccination in humans. This would appear to be very 
unlikely from considerations arising from basic immunology. DNA vaccination 
induces CD8+ T cells as assayed by conventional chromium release lysis assays 
(Wang et. al., 1998). Such assays have not been conducted after DNA/MVA 
vaccination, so a direct comparison is not available. 1x 108 pfu FP9/ 1.5 x 108 pfu 
MVA delivery of ME-TRAP led to 2/5 complete protection against sporozoite 
challenge 2 weeks after final vaccination in one phase Ila trial (D Webster, 
unpublished data). In a follow-up Ila trial using the same immunization regime 
statistically significant delay in time to parasitaemia was observed with a7 week 
challenge. Interestingly ex vivo ELISPOT responses appeared to be of lower 
magnitude than after 2mg DNA/ 1.5 x 108 pfu MVA vaccination. Detailed 
characterization of T cell responses induced by FP9/MVA ME-TRAP vaccination 
may determine the immunological mechanism of protection. It may be that the 
CD8/CD4 ratio is higher after FP9/MVA compared to DNA/MVA vaccination. 
The poor induction of antibodies by DNA/MVA vaccination may not preclude 
successful development of a liver-stage P. falciparum candidate. However it does 
indicate that DNA/MVA regimens and other regimens with poor antibody 
induction will require combination with other platforms which are strong antibody- 
inducers for formulation of an effective deployable vaccine. The CS antigen 
offers an excellent opportunity for evaluation of such combination strategies. 
Apovia has developed a hepatitis B core platform which to date has been used to 
deliver CS B cell epitopes together with a single CD4 T cell epitope in the 
candidate ICC-1132. This induces high titres of antibody by ELISA and 
sporozoite IFA. RTS, S/AS02 is an alternative CS-based recombinant protein 
particle vaccine. 
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The following questions need to be answered with regard to combination of the 
DNA/MVA platform (or FP9/MVA) with recombinant protein based platforms. 
When the constructs contain significant overlap of malaria T cell epitopes can a 
protein vaccine either replace the DNA prime or the MVA boost for T cell 
amplification? What is the most effective method of simultaneous vaccination 
with antibody-inducing vaccines and DNA/MVA prime-boost regimens? (i. e. how 
does mixing of vaccine in the same syringe compare to concomitant vaccination 
in the same or opposite arms). Interference between antibody-inducing vaccines 
and DNA/MVA regimens may well occur but be surmountable by modifying 
vaccine regimens (for example by staggering vaccinations by a week or so if 
necessary). 
A related question is how to combine two antigens delivered by the same 
platform. A great deal of work will be necessary to determine the mechanisms for 
combination, i. e. prevention of interference and competition. It is unclear how 
cocktails of constructs encoding two antigens individually will compare with a 
single construct encoding a multi-antigen. The order of encoding within the multi- 
antigen may also be important. Should emphasis be placed on determining the 
mechanisms for interference and competition in animal models? Or should we 
essentially perform clinical research to determine empirically certain successful 
candidate vaccine combinations? I believe the two must run in parallel. The risk 
with waiting for results for animal models is that this may be a very long term 
outcome of one or more decades and that particular successful combinations in a 
P. berghell BALB/c model for example will not transfer to humans. The true goal 
of the animal model research would be an understanding of mechanisms for 
interference and competition which may well transfer to human infection with P. 
falciparum even though particular examples of successful antigen combinations 
do not transfer, but this appears to be a long way ahead. Some insight into the 
challenging complexity of immunogenicity with multi-antigen constructs has 
emerged from years of murine research by researchers in Professor Hill's 
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laboratory. This work has indicated that insertion of an antigen into a multi- 
antigen can remove immunogenicity to other antigens present with the construct 
pre-insertion. An example of this in human trials using two recombinant proteins 
was the combination of RTS, S/AS02 with TRAP. Protection conferred by 
RTS, S/AS02 was completely removed by combination vaccination with the TRAP 
protein vaccine. 
Combination of antigens between stages should prevent issues no different to 
those discussed above for within-stage combination in terms of immunogenicity 
but the complexity which arises is in study design for evaluation of efficacy of 
such combination vaccines. Data from efficacy studies will need to enable 
evaluation of the efficacy of individual components as well as the combination 
and in the case of between-stage combination, this will require inclusion of 
mutiple endpoints. For example both time to infection and parasite density may 
independently give indications of efficacy of pre-erythrocytic and blood-stage 
components, but components of the combination vaccine may act as 
confounders for the efficacy of each other. Factorial designs may be able to 
address such considerations and so transmission settings will need to be chosen 
carefully to minimize the increases in sample size such designs will require. 
Evaluation of combinations of sexual stage vaccines with other stages would 
probably require a community randomized design and a factorial design. There 
may be some benefit to conducting mathematical modeling experiments of 
various between-stage combination vaccine efficacy study designs. 
One positive outcome of this thesis was the ability to evaluate an efficacy 
hypothesis in adults living in endemic areas within an appropriately short 
timeframe. Funding was obtained in April 2002 for the efficacy trial and within 9 
months the primary endpoint reported in chapter 11 was determined. However 
this highlights one tension in choices for vaccine development plans in the 
malaria field. We promptly determined that DNA ME-TRAP in combination with 
MVA ME-TRAP did not protect men aged 15-45 living in villages close to 
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Farafenni in The Gambia from infection with P. falciparum. But we did not answer 
the more relevant questions as to whether protection against mild disease, 
severe disease or death could be afforded in children living in endemic countries. 
The more relevant the endpoint the more subjects would be required and 
paediatric study designs are required for anti-disease endpoints. I believe this 
work therefore should encourage the use of complete protection in the Ila 
artificial challenge model as a valid screening tool for candidate pre-erythrocytic 
malaria vaccines. The decision about when to proceed directly to paediatric study 
designs from Ila studies with only intervening adult phase I studies in endemic 
countries will be aided by the knowledge of efficacy of RTS, S/AS02 in children 
aged 1-5, which is currently being evaluated in Mozambique. This will provide the 
first comparison between Ila efficacy and anti-disease efficacy in children aged 1- 
5 living in endemic countries. 
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